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Summary 
Chronic pathological variation in thyroid function has major adverse 
outcomes on adult health, pregnancy and childhood development. 
However, it is less clear whether more minor variation, including 
variation across and just outside the reference-range has sufficient 
impact to justify intervention in selected individuals.  
 
Aims 
To investigate the relationship between modest variation in thyroid 
function on health outcomes, and how our treatment of hypothyroidism 
may relate to this, including screening for and treating low thyroid 
function in pregnancy.   
 
Scope 
I investigated the relationship between variation in thyroid function 
within the normal reference-range on health outcomes and identified 
that lower thyroid function was associated with adverse cardiovascular 
and metabolic outcomes and higher thyroid function was associated with 
adverse bone outcomes. I also identified in the ALSPAC cohort that TSH, 
FT3 and FT4 were all associated with body composition. However, FT3 
was surprisingly positively associated with fat mass and genetic analyses 
indicated that higher fat mass was driving the higher FT3 levels.  
 
I then investigated current UK management of hypothyroidism utilising a 
large primary care database. Here I demonstrated a falling TSH threshold 
at levothyroxine initiation and a high risk of over-treatment. Individuals 
with depression or tiredness were more likely to be over-replaced. 
Women with suboptimal replacement during pregnancy had a higher risk 
of foetal loss. I then utilised data from the CATS trial and data linkage 
via SAIL to demonstrate that screening for and treating low thyroid 
function during pregnancy reduces foetal loss.   
 
Conclusion 
Common variation in thyroid status appears to be a modifiable risk factor 
for adverse health outcomes. Targeted treatment in patient sub-groups 
may provide substantial benefit. Furthermore, FT3 appears to be more 
fluid and influenced by external factors. Further research into novel 
methods of assessing tissue thyroid hormone levels may provide clarity to 
the treatment of borderline thyroid function.  
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Chapter 1 – Introduction 
 
Thyroid status is critical to childhood development and adult health. 
Whilst overt thyroid disease has substantial negative health 
consequences, it is unclear whether more modest variation in thyroid 
status has sufficient impact on health to warrant intervention. This is an 
important issue to address as thyroid disease is easily treatable and 
borderline thyroid dysfunction is common in the general population.  
 
In particular, thyroid hormone has substantial effects on cardiovascular 
risk factors, metabolism, bone maintenance, mental health, as well as 
pregnancy outcomes and childhood development [1-3]. Effects are likely 
to be causal as outcomes are influenced by thyroid hormone replacement 
or anti-thyroid medication. Furthermore, pregnancy is a period of key 
vulnerability to sub-optimal thyroid function although data on early 
intervention are limited [4].   
 
Taken together there is a pressing need to investigate the impact of 
common variation in thyroid status including variation across the normal 
population. Given that hypothyroidism is particularly common, and 
widely tested for, the impact or current UK practice will also be assessed. 
As the majority of studies to date have been performed in adults I will 
also explore the effect of variation in thyroid status on outcomes in 
children to assess the effect of variation in thyroid home during a key 
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time in development.  In this thesis, I will therefore assess the following 
key areas:  
1) The effect of common variation in thyroid hormone status within 
the population reference range on key health outcomes using 
existing published data from epidemiological cohorts.  
2) The relationship between thyroid function and body composition 
in children using data from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) to assess the impact of common 
variation in thyroid function in children. 
3) UK practice regarding thyroid hormone replacement in primary 
hypothyroidism, with a focus on its management and 
consequences during pregnancy, using primary care registry data. 
4) The benefits of screening for and correcting low thyroid function 
in pregnancy using data linkage and the Controlled Antenatal 
Thyroid Study (CATS) trial.  
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1.1 THYROID HORMONE EFFECTS 
Thyroid hormones have fundamental but diverse physiological roles 
across vertebrate species, ranging from photoperiodic regulation of 
seasonal breeding in birds to induction of metamorphosis in amphibians 
[5]. In humans, they act on almost all nucleated cells and are essential 
for normal growth and differentiation, as well as regulation of energy 
metabolism and correct physiological function. The consequences of 
pathological thyroid dysfunction (hyper/hypothyroidism) can be profound 
[1, 2]. Extreme hypothyroidism, myxoedema coma is a rare endocrine 
emergency with a high mortality rate of 25-70% [6] similarly poor 
outcomes are observed with extreme hyperthyroidism -thyroid storm [1]. 
The consequences of hypo and hyperthyroidism are summarized in Table 
1.  
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Table 1 Signs and Symptoms of Hyper- and Hypothyroidism 
Hyperthyroidism Hypothyroidism 
Hyperactivity Slowing of mental functions 
Emotional lability Emotional lability 
Insomnia Inability to concentrate, poor 
memory 
Fatigue Fatigue, lethargy  
Anxiety Depressive symptoms 
Weight loss despite increased 
appetite 
Weight gain despite decreased 
appetite 
Heat intolerance Cold intolerance 
Palpitations Deranged lipid profile 
Atrial fibrillation Heart failure 
Excess sweating  Decreased sweating 
Dry Skin Dry skin, Hair loss 
Diarrhea Constipation 
Muscle weakness Muscle weakness  
Osteoporosis Joint pain 
Lighter menses Heavier Menses 
Impaired fertility Impaired fertility 
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1.2 EPIDEMIOLOGY OF THYROID DISEASE 
Hypothyroidism and hyperthyroidism are common conditions that affect 
all populations worldwide. Iodine nutrition is a key determinant of 
thyroid disease risk [7]; however, other factors such as ageing [1], 
smoking status [8], genetic susceptibility [9], ethnicity [10], endocrine 
disruptors [11] also influence thyroid disease epidemiology. These factors 
are summarized in Table 2. 
 
Table 2 Risk factors for developing Hypothyroidism and 
Hyperthyroidism 
Risk factor Hypothyroidism Hyperthyroidism Comment 
Female sex + + Sex hormones and the skewed 
inactivation of the X 
chromosome are suspected to 
be triggers for hypothyroidism 
and hyperthyroidism [12].  
    
Iodine 
deficiency 
+ + Severe iodine deficiency can 
cause hypothyroidism and 
hyperthyroidism [13].  
    
Iodine 
excess 
+ + Excess iodine status can trigger 
hyperthyroidism typically in 
elderly individuals with 
longstanding thyroid nodules 
and hyperthyroidism [13].  
    
Transition 
from iodine 
deficiency to 
sufficiency 
+ + Transition from iodine 
deficiency to sufficiency was 
associated with an increase in 
thyroperoxidase antibodies, 
one study reported an increase 
from 14.3% to 23.8% [14].  
    
Other 
autoimmune 
conditions 
+ + One study reported that 
another auto-immune disease 
was present in almost 10% of 
patients with Graves’ disease 
and in 15% of patients with 
Hashimoto’s thyroiditis, with 
rheumatoid arthritis being the 
most common [15].  
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Risk Factor Hypothyroidism Hyperthyroidism Comment 
    
Genetic risk 
factors 
+ + Both Graves’ disease and 
Hashimoto thyroiditis have 
genetic predispositions. 
Genome wide association data 
have identified regions 
associated with 
thyroperoxidase antibody 
positivity [16] and thyroid 
disease [16]. 
    
Smoking — + Current smoking increases the 
odds of Graves’ 
hyperthyroidism almost 2-fold 
and increases the risk of 
Graves’ ophthalmopathy 
almost 8-fold [17]. Smokers 
also have a slower response 
during anti-thyroid drug 
treatment [18]. Smoking might 
protect against hypothyroidism 
[19, 20].  
    
Alcohol — n/a Moderate alcohol intake might 
be associated with a reduced 
risk of hypothyroidism [21]. 
    
Selenium 
deficiency 
+ + One study reported that 
patients with newly diagnosed 
Graves’ disease and 
hypothyroidism had lower 
selenium levels than the 
normal population [22]. 
    
Drugs + + Examples of drugs that can 
cause hyperthyroidism and 
hypothyroidism include 
Amiodarone [23], Lithium [24] 
and interferon γ. 
    
Syndromic 
conditions 
+ n/a Almost 25% of patients in a 
large registry of patients with 
Down syndrome had thyroid 
disease, the most common 
being primary hypothyroidism 
[25]. The prevalence of 
hypothyroidism in Turner 
syndrome is approximately 13% 
[26].  
–, reduced risk; + increased risk, n/a unclear if a risk factor 
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Iodine deficiency and auto-immune disease (known as Hashimoto 
thyroiditis)  account for the vast majority of cases of primary 
hypothyroidism [2]. A third of the world’s population live in iodine 
deficient areas and the devastating consequences of severe iodine 
deficiency on the neurological development of fetuses and children are 
well recognized [7].  
 
In iodine sufficient countries, the prevalence of hypothyroidism ranges 
from 1–2% [27, 28], rising to 7% in individuals aged between 85–89 years 
[29]. In the absence of age-specific reference ranges for TSH, an ageing 
population is likely to result in a higher prevalence of hypothyroidism. 
Hypothyroidism is approximately 10 times more prevalent in women than 
men [27]. In the developed world, the prevalence of undiagnosed overt 
hypothyroidism is likely falling due to widespread thyroid function testing 
[30]. Data from Norway showed that the prevalence of untreated overt 
hypothyroidism was low at 0.1%, reflecting a fall of 84% from the 1990s 
[30]. 
 
The prevalence of overt hyperthyroidism ranges from 0.2% to 1.3% in 
iodine sufficient parts of the world [12, 31]. In 1977, the UK Whickham 
study reported that the incidence of hyperthyroidism was estimated at 
between 100–200 cases per 100,000 per year with a prevalence of 2.7% in 
women and 0.23% in men, taking into account both established and 
possible cases[32]. These figures were considerably higher than earlier 
retrospective data from the USA which reported an incidence of 30 cases 
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per 100,000 a year for Graves’ disease in the period 1935–1967 [33]. A 
20-year follow up of the Whickham cohort showed an ongoing incidence 
of 80 cases per 100,000 women per year [31, 34]. In the 2002, United 
States National Health and Nutrition Examination Survey (NHANES III), 
overt hyperthyroidism was detected in 0.5% of the population while 0.7% 
of the population had subclinical hyperthyroidism [31] with an overall 
prevalence of 1.3%. Studies from several other countries including 
Sweden [35, 36], Denmark [37], Norway [38] and Japan [39] have all 
reported comparable incidence and prevalence rates. A meta-analysis of 
European studies estimated a mean prevalence rate of 0.75% and an 
incidence rate of 51 cases per 100,000 per year [12].  
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An overview of the prevalence of hypothyroidism based on 
epidemiological surveys, is summarized in Table 3 and Figure 1. Most of 
the available data are from Europe and North America and data from 
Africa in particular is lacking [40]. These data show that hypothyroidism 
is common throughout the world, and is particularly common in the UK. 
This raises the possibility that the UK may also have a substantial number 
of individuals with thyroid function in the lower point of the population 
reference range.  
 
The prevalence of overt hypothyroidism in the general population ranges 
between 0.2% and 5.3% in Europe [30, 41] and 0.3% and 3.7% in the USA 
[42] depending on the definition used and population studied (Table 3). 
Longitudinal studies from large UK cohorts report an incidence rate of 
spontaneous hypothyroidism of 3.5–5.0 per 1000 per year in women and 
0.6 – 1.0 per 1000 per year in men [34, 43]. A survey conducted in Spain 
reported a prevalence of treated hypothyroidism, untreated subclinical 
hypothyroidism, and untreated clinical hypothyroidism of 4.2%, 4.6% and 
0.3%, respectively [44]. A 2010 study from Australia reported the five-
year incidence of hypothyroidism in individuals aged >55 years was 0.5% 
and 4.2%, respectively[45], while the prevalence of overt and subclinical 
hypothyroidism was estimated at 0.5% and 5.0%, respectively [46]. The 
longest follow-up study is from the UK Whickham cohort [32, 34], where 
the mean annual incidence of spontaneous hypothyroidism during a 20-
year follow-up period was 35 cases per 10,000 surviving women and 6 per 
10,000 surviving men [34]. Higher TSH levels and the presence of thyroid 
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antibodies were associated with an increased risk of developing 
hypothyroidism with a positive interactive effect [34].  
 11 
Table 3 Prevalence of hypothyroidism in iodine sufficient and iodine 
deficient countries 
 
Author, 
country, 
publication 
year 
Study 
date 
Sample 
size (N) 
Age 
(yrs) 
Female 
(%) 
Iodine 
intake/UI
C 
Prevalence, % 
M F Total 
IODINE SUFFICIENT      
Tunbridge, UK, 
1977[32] 
1972–
1974 
2,779 >18 54 811 
nmol/24h 
0.1 1.4 1.8 
Konno, Japan, 
1993 [39] 
1990–
1991 
4,110 Adult 29 n/a 0.7 3.1 n/a 
Galofre, Spain, 
1994 [47] 
1990–
1992 
103,098 15–85 57 n/a n/a n/a n/a 
Vanderpump, 
UK, 1995[34] 
1975–
1994 
1,877 38–93 56 102µg/g-
cr 
1.3 9.3 5.8 
Bjoro, Norway, 
2000[38] 
1995–
1997 
94,009 >20 50 n/a 0.4 0.8 0.7 
Canaris, USA, 
2000[42] 
1995 24,337 >18 56 n/a n/a n/a 0.4 
Hollowell, 
USA, 2002[31] 
1988–
1994 
13,344 >12  145 µg/l n/a n/a 0.3 
Volzke, 
Germany, 
2003[48] 
1997–
2001 
3,941 20–79 48 12µ g/dL n/a n/a 0.7 
Flynn, UK, 
2004[43] 
1993–
1997 
369,885  >0 n/a n/a   3.0 
O’ Leary 
Australia 
2006[49] 
1981 2,115 16–89 50 n/a 0.4 0.7 0.54 
Teng†, China, 
2006 (total) 
[50] 
1999 3761 
(total) 
≥18 69 n/a n/a n/a n/a 
Teng†, China, 
2006 (excess) 
[50] 
1999 1074 ≥18 n/a n/a n/a n/a 2.0 
Teng†, China, 
2006 
(sufficient) 
[50] 
1999 1584 ≥18 n/a n/a n/a n/a 0.9 
Sichieri, 
Brazil, 2007 
[51] 
2004–
2005 1200 (white) ≥35 100 
n/a n/a 1.6 n/a 
Sichieri, 
Brazil, 2007 
[51] 
2004–
2005 
(Mixed) n/a n/a n/a n/a 1.3 n/a 
Sichieri, 
Brazil, 2007 
[51] 
2004–
2005 
(Black) n/a n/a n/a n/a 0.6 n/a 
Leese, UK, 
2007[52] 
1994–
2001 
388,750 >0 52 n/a 1.0 5.5 3.0 
Kasagi, Japan, 
2009[53] 
2005–
2006 
1818 51.3+
/-9.0 
56 n/a 0.2 0.5 0.66 
Lucas, Spain, 
2010[54] 
 
2002 1,124 18–74 56 150 µg/l 0 0.5 0.2 
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Data is for cases of overt hypothyroidism except where otherwise stated. 
Iodine status is based on reported status by authors; spaces are left blank 
where there is no data on prevalence or where the data is unclear from 
the report. Studies in specific population groups such as children, 
pregnant women, specificied co-morbid states, and unstable iodine 
nutrition are excluded. UIC, urinary iodine concentrations 
         
Author, 
country, 
publication 
year 
Study 
date 
Sample 
Size (N) 
Age 
(yrs) 
Female 
(%) 
Iodine 
intake/UI
C 
 
Prevalence, % 
M F Total 
Asvold, 
Norway, 
2012[30] 
1995–
2008 
15,106 >20 67 n/a n/a n/a n/a 
Marwaha, 
India, 2012[55] 
2007–
2010 
4402 18–90 63 n/a n/a n/a 4.2 
Delshad, Iran, 
2012 [56] 
1999–
2005 
1,999 >20 61 n/a n/a n/a  
Unnikrishnan, 
India, 
2013*[57] 
2011 5376 18–
100 
54 n/a n/a n/a 10.95 
Sriphrapradan
g, Thailand, 
2013[58] 
2009 2545 ≥14 n/a n/a n/a n/a 0.74 
IODINE DEFICIENT      
Laurberg, 
Denmark, 
1999[59] 
24 
months 
569,108 >0 51 60 µg/day n/a n/a n/a 
Aghini-
Lombardi, 
Italy, 1999[60] 
1995 992 >15 58 55 µg/l 0 0.3 0.2 
Knudsen, 
1999, 
Denmark[61] 
1993-
1994 
2,613 41-71 49 70 µg/l 0.2 0.5 0.3 
Knudsen, 
2000, 
Denmark[37] 
1997-
1998 
2,293 18-65 79 45 µg/l n/a n/a 0.2 
Knudsen, 
2000, 
Denmark[37] 
1997-
1998 
2,067 18-65 79 61 µg/l n/a n/a 0.6 
Hoogendoorn, 
2006, 
Netherlands[6
2]  
2002-
2003 
5,167 >18 54 n/a 0.2 0.6 0.4 
Laurberg, 
2006, 
Denmark[63] 
1997-
1998 
310,124 18-65 50 68 µg/l n/a n/a n/a 
Laurberg, 
2006, 
Denmark[63] 
1997-
1998 
225,707 18-65 53 53 µg/l n/a n/a n/a 
Teng†, China, 
2006 
(deficient) 
[50] 
1999 1103 ≥18 n/a n/a n/a n/a 0.3 
Du, China, 
2014 (mildly 
deficient) [64] 
n/a 667 ≥18 71 n/a 0.2 0.9 1.05 
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 †Same study population, studied at 5 and 11 year intervals post 
iodization. Data in follow-up available on excess replacement as in some 
individuals excess levels were recorded (median in this group, 651 microg 
per liter).*Data from 8 cities with a wide mix of iodine status from 
sufficient to deficient.  
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Figure 1 Global epidemiology of hypothyroidism 
 
Figure created using Tableau software version 10.3.  World map showing 
global prevalence of hypothyroidism based on epidemiological surveys. If 
multiple studies have been performed on the prevalence of 
hypothyroidism from one country, the median value was used. The 
deeper the shade of blue the higher the prevalence of hypothyroidism.  
 
Hyperthyroidism is less common than hypothyroidism but also has an 
uneven distribution globally. Its prevalence and incidence of thyroid 
dysfunction is difficult to compare across countries due to differences in 
diagnostic thresholds, assay sensitivities, population selection, and fluxes 
in iodine nutrition and population dynamics although epidemiological 
surveys are still available (Table 4, Figure 2). As with hypothyroidism, 
the majority of studies are from Europe and North America. The 
prevalence of overt hyperthyroidism is roughly similar in Europe and the 
United States (0.7 versus 0.5%) [12, 31] although the prevalence of overt 
hyperthyroidism ranges from 0.2% to 1.3% in iodine sufficient parts of the 
world[12, 31] (Table 4). In 1977, the UK Whickham study reported that 
the incidence of hyperthyroidism was estimated at between 100–200 
cases per 100,000 per year with a prevalence of 2.7% in women and 0.23% 
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in men, taking into account both established and possible cases [32]. 
These figures were considerably higher than earlier retrospective data 
from the USA which reported an incidence of 30 cases per 100,000 a year 
for Graves’ disease in the period 1935–1967 [33]. A 20-year follow up of 
the Whickham cohort showed an ongoing incidence of 80 cases per 
100,000 women per year [31, 34]. In the 2002, United States National 
Health and Nutrition Examination Survey (NHANES III), overt 
hyperthyroidism was detected in 0.5% of the population while 0.7% of the 
population had subclinical hyperthyroidism [31] with an overall 
prevalence of 1.3%. Studies from several other countries including 
Sweden [35, 36], Denmark [37], Norway [38] and Japan [39] have all 
reported comparable incidence and prevalence rates. A meta-analysis of 
European studies estimated a mean prevalence rate of 0.75% and an 
incidence rate of 51 cases per 100,000 per year [12].  
 
Higher rates of hyperthyroidism are observed in iodine deficient 
countries, mostly due to an excess of nodular thyroid disease in the 
elderly [63, 65], mostly due to an excess of cases of toxic nodular goiters 
[60].  
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Table 4 Prevalence of hyperthyroidism in iodine sufficient and iodine 
deficient countries 
 
 
Author, 
country, 
publication 
year 
Study 
date 
Sample 
no.   
Age 
(yrs) 
Female 
(%) 
Iodine 
intake 
(UIC) 
Prevalence, % 
M F Total 
IODINE SUFFICIENT 
Tunbridge, UK, 
1977 [32]  
1972–
1974 
2,779 >18 54 811 
nmol/24h 
0.2 1.9 1.1 
Mogensen, 
Denmark, 
1980[66] 
1972–
1974 
439,756 >0 50 n/a n/a n/a n/a 
Berglund, 
Sweden, 
1990[67] 
1970–
1974 
258,000 >0 52 n/a n/a n/a n/a 
Konno, Japan, 
1993[39] 
1990–
1991 
4,110 Adult 29 n/a 0.3 0.5 0.3 
Galofre, Spain, 
1994[47] 
1990–
1992 
103,098 15–85 57 n/a n/a n/a n/a 
Berglund, 
Sweden, 
1996[35] 
1988–
1990 
231,774 >0 53 n/a n/a n/a n/a 
Vanderpump, 
UK, 1995[34] 
1975–
1994 
1,877 38–93 56 102 µg/g 
cr 
0.2 3.9 2.5 
Bjoro, Norway, 
2000[38] 
1995–
1997 
94,009 >20 50 n/a 0.1 0.3 0.2 
Canaris, USA, 
2000[42] 
1995 24,337 >18 56 n/a n/a n/a 0.1 
Hollowell, 
USA, 2002[31] 
1988–
1994 
13,344 >12  145 µg/l n/a n/a 0.2 
Volzke, 
Germany, 
2003[48] 
1997–
2001 
3,941 20–79 48 12 µg/dL n/a n/a 0.4 
Flynn, UK, 
2004[43] 
1993–
1997 
369,885  >0  n/a n/a n/a 0.6 
O’ Leary 
2006[49] 
1981 2,115 16-89 50 
 
2,115 16-89 50 n/a 0.1 0.2 0.1 
Leese, UK, 
2007[52] 
1994–
2001 
388,750 >0 52 n/a 0.2 1.3 0.8 
Lucas, Spain, 
2010[54] 
2002 1,124 18–74 56 150 µg/l 0.2 0.2 0.2 
Asvold, 
Norway, 
2012[30] 
1995–
2008 
15,106 >20 67 n/a n/a n/a n/a 
Delshad, Iran, 
2012 [56] 
1999–
2005 
1,999 >20 61 n/a n/a n/a n/a 
n/a 
Unnikrishnan, 
India, 
2013*[57]  
 
2011 5376 18–
100 
53.7 n/a 0.6 0.7 0.67 
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Data is for cases of overt hyperthyroidism except where otherwise stated. 
Iodine status is based on reported status by authors; spaces are left blank 
where there is no data on incidence or prevalence or where the data is 
unclear from the report.  
*Study from 8 cities with a wide mix of iodine status ranging from 
sufficient to deficient. Studies in specific population groups such as 
children, pregnant women, specified co-morbid states, and unstable 
iodine nutrition are excluded. UIC, urinary iodine concentrations. 
 
 
  
Author, 
country, 
publication 
year 
Study 
date 
Sample 
size (N). 
Age 
(yrs) 
Female 
(%) 
Iodine 
intake 
UIC 
Prevalence, % 
      M F Total 
Sriphrapradan
g, Thailand, 
2014[58] 
2009 2545 ≥14 46 n/a n/a n/a 0.94 
Nystrom, 
Sweden, 
2013[36] 
2003–
2005 
631, 239 >0 n/a 125 µg/l n/a n/a n/a 
Valdes, Spain, 
2017[44] 
2009–
2010 
4,554 18–93 58 117 µg/l n/a n/a 0.4 
IODINE DEFICIENT 
Kalk, South 
Africa, 
1981[68] 
1974–
1984 
1,246,294 >15 48 n/a n/a n/a n/a 
Aghini-
Lombardi, 
Italy, 1999[60] 
1995 992 >15 58 55µg/l 2.9 3.0 2.9 
Knudsen, 
1999, 
Denmark[61] 
1993–
1994 
2,613 41-71 49 70µg/l 0 1.2 0.6 
Knudsen, 
2000, 
Denmark[37] 
1997–
1998 
2,293 18–65 79 45µg/l n/a n/a 0.4 
Knudsen, 
2000, 
Denmark[37] 
1997–
1998 
2,067 18–65 79 61µg/l n/a n/a 0.8 
Hoogendoorn, 
2006, 
Netherlands[6
2] 
2002–
2003 
5,167 >18 54 n/a 0.2 0.6 0.4 
Laurberg, 
2006, 
Denmark[63] 
1997–
1998 
310,124 18–65 50 68µg/l n/a n/a n/a 
Laurberg, 
2006, 
Denmark[63] 
1997–
1998 
225,707 18–65 53 53µg/l n/a n/a n/a 
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Figure 2 Global epidemiology of overt hyperthyroidism 
 
Figure created using Tableau software version 10.3.  World map showing 
global prevalence of hypothyroidism based on epidemiological surveys. If 
multiple studies have been performed on the prevalence of 
hyperthyroidism from one country, the median value was used. The 
deeper the shade of red the higher the prevalence of hyperthyroidism.  
 
1.3 THYROID FUNCTION TESTING AND REFERENCE RANGES 
Thyroid status is tightly regulated by the hypothalamus-pituitary-thyroid 
(HPT) axis [69] (Figure 3). Only unbound (free) hormones are biologically 
active. Clinically, thyroid function is assessed by measuring free 
thyroxine (FT4), free tri-iodothyronine (FT3) and the pituitary hormone 
thyrotropin (TSH); the complex inverse relationship between them 
renders TSH the more sensitive marker of thyroid status [70].  TSH levels 
are therefore used to ascertain the extent of thyroid dysfunction. Overt 
hypothyroidism is defined as an elevated TSH and decreased serum levels 
of FT4 or FT3. Subclinical hypothyroidism (SCH) is defined as an elevated 
TSH (>5 mU/mL), but normal circulating thyroid hormone levels. In 
healthy individuals, intra-individual variation in TSH, FT3 and FT4 is less 
than 50% of inter-individual variation, [71] thyroid parameters are also 
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stable over time in healthy adults and are largely genetically determined 
[72]. However, in children cross-sectional studies suggest that FT3 
substantially falls and FT4 rises from age 4, but there are no longitudinal 
studies to confirm these observations [55, 73]. Studies have also shown 
that adult reference intervals for thyroid hormone levels are not 
universally applicable before puberty [74, 75]. Taken together, this raises 
the possibility that thyroid hormones do not necessarily track over 
childhood. 
 
Recently there has been increasing interest in viewing thyroid function 
as a continuous variable in determining risk of adverse outcomes. Studies 
have shown a “U” shaped curve throughout the normal range with 
maternal thyroid function and offspring neuro-development [76]. Other 
studies have shown variation in FT4 to be a continuous risk factor [77] or 
with increased risk arising well below traditional thresholds for defining 
abnormal thyroid function [78]. This continuous approach may be more 
clinical meaningful, particularly when determining who might benefit 
from treatment rather than a binary cut-off. 
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Figure 3 Hypothalamus-Pituitary-Thyroid feedback loop 
 
 
Figure used with permission from Vijay Panicker. 
 
In the last 20 years, there has been a steady increase in thyroid function 
testing [79] which has resulted in many individuals being identified with 
overt and subclinical thyroid disease. The reasons behind this widespread 
thyroid function testing are unclear. This is of increasing clinical 
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importance as there is current controversy as to appropriate reference 
ranges for serum thyroid hormone levels with large number of individuals 
around the borders of the range and we are unsure as to the 
consequences of this.  For instance, the reference range is defined, as 
two standard deviations above and below the mean in a group of 
apparently disease-free individuals. However, it has been argued that an 
epidemiological approach is perhaps more meaningful, defining abnormal 
values as those associated with adverse consequences [80]. To take this 
further, one could view TSH and FT4 as continuous measures with optimal 
sub-optimal and pathological zones.  
 
1.4 RISK BENEFITS OF CORRECTING ABNORMAL THYROID 
FUNCTION 
It is well established that correct of overt hypothyroidism and 
hyperthyroidism is associated with substantial health benefits [1, 2]. 
Subclinical thyroid disease is associated with adverse bone outcomes, 
atrial fibrillation and to a lesser extent, quality of life [3, 81-83]. It is 
subclinical hypothyroidism and its impact on cardiovascular outcomes 
that will drive the majority of clinical management decisions as well as 
determining the cost-effectiveness of detecting and treating subclinical 
thyroid disease [84]. 
 
International guidelines [85] only recommend consideration of 
levothyroxine therapy at TSH levels less than 10mU/l when there are 
clear symptoms of hypothyroidism, positive thyroid antibodies or 
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evidence of atherosclerotic cardiovascular disease or heart failure 
(evidence level B). However, it is unclear which patients with a TSH 
between 4.5-10.0mU/l will benefit most [86, 87].  
 
Although awareness of subclinical thyroid disease and its potential for 
adverse effects on health has substantially increased, the optimal 
management remains uncertain. This is not due to safety concerns 
regarding therapeutic options as treatments for subclinical thyroid 
disease are effective, cheap and easy to monitor. It is only the 
uncertainty regarding the magnitude of the clinical benefit of treatment 
that has led to divergent opinions regarding both screening and 
management [79, 81, 88, 89]. At present data remain lacking due to 
limited trials in this area with adequate power [3]. This is further 
compounded because the diagnosis of subclinical thyroid disease is based 
on an individual having abnormal TSH levels with normal FT3 and FT4 
levels and the exact definition of the upper limit of a normal TSH remains 
contentious [90, 91]. Screening and correction of thyroid disease in the 
healthy adult population is likely to have an unfavourable cost to benefit 
ratio. However, pregnancy may be a special situation which would merit 
screening for and correction of borderline thyroid disease. 
 
1.5 TREATMENT OF HYPOTHYROIDISM AND HYPERTHYROIDISM 
In both hypothyroidism and hyperthyroidism, the goal of treatment is to 
restore well-being and TSH levels to the normal range. In primary 
hypothyroidism treatment is usually life-long.  Levothyroxine (T4) is the 
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mainstay of treatment and is well tolerated by the majority of patients, 
however a minority require liothyronine (T3) or desiccated thyroid 
extract  [92].  Treatment for hyperthyroidism does not usually require 
greater than 18 months therapy with anti-thyroid drugs such as 
carbimazole or propylthiouracil [1]. However definitive treatment 
(Radio-iodine or Surgery) may be required and these usually result in 
individuals becoming hypothyroid and requiring long term treatment with 
levothyroxine. Again, treatment targets may be best regarded on a 
continuum rather than a binary in-range, out of range set-point. 
 
1.6 THYROID FUNCTION IN PREGNANCY 
Thyroid dysfunction, particularly lower thyroid function is common in 
women of childbearing age [93]. Furthermore, pregnancy results in 
additional demands being placed on the thyroid axis these are 
summarized in Table 5. Some women cannot meet this demand, and this 
results in low thyroid function during pregnancy.   
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Table 5 Summary of physiological changes during pregnancy and 
their impact on thyroid function. 
 Physiological change Effect on thyroid 
function test 
Key point for 
clinicians 
↑ Thyroxine-binding 
globulin 
↑ Serum total T3 and 
T4 concentration 
 
Total thyroid hormone 
levels may be 
misleading rely on 
free thyroid hormone 
levels. 
   
Secretion of human 
chorionic 
gonadotrophin 
↑ Free T4 and ↓ TSH 
 
High human chorionic 
gonadotrophin levels 
may result gestational 
thyrotoxicosis. This 
usually only requires 
symptomatic 
treatment but needs 
to be distinguished 
from pathological 
thyroid disease.   
   
↑ Iodine clearance ↓Hormone 
production in iodine 
deficient areas 
 
Need to be mindful of 
iodine deficiency and 
ensure optimal intake 
ideally prior to 
conception. 
	 	  
↑ Plasma volume  ↑ T3 and T4 pool size  
   
Increased Type 3 5-
deiodinase (inner ring 
deiodination) activity 
from the placenta  
 
↑ T3 and T4 
degradation 
 
Another cause of 
increasing thyroid 
demand in pregnancy. 
Thyroid enlargement 
(in some women) 
Increased 
thyroglobulin 
Be aware that a small 
goitre is common in 
pregnancy, but may 
be a sign of low 
thyroid function so 
merits thyroid 
function testing 
 
As a result of these major changes to physiology during pregnancy, 
gestational thyroid disease is best diagnosed using pregnancy specific 
reference ranges [4]. Ideally locally derived reference ranges should be 
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used where possible which take into account additional factors such as 
the iodine status and ethnicity of the local population [93]. 
 
1.6.1 Epidemiology of thyroid disease in pregnancy 
Thyroid disease is common in pregnancy and approximately 1-2% of 
women who are pregnant are established on levothyroxine prior to 
pregnancy [94]. Overt maternal hypothyroidism - elevated 
concentrations TSH and low maternal free FT4 occurs in approximately 
0.2-0.6% of pregnant women [95, 96], whereas subclinical hypothyroidism 
(SCH - elevated TSH and normal FT4) can occur in up to 18% of 
pregnancies depending on the precise definition and TSH cut-point used 
[4, 93]. Isolated hypothyroxinemia (IH) is defined as a normal TSH with 
FT4 below the 2.5 percentile was originally considered to be a pregnancy 
specific condition possibly arising as a consequence of mild iodine 
deficiency. This concept has been more recently challenged as it occurs 
in iodine sufficient areas and does not typically resolve with iodine 
supplementation [97, 98]. Other factors including elevated BMI, older 
age, iron status and placental angiogenic factors have all been identified 
as likely risk factors for IH [99-101]. Overt hyperthyroidism, is less 
common and is usually due to Graves’ disease occurs with a frequency of 
approximately 0.2% [102] however previously treated maternal Graves’ 
disease prior to pregnancy is more common and can occur prior to 1% of 
pregnancies [102]. New onset pathological hyperthyroidism during 
pregnancy is much rarer with a prevalence of 0.05% for Graves’ disease 
[102]. Gestational thyrotoxicosis (suppressed TSH and elevated FT4) 
mainly through excess hCG and usually associated with hyperemesis 
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gravidarum, occurs in up to 3% of pregnancies [102]. Subclinical 
hyperthyroidism most commonly occurs as a result of peak hCG levels 
[103] although may occur due to pathological thyroid disease. Owing to 
this dual cause of subclinical hyperthyroidism its true consequences and 
prevalence are poorly studied.   
 
1.6.2 Consequences of maternal thyroid dysfunction in pregnancy 
Overt hypothyroidism has been repeatedly associated with a higher risk 
of adverse obstetric outcomes including foetal loss, premature delivery, 
low birthweight and pre-eclampisa [95, 104]. Effects have been observed 
on foetal neuro-development, a large case-control study demonstrated 
children born to women with untreated hypothyroidism had a 7 point 
lower IQ than women with normal thyroid function [105]. SCH is also 
associated with similar adverse obstetric outcomes as overt 
hypothyroidism, albeit with a more modest effect. Studies have 
demonstrated an increased incidence of adverse pregnancy outcomes 
including preterm delivery, placental abruption, respiratory distress, 
early pregnancy loss and admissions to the intensive care unit [106-110] 
but it has not been associated with impaired development of offspring. 
 
 Although IH is also regarded as a mild form of thyroid failure it is 
associated with offspring developmental outcomes [76] but not obstetric 
outcomes in stark contrast to SCH. Intriguingly, the relationship between 
maternal FT4 and offspring IQ appears to be “U” shaped with individuals 
with hypothyroxinemia having lower IQ, and lower grey matter and 
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cortical volume [76]. Maternal IH has also been shown to increase the risk 
of autism [111]. 
 
TPO antibody positivity is a major risk factor for SCH [112]. However, the 
combination of SCH and TPO antibody positivity appears to have a 
synergistically adverse outcome. In particular, adverse synergistic 
associations occur for miscarriage, premature delivery and gestational 
diabetes mellitus [113]. It also appears to be a risk factor in its own right 
for miscarriage and pre-term delivery [114].  TPO positivity may also 
impair thyroidal response to hCG [103] and result in more profound 
hypothyroidism due to unmet pregnancy demands. 
 
Whether or not all pregnant women should be screened for thyroid 
disease remains controversial. This is despite thyroid dysfunction being 
common and often asymptomatic in women of child-bearing age with 
substantial adverse implications for foetal and maternal wellbeing [4, 95, 
115].  
 
Data are less clear as to whether treatment of thyroid disease initiated 
during pregnancy results in clear benefits. Whilst data are compelling for 
correction of overt thyroid disease [105] at present the benefits of 
treating SCH and IH in pregnancy remain unclear. Two large prospective 
intervention trials demonstrated no impact on offspring IQ [116, 117], 
and one of these also failed to identify benefits on obstetric outcomes 
[118] and one prospective trial demonstrated a decrease in the composite 
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number of adverse pregnancy/neonatal outcomes in thyroid peroxidase 
antibody positive women with subclinical hypothyroidism [110].  
 
1.7 AIM OF THIS PhD THESIS 
Although it is widely accepted that pathological variation in thyroid 
hormone levels has major adverse outcomes on both childhood 
development and adult health it is less clear whether more minor 
variation in thyroid function – including variation across and just outside 
the reference range – has sufficient impact on key health outcomes to 
justify intervention with thyroid hormone supplementation in selected 
individuals. Assessing the magnitude of this potential benefit will be a 
key component of this thesis. Given that pregnancy places additional 
demands on the thyroid and requires tighter control, this will be a key 
focus of my work. The impact of current practice of thyroid hormone 
prescribing and potential impact of screening for low thyroid function in 
pregnancy will also be explored. 
 
The thesis will comprise of the following research chapters 
1) Analysis of the effects of variation in thyroid status within the 
population reference range on key cardiovascular, metabolic and 
bone outcomes. 
2) Assessment of the effect of variation in thyroid status on body 
composition in children. 
3) Assessing trends in UK management of primary hypothyroidism. 
4) Assessing the quality of levothyroxine prescribing in pregnancy 
and the effects on obstetric outcomes. 
5) Analysis of the potential obstetric benefits of screening for and 
treating low thyroid function in pregnancy.   
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Chapter 2 Methods 
 
In this chapter I summarize the various cohorts and datasets used in my 
PhD analyses. Further details of the phenotypes, biochemical measures  
and statistical analyses used are described in the relevant chapters. 
 
2.1 COHORTS AND DATASETS USED IN THIS THESIS. 
2.1.1 The Avon Longitudinal Study of Parents and Children (ALSPAC) 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a 
geographically based birth cohort that recruited pregnant women 
residing in Avon, UK, with an expected delivery date between 1st April 
1991 and 31st December 1992. 14,541 pregnant women were initially 
enrolled with 14,062 children born; this was increased to 14,633 by 
recruiting children at age 7 who were initially eligible, but not recruited. 
Approximately 80–90% of the eligible population was recruited. 
Participants have been extensively followed from the 8th gestational 
week using a combination of self-reported questionnaires, medical 
records and physical examinations. This cohort is described in detail 
elsewhere (http://www.alspac.bris.ac.uk)[119, 120]. 
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2.1.2 The General Practice Research Database (GPRD) 
The GPRD (now called the Clinical Practice Research Datalink 
www.CPRD.com) has been well described previously [121]. It is currently 
the largest computerized database of anonymized medical records from 
primary care that is linked with other healthcare data.  
 
The CPRD contains computerized medical records of over 5,000,000 
people from 508 primary care practices throughout the UK. The CPRD has 
been validated for use in research on disease epidemiology, drug safety 
and adverse drug reactions [122-124]. In particular, data on drug 
exposure and diagnoses [125] are of high quality [126]. It is also 
representative of the overall UK population with regard to age and sex 
[127, 128]. Few practices opt out of the CPRD system so this is unlikely 
to cause bias in the dataset [127]. 
 
CPRD contains detailed clinical information on diagnoses, patient 
symptoms, laboratory results, drug prescriptions and hospital referrals 
[127]. These are identified through read codes. Validation studies have 
confirmed the high quality and accuracy of studies undertaken using 
CPRD [125].  
 
THE CPRD dataset used for this work consisted of patients aged between 
18-99 years at their first-ever (index) prescription of levothyroxine which 
occurred between 01/01/2001 - 30/10/2009. Patients also had to have at 
least 12 months of up-to-standard (data that met GPRD quality standards) 
follow-up prior to their index levothyroxine. Patients with a prescription 
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record at any time on the database of amiodarone, carbimazole, 
propylthiouracil, lithium, interferon, thalidomide or sunitinib were 
excluded; as were patients previously diagnosed with or treated for 
hyperthyroidism prior to their index levothyroxine as evidenced by 
medical codes and referral codes in the GPRD relating to Graves’ disease, 
thyrotoxicosis, hyperthyroidism, toxic multi-nodular goiter, 
thyroidectomy and radio-iodine. Patients with a documented diagnosis of 
thyroid cancer or a diagnosis of pituitary disease or pituitary surgery were 
also excluded.  
 
In all, 59,781 individuals matched our initial inclusion criteria  57,318 
individuals matching our study inclusion criteria were included of whom 
53,333 (93.0%) had a prescription within 90 days after a documented TSH 
level. 1,035 individuals were classified as having received levothyroxine 
related to pregnancy and were analyzed separately (Figure 4).  
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Figure 4 Flow of individuals studied in CPRD  
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2.1.3 Controlled Antenatal Thyroid Screening Study (CATS)  
The Controlled Antenatal Thyroid Screening study was a large randomised 
controlled trial to investigate  the benefits of screening treating low 
maternal thyroid function on offspring IQ. In this study, pregnant women 
were invited to participate at their first antenatal hospital visit. The 
women were recruited from 10 centres in the United Kingdom (Bristol, 
Glan Clwyd, Llandough, Neville Hall, Princess of Wales, Royal Glamorgan 
Hospital, Royal Gwent, Singleton and Morriston, University Hospital of 
Wales and Wrexham) and 1 center in Italy (Turin). Exclusion criteria were 
an age of less than 18 years, a gestational age of more than 15 weeks 6 
days, twin pregnancies, and known thyroid disease. Approval of the study 
was obtained from research ethics committees in the United Kingdom and 
Italy, and all participants provided written informed consent. 
 
Blood samples were sent to the laboratory at the University Hospital of 
Wales, Cardiff (for UK centres), or to Ospedale Sant’Anna, Turin, Italy, 
for measurement of TSH and FT4  levels. On receipt of samples, women 
were randomly assigned with the use of a computer-generated block 
design to the screening or control group. 
 
Serum samples from the screening group were immediately assayed for 
levels of TSH and FT4. Serum samples from women in the control group, 
stored at −40°C, were assayed for levels of TSH and FT4 after delivery. 
Women were classified as positive if they had TSH in the highest 2.5 % 
and or FT4 in the lowest 2.5%. They were treated with levothyroxine 
(proposed starting dose, 150 mcg per day). Levels of TSH and free T4 were 
 
 
34 
checked 6 weeks after the start of levothyroxine therapy and at 30 weeks' 
gestation, with adjustment of the dose as necessary. The target 
thyrotropin level was 0.1 to 1.0 mIU/l.  
 
Women in the screening and control groups who had positive test results 
received standard routine care and were advised to visit their family 
physician after delivery to determine whether levothyroxine therapy 
should be continued or initiated, respectively. 
 
In the United Kingdom, levels of serum TSH and free T4 were measured 
using immunochemiluminescence (ADVIA Centaur, Siemens Healthcare 
Diagnostics). The 95% range of TSH was 0.15 to 3.65 mIU/l, and the 95% 
range of free T4 levels was 8.4 to 14.6 pmol/l.  
 
The study recruited 21, 846 women (16,346 from the 10 centres in the 
UK) and 5,500 from Turin in Italy (although women recruited in Italy were 
not used in my analysis). To summarize the original CATS study 10,924  
women were assigned to the screening group and 10,922 were assigned 
to the control group. 4.6% of women were defined as having a positive 
screening result in the screening group and 5.0% had a positive screening 
result in the control group. In both groups, similar proportions were 
classified as having a high TSH or low FT4. Approximately 5% of women 
in each of the groups had both a high TSH and a low FT4. There was no 
difference between the treatment groups in the baseline characteristics 
(gestational age at screening, maternal weight, maternal smoking, age 
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when mother left full time education, maternal age at delivery paternal 
age at delivery, % male children). The only substantial difference due 
between groups is that TSH levels were slightly higher in the screening 
group than the control group (Median 3.8 mU/l IQR 1.5-4.7) vs (3.2 mU/l 
IQR 1.2-4.2). The IQ of the children was assessed at age 3 in the original 
study and then again in an additional study at age 9 [129].  
 
Detailed obstetric data was not collected in the original CATS study, 
however some records were kept on some patients with abnormal thyroid 
function regarding whether there was a miscarriage or a stillbirth or 
whether there was a termination. As data was not routinely collected 
analysis of outcomes were limited in the original study. A summary of the 
participants used in my analysis in this thesis is shown in Figure 5. 
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Figure 5 Flow diagram of the CATS participants used in my analyses 
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2.1.4 Secure anonymised information linkage (SAIL) 
The SAIL databank is held and managed within the Health Information 
Research Unit at Swansea University and contains health social and 
education data on three million residents of Wales [130]. The 
demographic data comprises the commonly-recognised person-based 
variables of first name, surname, sex, date of birth, postcode and 
NHS/hospital number. Matching records in SAIL has been demonstrated 
to be highly sensitive and specific [130]. The clinical data covers data 
such as diagnostic tests, therapeutic procedures and interventions. The 
clinical data used in this analysis was from the  Patient Episode Database 
for Wales (PEDW)[130]. PEDW is a register of all clinic and inpatient 
activity undertaken in Welsh NHS hospitals and processes over a million 
hospital episodes annually including information on diagnoses, 
admissions, hospital births, and surgical operations including Caesarean 
sections. This data was linked to key trial data from the CATS study to 
enable us to explore obstetric outcomes in trial participants. 
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Chapter 3 A meta-analysis of the consequences of 
variation in thyroid function across the population 
reference-range using data from population based 
birth cohorts 
 
In the introduction to this thesis I highlighted the importance of thyroid 
hormone and the clinical consequences of overt thyroid disease. In order 
to appraise the impact of more modest variation of thyroid status I 
undertook a meta-analysis of studies using population based cohorts 
which assessed the effect of variation in thyroid status within the 
population reference-range on key health outcomes. This approach 
enabled me to explore both the magnitude and consistency of these 
effects. 
 
3.1 INTRODUCTION 
As we have already seen thyroid disease is common and its treatment is 
simple, inexpensive with well-established safety data [1, 2]. It is 
therefore essential to determine the consequences and the potential 
benefits of correcting subclinical thyroid disease [3]. 
 
Increased use of thyroid function testing [79] has resulted in many 
individuals being identified with subclinical thyroid disease. The 
prevalence of subclinical hypothyroidism is between 4-8.5% [31, 42] rising 
to 15% in elderly populations [3, 131].  Subclinical hyperthyroidism is less 
common with a prevalence of 1-5% in the elderly [132]. Treatments for 
subclinical thyroid disease are effective, cheap and easy to monitor; it is 
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the uncertainty regarding the magnitude of the clinical benefit of 
treatment that has led to divergent opinions regarding screening and 
management [79, 81, 88, 89]. Data are lacking due to limited trials in this 
area with adequate power [3]. This is further compounded because the 
diagnosis of subclinical thyroid disease is defined on having abnormal 
thyroid stimulating hormone (TSH) levels with normal free tri-
iodothyronine (FT3) and free thyroxine levels (FT4) and the exact 
definition of the upper limit of a normal TSH remains contentious [90, 
91].  
 
Whilst subclinical thyroid disease is robustly associated with adverse bone 
outcomes, atrial fibrillation and to a lesser extent, quality of life [3, 81-
83], it is subclinical hypothyroidism and its impact on cardiovascular 
outcomes that will drive the majority of clinical management decisions 
as well as cost-effectiveness considerations for its detection and 
treatment [84]. A meta-analysis [87] identified that subclinical thyroid 
disease might be associated with adverse coronary heart disease and 
mortality outcomes; although the point estimates for the relative risk for 
coronary heart disease extended below equality. Limiting analyses to 
studies with the more robust methodologies and lower risk of selection 
bias decreased risk estimates. Whilst this meta-analysis [87] was unable 
to confirm a positive association between subclinical thyroid disease and 
coronary heart disease and mortality in the general population; it did 
indicate that the negative impact of sub-clinical hypothyroidism may be 
more substantial in younger individuals RR=1.51 (95%CI 1.09-2.09). 
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American Thyroid Association guidelines [85] recommend consideration 
of levothyroxine therapy at TSH levels less than 10mU/l when there are 
clear symptoms of hypothyroidism, positive thyroid antibodies or 
evidence of atherosclerotic cardiovascular disease or heart failure 
(evidence level B), but it is unclear which patients with a TSH between 
4.5-10.0mU/l will benefit most [86, 87].  
 
Analyzing cohorts of individuals identified to have subclinical thyroid 
disease has key limitations, due to small study size and potential for 
substantial selection bias. This selection bias arises, as subclinical thyroid 
disease is often asymptomatic and individuals have their thyroid function 
measured for a variety of reasons, including screening in patients with 
diabetes, therefore individuals who have their thyroid function measured 
are not representative of the general population. 
 
An alternative approach is to study the phenotypic consequences of 
variation in thyroid hormone parameters within the general population. 
Studies here are considerably larger and less prone to selection bias than 
any available in subclinical thyroid disease. Given the consequences of 
overt thyroid disease are well established [133, 134] it would then be 
possible to make assumptions of the consequences of subclinical thyroid 
disease if the nature of the effects of variation within the reference 
range and the effects of overt thyroid disease were concordant. This 
review will therefore highlight the phenotypic consequences of modest 
variation in thyroid function within the population reference-range.  
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I therefore undertook a review and meta-analysis of the effects of 
variation in thyroid status within the population reference range on 
cardiovascular, metabolic and bone outcomes.  
 
3.2 METHODS AND DATA SYNTHESIS 
Combinations of ‘TSH’, ‘FT4’, ‘FT3’, ‘thyroid function’, ‘blood pressure’, 
‘cholesterol’, ‘lipid levels’, ‘cardiovascular disease’, ‘myocardial 
infarction’ ‘arrhythmia’ ‘atrial fibrillation’ ‘stroke’ ‘bone mineral 
density’, ‘osteoporosis’, ‘osteopenia’, ‘peak bone mass’ ‘fracture’ ‘BMI’ 
‘weight’ ‘metabolic syndrome’ ‘ATP-III’ ‘pregnancy’ ‘cancer’ 
‘neurological development’ ‘mood’ ‘behavior’ ‘depression’ ‘anxiety’ 
‘neurological’ separately and in conjunction with the terms ‘reference-
range’ and ‘normal range’  up to September 2013 were used to search 
MEDLINE via an Ovid Server and the Cochrane database. The references 
of retrieved papers were also reviewed. Only English-language papers 
were studied. 
 
The nature of this review, limited the use of the GRADE scoring criteria 
[135] as all our studies were observational. However, the GRADE criteria 
for decreasing and increasing evidence levels was used when appraising 
papers. Evidence quality was regarded as good if derived from several 
consistent studies from large epidemiological cohorts with adjustment 
for important confounders. Evidence quality was regarded as moderate 
if the number of papers on a topic were limited, or studies were 
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conflicting, but still from good data sources, finally evidence was 
regarded as poor if it was derived from studies with imprecise or sparse 
data or with a high probability of reporting bias.  
 
I then undertook an inverse-variance, fixed-effects weighted meta-
analysis, to demonstrate the odds of developing adverse outcomes in 
individuals with TSH levels in the upper part (upper third) of the 
reference-range versus those in the lower part (lower third) of the 
reference-range for cardiovascular, metabolic and bone outcomes.  
Analyses were then repeated using a random-effects meta-analysis as it 
is not unreasonable to assume different effects for different aspects of 
cardiovascular metabolic and bone outcomes. Additional analysis was 
done for neuropsychological outcomes but this was not included in the 
meta-analysis due to the lower quality of data.  
 
Salman Razvi and Simon Pearce from Newcastle University acted as 
second readers and were in complete agreement with me for papers to 
be included.   
 
3.3 RESULTS 
A total of 985 English-language papers were reviewed; studies analysing 
associations in thyroid hormone parameters outside the reference-range, 
editorials, individual case studies were excluded. 40 papers were found 
to be suitable, no published papers studying variation in thyroid function 
within the reference-range were found to be unsuitable.  Information 
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related to authorship, year of publication, number of subjects, study 
design, and results were extracted and formed the basis for the report.    
 
Overall the evidence base was consistent and of good quality for 
cardiovascular and metabolic outcomes, was of moderate quality for 
metabolic and pregnancy outcomes and was of poor quality for 
neuropsychological outcomes. An overview of the phenotypic associations 
of variation in thyroid function within the reference-range is shown in 
Table 6. 
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Table 6 Summary table of the associations between variation in 
thyroid hormone parameters within the population reference range 
and key phenotypic outcomes  
 
Outcome Association Parameter Studies Evidence 
quality 
Blood Pressure Yes TSH [136-
138] 
Good 
     
Cholesterol 
and lipid 
levels 
Yes TSH [139, 
140] 
Good 
     
Cardiovascular 
mortality 
Possible TSH [141, 
142] 
Moderate 
     
BMI Yes TSH [143-
146] 
Good 
     
Metabolic 
syndrome 
Yes TSH [140, 
147]  
 
Moderate 
Pregnancy 
outcomes 
Yes TSH [148] Moderate 
     
BMD Probable TSH [149-
154] 
 
 
Good in 
females. 
Moderate  
in males. 
     
BMD Probable FT3 FT4 [155, 
156] 
Moderate 
     
Depression Unclear TSH [157] Poor 
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3.3.1 The effect of variation in thyroid status within the population 
reference range on cardiovascular outcomes 
 
Cardiovascular outcomes are summarized in Table 7. There is growing 
evidence that higher levels of TSH are associated with worsening blood 
pressure [136-138] and also lipid levels [139, 140]. Furthermore these 
associations are also present in children [138] highlighting that TSH 
influences cardiovascular risk factors throughout life. From these studies, 
it appears that variation in TSH levels is associated with a change in both 
systolic and diastolic blood pressure, with approximately a 2mmHg 
increase per 1mU/l rise in TSH. Whilst a modest effect; over the 
reference-range this difference is equivalent to between 33-50% of the 
blood pressure change observed with anti-hypertensive monotherapy 
[158].  
 
The impact of variation in TSH over the reference on lipid levels is more 
modest with a change in total cholesterol of only 0.12-0.20mmol/l 
between the upper and lower part of the reference-range [139]. This 
beneficial impact of thyroid hormone on lipids may have become inflated 
in current prescribing practice as modest dyslipidemia was found to be a 
major motivator in prescribing levothyroxine for borderline thyroid 
function [159].  
 
Analysis in the Nord-Trøndelag Health Study (HUNT Study), identified that 
higher TSH levels within the reference-range were associated with higher 
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mortality from coronary heart disease in females [141]. This is in keeping 
with the observed negative impact of rising TSH on blood pressure and 
lipid levels. Compared to women with a TSH level in the lower third of 
the reference-range the hazard ratios for coronary heart disease 
mortality were 1.41 (95%CI 1.02-1.96) and 1.69 (95%CI 1.14-2.52) for 
women in the middle and higher third respectively [141]. After adjusting 
for age and smoking the hazard ratio for a 1.0mU/l rise in TSH was 1.37 
(95%CI 1.12–1.68).  Intriguingly the association between TSH and 
cardiovascular mortality appears to be mediated by components other 
than lipids and blood pressure as adjusting for age, smoking, serum 
creatinine, cholesterol, use of hypertensives, systolic blood pressure and 
diastolic blood pressure resulted in only a modest fall in the hazard ratio 
for a 1.0mU/l rise in TSH to 1.30 (95%CI 1.06–1.60) although residual 
confounding remains a possibility. 
 
The lack of an observed association between TSH and cardiovascular 
mortality in males may be due to insufficient power as there were over 
twice the number of females in this study than males; however, there 
was weak evidence of interaction by sex. Notably extending the 
observation period for a further 4 years [142] identified that the 
association between TSH and mortality from coronary heart disease in 
women remained similar over the increased follow-up time and also 
demonstrated stronger evidence of interaction by sex. This study also 
identified that compared to women with a TSH level in the lower third of 
the reference range the risk of mortality from coronary heart disease was 
 
 
47 
higher in women with subclinical hypothyroidism HR=1.76; (95%CI 1.21, 
2.56) or subclinical hyperthyroidism HR=2.29; (95%CI 1.27, 4.13). This 
important observation demonstrates that the relationship between TSH 
and mortality heart disease is likely “u” shaped and highlights that if 
individuals are excessively treated with levothyroxine for subclinical 
hypothyroidism which results in a suppressed TSH then any benefit on 
cardiovascular mortality may be lost and mortality even potentially 
increased. There is also evidence of a similar “u” shaped association with 
TSH for both cardiovascular outcomes and fracture incidence in 
individuals on levothyroxine [160]. 
 
Although positive associations between TSH levels and cardiovascular risk 
factors and cardiovascular mortality [142] have been identified there was 
no evidence of association between TSH levels and risk of being 
hospitalized with a first myocardial infarction (MI). This finding therefore 
does not confirm the suggestion that low thyroid function within the 
reference-range is associated with an increased risk of MI. This finding is 
difficult to reconcile with the above observations, it may simply be due 
to lack of power, but another possible explanation is that higher TSH 
levels within the reference-range may increase the risk of heart disease 
but this is mechanistically distinct from a typical MI, for example silent 
MI or diastolic dysfunction. This hypothesis is supported by a large meta-
analysis showing an increased risk of heart failure in individuals with 
subclinical hypothyroidism [161] although evidence for a substantial 
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impact of TSH variation within the population on heart failure remains 
limited at present. 
 
Overall these studies demonstrate that higher TSH levels within the 
population reference-range is associated with worse cardiovascular risk 
factors and higher mortality, data remain limited and are conflicting for 
FT4 and FT3 levels [162-164]. It is noteworthy that further studies are 
required for other important health outcomes in particular stroke. This 
is particularly relevant as higher thyroid hormone levels are associated 
with atrial fibrillation [133, 160] a key stroke risk factor. 
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Table 7 The effect of variation in thyroid status within the 
population reference range on cardiovascular outcomes 
 
Report Study Type Outcome Comments 
Iqbal  
Norway  
2006 
[136] 
Cross-sectional 
analysis of a 
population 
cohort, the 5th 
Tromsø study 
(N=5,872 M:F 
1:1.24) 
Blood pressure Variation in TSH within 
the population 
reference range was 
positively associated 
with blood pressure.  
  
    
Asvold  
Norway 
2007  
[137] 
Cross-sectional 
analysis of a 
sub-group of 
the HUNT 
study, a 
population 
cohort 
(N=27,786) M:F 
1:1.84) 
 
Blood pressure There was a linear 
increase in systolic 
blood pressure over the 
population reference 
range, for TSH.  
Asvold 
Norway 
2007 
[139]  
Cross-sectional 
analysis of a 
sub-group of 
the HUNT study 
a population 
cohort 
(N=34,851 M:F 
1:1.90) 
Cholesterol and 
lipid levels 
With increasing TSH 
levels within the 
reference range there 
was linear increase in 
concentrations of total 
serum cholesterol, LDL 
cholesterol, non-HDL 
cholesterol and 
triglycerides 
 
Asvold   
Norway 
2008 
[141] 
Sub-group of 
HUNT study a 
population 
cohort 
(N= 25,313 M:F 
1:2.16) 
410 
participants 
had died from 
coronary heart 
disease during a 
median of 8.3 
years of follow-
up 
 
Cardiovascular 
mortality 
The hazard ratio for 
cardiovascular 
mortality in females 
with a TSH in the upper 
third of the reference 
range compared to the 
lower third was 1.69 
(95%CI 1.14 - 2.52), p 
for trend = 0.005 after 
adjusting for age, sex 
and smoking status. No 
clear association was 
observed in men.  
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Lee 
Korea 
2011 
[140] 
 
Cross-sectional 
study from 
individuals 
attending clinic 
(N=7,270 M:F 
1:0.74))  
Cholesterol and 
lipid levels 
TSH showed modest but 
statistically significant 
positive associations 
with serum total 
cholesterol, 
triglyceride, and low 
density lipoprotein 
cholesterol (p<0.001). 
 
Itterman 
Germany 
2012  
[138] 
KiGGS study of 
children and 
adoloescents 
(N= 6,435 
children M:F 
1:0.94, N=5,918 
adolescents M:F 
1:0.94) 
Blood pressure Serum TSH levels were 
associated with 
hypertension in 
children OR=1.12 
(95%CI 1.00-1.25; p = 
0.05) and adolescents 
OR = 1.19 (95%CI 1.12-
1.26 p=< 0.001)  
 
 
 
Debeij 
Norway 
2012 
[165] 
Nested case 
control in HUNT 
2 Cohort 
(N=515 cases, 
1476 controls) 
Venous 
thrombosis 
In individuals with FT4 
levels above the 98th 
percentile of the 
reference range (17.3 
pmol/l), the odds of 
venous thrombosis 
within one year 
compared to individuals 
with FT4 levels below 
this level were 2.5 
(95%CI 1.3-5.0) For TSH 
the relation was inverse 
and less pronounced.  
  
Asvold  
Norway 
2012 
[142] 
 
12 year follow-
up in the HUNT 
cohort 
(N=26,707 M: F 
1:2.10) 
558 
participants 
had died from 
coronary heart 
disease during a 
median of 12.3 
years of follow-
up 
960 
participants 
had been 
Cardiovascular 
mortality, 
hospitalisation 
from 
myocardial 
infarction 
The risk of mortality 
from coronary heart 
disease was higher in 
women with TSH in the 
middle (HR = 1.41; 
95%CI 1.06 -1.87) and 
upper (HR =1.45; 95%CI 
1.01 - 2.08) thirds of 
the reference range 
compared to women 
with TSH in the lower 
third (p for trend = 
0.005). The risk of 
mortality from coronary 
heart disease in women 
with subclinical 
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hospitalized 
with first-time 
acute 
myocardial 
infarction 
during 12.2 
years (median) 
of follow-up 
hypothyroidism (HR = 
1.76; 95%CI 1.21 - 2.56) 
or subclinical 
hyperthyroidism (HR = 
2.29; 95%CI 1.27 - 4.13) 
was also higher 
compared to women 
with TSH in the lower 
third of the reference 
range 
  
 
    
Iida 
Japan 
2012 
[162] 
Patients with 
hypertension 
and normal 
thyroid 
function 
(N=293 M:F 
1:0.96) 
Left ventricular 
mass 
Both FT3 (β =0.13) and 
FT4 (β =0.13) were 
positively associated 
with left ventricular 
mass whereas TSH was 
negatively associated 
(β = -0.15) 
 
Kim 
Korea 
2012 
[163] 
Cross-sectional 
analysis of 
hospital clinic 
attenders  (N = 
669 M: F 1:0.71) 
 
Coronary artery 
calcium scores 
measured by CT 
FT4 levels were 
inversely associated (β=-
0.823, p=0.032), with 
coronary artery 
calcification in 
euthyroid healthy 
subjects. No association 
was observed with TSH.  
Ertas 
Turkey 
2012 
[164] 
Cross-sectional 
analysis of 
consecutive 
patients 
attending 
coronary 
angiography 
(N=119 M:F 
1:0.55) 
Presence of 
coronary artery 
disease 
Lower FT3 levels within 
the reference range 
were associated with 
increased odds for both 
the presence and 
severity of coronary 
artery disease. 
 
3.3.2 The effect of variation in thyroid status within the population 
reference range on metabolic outcomes 
A summary of the effect of variation in TSH and thyroid hormone 
parameters within the population reference-range on metabolic 
outcomes is shown in Table 8. Associations have been identified with 
weight and BMI, metabolic syndrome and glomerular filtration rate (GFR). 
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Over the past decade cross-sectional studies, mainly in adults, have 
shown that variation in thyroid status across the population reference-
range is associated with substantial differences in body mass index and 
body composition [143, 145, 146]. Rising TSH levels in an individual are 
associated with increased weight gain [144, 145]. Baseline TSH may also 
be associated with weight gain over time, although this may not be 
apparent for several years [143]. In contrast a reciprocal effect was 
observed for FT4 which was strongly negatively associated with BMI [143]. 
 
Cross–sectional analysis in cohort studies highlighted that the odds of 
metabolic syndrome as defined by the ATP-III criteria are positively 
associated with higher TSH levels within the reference-range [147, 166, 
167]. It should be highlighted that this association in particular may be 
due to reverse causation through the impact of the metabolic syndrome 
on the hypothalamic-pituitary-thyroid axis. Therefore, prospective 
cohort studies with serial measurements of both thyroid function and 
metabolic properties assessing the changes in both thyroid hormone 
status and ATP-III score over time are required. 
 
Variation in TSH within the population reference-range was positively 
associated with changes in eGFR and also a higher prevalence of chronic 
kidney disease [168].  Furthermore, the strength of this association was 
magnified over the subclinical and overt hypothyroid range. The 
association between TSH and GFR was approximately the same in TPO 
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positive and TPO negative individuals indicating that immunological 
processes are unlikely to explain this association. It has been previously 
observed that GFR increases following T4 treatment for hypothyroidism 
[169, 170] and decreases after treatment of hyperthyroidism [169] or 
after withdrawal of T4 therapy indicating that variation in thyroid 
hormone status drives this association. This association between GFR and 
thyroid status may be explained, at least partially by a diminished ability 
to excrete free water [171, 172] in hypothyroidism which may result in 
subsequent changes in volume status.  
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Table 8 The effect of variation in thyroid function within the 
population reference range on metabolic outcomes  
Report Study Outcome Comments 
Knudsen 
Denmark 
2005 
[143] 
Cross-sectional 
analysis of 
DANTHYR study 
in individuals 
without thyroid 
disease 
(N=4,082)  
BMI A positive association 
was identified between 
serum TSH and BMI with 
a negative association 
between serum FT4 and 
BMI. No association was 
observed between serum 
FT3 and BMI.  
 
Fox 
USA 
2008 
[145] 
Framingham 
Offspring Study.  
(N=2,407 M:F 
1:0.87) 
Change in 
weight over 
follow-up 
Baseline TSH 
concentrations were not 
associated with weight 
change during follow-up. 
However, an increase in 
TSH concentration at 
follow-up was positively 
associated with weight 
gain in women  
    
Asvold 
Norway 
2009 
[146]  
Subgroup of the 
HUNT 
population 
cohort 
(N=27,097 M:F 
1:1.96) 
BMI Variation in TSH within 
the reference range was 
positively associated 
with BMI.  
  
    
Ruhla 
Germany 
2010 
[147] 
 
Metabolic 
Syndrome Berlin 
Potsdam 
(MeSyBePo) 
cohort (N=1,333 
M: F 1:1.77) 
 
ATP III 
criteria of the 
metabolic 
syndrome 
Individuals with TSH in 
the upper normal range 
(2.5-4.5 mU/l) had 
increased odds of 
fulfilling the ATP III 
criteria of the metabolic 
syndrome. 
    
Kim 
Korea 
2011 
[140] 
 
Cross-sectional 
study from 
individuals 
attending clinic 
(N=7,270 M:F 
1:0.74) 
ATP III 
criteria of the 
metabolic 
syndrome 
Individuals with high-
normal TSH levels had an 
almost two-fold higher 
odds of metabolic 
syndrome compared to 
those within the lower 
part of the reference 
range. 
    
Asvold  
Norway 
2011 
Cross-sectional 
analysis of a 
sub-group of 
GFR High TSH within the 
reference range was 
associated with reduced 
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[168] the HUNT 
population 
cohort 
(N=29,480 M:F 
1:2.02) 
eGFR, although the 
effect was modest. This 
trend continued through 
the sub-clinical range 
and into overt 
hypothyroidism.  
 
    
Svare 
Norway 
2011 
[144] 
Prospective 
data from the 
HUNT 2 and 
HUNT 3 
population 
cohort studies 
(N=15,020: M:F 
1:1.97) 
Weight/BMI For each 1.0 mU/l 
increase in TSH amongst 
women, weight 
increased by 0.99 kg and 
BMI increased by 0.3 
kg/m2. In men, for each 
1.0 mU/l increase in 
TSH, weight increased by 
0.8 Kg and BMI increased 
by 0.2 kg/m2  
    
Bassols 
2011 
[167] 
 
Cross-sectional 
analysis of a 
cohort of 
healthy 
euthyroid 
pregnant 
women at 24-28 
weeks 
gestation. 
(N=321) 
 
Hba1c, HMW 
adiponectin, 
placental 
weight 
Low normal serum FT4 
was associated with 
adverse metabolic 
parameters. 
Prats-
Puig 
Spain 
2012 
[166] 
Cross-sectional 
study of 
children 
attending 
primary care 
clinics. 
(N=234: M:F 
1:1.07) 
HMW 
adiponectin, 
HOMA (IR), 
visceral fat 
Pre-pubertal girls with 
low-normal FT4 levels 
have a more 
dysmetabolic 
phenotype. S  
    
BMI = body mass index, TSH = thyroid stimulating hormone, HOMA(IR) = 
insulin resistance 
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3.3.3 The effect of variation in thyroid status within the population 
reference range on bone phenotypes and fracture risk  
Data are summarized in Table 9. Cross-sectional analyses have identified 
that lower levels of TSH and higher levels of thyroid hormone within the 
population reference-range are associated with an increased risk of 
osteoporosis [149-151, 156, 173] and fracture [152, 156]. Data from these 
studies are largely from healthy post-menopausal women; although this 
represents the group at greatest risk, generalizability is limited. Even 
modest variation of 1 unit in TSH and thyroid hormone levels were 
associated with a substantial change in the odds of osteoporosis and 
fracture. There may however be a “threshold effect” as the prevalence 
of vertebral fracture was only substantially increased in individuals with 
a TSH lower than 1.0 mU/l [152]. In keeping with these findings, greater 
bone loss occurs in levothyroxine treated patients with suppressed TSH 
levels than in those without suppression [160, 174]. This reinforces that 
the potential advantages of treating subclinical hypothyroidism may be 
lost if patients develop high-normal or subclinical hyperthyroidism 
through over-replacement. 
 
Data from these studies also highlighted that low levels of TSH, 
independent of thyroid hormone levels, may have an adverse effect on 
bone [150, 152] even in younger individuals [155]. This is particularly 
relevant as peak bone mass determines the structural strength of bone in 
later life [175] and is a major determinant of an individual’s risk of 
osteoporosis and fracture. The relationship between FT3 and fracture 
may be more complex than previously believed as FT3 was strongly 
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positively associated with handgrip and balance [156] key protective 
factors in determining an individual’s falls risk.  
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Table 9 The effect of variation in thyroid status within the 
population reference range on bone outcomes 
Report Study Type Outcome Comments 
Kim 
Korea 
2006 
[149] 
 
Cross-sectional 
hospital-based 
survey of healthy 
postmenopausal 
women.  
(N=950) 
BMD Individuals with low 
normal TSH levels (0.5-
1.1 mU/l) had a 2.2-fold 
increased risk of 
osteoporosis than those 
with high normal TSH 
levels (2.8-5.0 mU/l). 
  
Morris 
USA 
2007  
[150] 
Cross-sectional study 
of healthy post-
menopausal women 
from the National 
Health and Nutrition 
Examination Survey 
(NHANES) (N=581) 
BMD Lower levels of TSH were 
associated with lower 
levels of BMD. 
Individuals with a TSH 
level within the 
reference range, but 
below the median level 
(1.8 mU/l) had increased 
odds of osteoporosis. 
 
Grimnes 
Norway 
2008 
[153] 
5th Tromsø study 
(N=1,961 M:F 1:1.03) 
BMD Individuals with serum 
TSH below the 2.5 
percentile had 
significantly lower BMD 
at the ultra-distal 
(women) and distal 
(both sexes) forearm 
than those with serum 
TSH in the normal range. 
However, within the 
normal range of serum 
TSH, serum TSH was not 
associated with BMD. 
This study had a 
relatively high 
proportion of males 
compared to similar 
studies in this area; 
which may explain the 
lack of association 
between TSH and BMD.  
 
Murphy 
2010 
 [156] 
Osteoporosis and 
ultrasound study 
(OPUS) a 6-year 
prospective 
population cohort 
BMD Within the reference 
range, FT3 (β =-0.087 
p=0.005) and FT4 (β =-
0.091; p=0.004) were 
negatively associated 
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study of healthy 
euthyroid 
postmenopausal 
women 
(N=1,278) 
 
with BMD at the hip. Per 
unit increase, even after 
adjusting for age, BMI 
and BMD, the risk of non-
vertebral fracture was 
increased by 33% in 
individuals with higher 
FT3 (p=0.006) and 20% in 
individuals with higher 
FT4 (p=0.002). In 
contrast, higher levels of 
TSH were protective and 
each unit increase in TSH 
reduced the risk of non-
vertebral fracture by 
35% (p=0.028). FT3 was 
associated with key falls 
risk factors being 
positively associated 
with grip strength 
p=<0.001) and balance 
(p=<0.001).  
 
Kim 
Korea 
2010 
[151] 
Cross-sectional study 
of healthy euthyroid 
men 
(N=1,478) 
BMD The odds of having 
osteopenia and 
osteoporosis were 
increased in subjects 
with low-normal TSH 
(0.4-1.2 mU/l), when 
compared to high-
normal TSH (3.1-5.0 
mU/l), after adjustment 
for confounding (OR = 
1.45, 95%CI = 1.02 - 
2.10). e.  
 
Mazziotti 
Italy 
2010 
[152] 
Cross-sectional study 
of post-menopausal 
women with normal 
thyroid function but 
low BMD 
(N=130) 
Vertebral 
fractures 
Vertebral fractures were 
found to be significantly 
(p = 0.004) more 
prevalent in first tertile 
(56.8%) of TSH values as 
compared with the 
second (23.3%) and third 
tertiles (32.6%). 
Individuals with lower 
serum TSH also had 
increased odds of 
vertebral fractures 
(OR=2.8, 95%CI 1.20–
6.79) even after 
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correction for age, BMD, 
BMI and serum FT4. 
 
Roef 
Belgium 
2011 
[155] 
Cross-sectional study 
of 677 healthy male 
siblings aged 25-45 
years 
BMD There was lower hip BMD 
with increasing FT3 
levels within the 
reference range  but no 
association was seen 
with FT4 or TSH. FT3 was 
also negatively 
associated with lumbar 
spine BMD (β =-0.10, 
p=0.008) but no 
association was 
identified with FT4  or 
TSH  
BMD = bone mineral density, BMI = body mass index, OR= odds ratio TSH 
= thyroid stimulating hormone  
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3.3.4 Overview  
 
 A summary of adverse outcomes by TSH level is shown in Table 10. A 
fixed-effects meta-analysis of the odds ratios of adverse health outcomes 
for higher TSH levels within the reference-range compared to lower 
levels of TSH is shown in Figure 6. There was very strong evidence in the 
fixed-effects meta-analysis that individuals with TSH levels in the upper 
part of the reference-range had increased odds of adverse cardiovascular 
outcomes OR=1.21 (95%CI 1.15-1.27) p=7.99 x10-15 and adverse metabolic 
outcomes OR=1.37 (95%CI 1.27-1.48) p=5.99 x10-15 but lower odds of 
adverse bone outcomes OR=0.55 (95%CI 0.41-0.72) p=1.93 x10-05 
compared to individuals with TSH levels in the lower part of the 
reference-range. Similar associations were observed in the random-
effects model (Figure 7). Overall the models produced similar results, 
however the random-effects is the more desirable, as the fixed effects 
assumes similar effects for each component studied. For instance in the 
various components of cardiovascular outcomes (hypertension, 
cholesterol and mortality) it is unlikely that variation in TSH has similar 
effects for each component. 
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Table 10 Summary of the odds of adverse outcomes for higher TSH 
levels in the top third of the reference-range against TSH levels in 
the lower third of the reference-range 
Report Outcome Odds 
ratio 
95%CI P 
value 
Cardiovascular 
Outcomes 
    
Asvold 2007 Hypertension (F) 1.23 (1.04, 1.46) 0.02 
Asvold 2007 Hypertension (M) 1.98 (1.56, 2.53) <0.001 
Itterman 2012  Hypertension 
(Children) 
1.12 (1.00, 1.25) 0.05 
Itterman 2012 Hypertension 
(Adults) 
1.19 (1.12, 1.26) <0.001 
Asvold 2008 CVS mortality (F) 1.69 (1.14, 2.52) 0.01 
Asvold 2008 CVS mortality (M) 1.20 (0.76, 1.88) 0.43 
Metabolic Outcomes     
Kim 2011 Metabolic Syndrome 1.92 (1.24, 2.98) 0.004 
Ruhla 2010 Metabolic Syndrome 1.70 (1.11, 2.60) 0.01 
Asvold 2009 Obesity (F) 1.30 (1.16, 1.46) <0.001 
Asvold 2009 Obesity (M) 1.53 (1.26, 1.84) <0.001 
Asvold 2011 CKD 1.31 (1.13, 1.52) <0.001 
Bone Outcomes     
Morris 2007 Osteoporosin (F) 0.29 (0.11, 0.77) 0.01 
Kim 2006 Osteoporosis (F) 0.45 (0.25, 0.83) 0.01 
Kim 2010 Osteoporosis (M) 0.69 (0.48, 0.98) 0.04 
Mazzioti Vertebral fracture 
(F) 
0.35 (0.15, 0.83) 0.02 
OR = Odds ratio 
95%CI = 95% confidence interval 
F= Female 
M = Male 
CVS = Cardiovascular 
CKD = Chronic Kidney disease 
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Figure 6 The odds of adverse outcomes for higher TSH levels within the reference range compared to lower levels of TSH 
within the reference range with fixed-effects meta-analysis. 
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Figure 7 The odds of adverse outcomes for higher TSH levels within the reference range compared to lower levels of TSH 
within the reference range with random-effects meta-analysis. 
 
Tau2 for random effects.Cardiovascular outcomes p=0.02 Metabolic outcomes p=0.04 Bone outcomes p=0.06 
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3.3.5 The effect of variation in thyroid status within the population 
reference range on neuropsychological outcomes  
 
Data are summarized in Table 11. Whilst thyroid dysfunction results in 
impaired CNS development [176] and possibly mood [82], the impact of 
variation within the population reference-range is less clear. Analysis in 
HUNT identified that there may be interaction by sex on the association 
between TSH and mood [157]. In this study [157] there was an inverse 
association between serum TSH and depression in males, but no evidence 
of association in females. In females on levothyroxine, TSH was positively 
associated with both depression and anxiety. Analysis of 
neuropsychological outcomes in cohorts of children [177, 178] and older 
individuals have been inconclusive [29, 156, 179-181] most likely due to 
lack of power as these cohorts have been smaller and are prone to type-
2 error or type-1 error and subsequent publication bias.  
 
A meta-analysis identified a positive association between depression and 
FT4 within the reference-range OR=1.12, (95%CI 1.02-1.22) p=0.01 [156]. 
This is in keeping with the observed inverse association between TSH and 
depression in males in the HUNT study [157], but in contrast to traditional 
thinking that higher levels of TSH are associated with increased levels of 
depression. Studies of selective cohorts of individuals with depression are 
inconsistent; individuals with serum TSH concentrations in the upper 25th 
percentile of the normal range were more likely to have more episodes 
of major depression, longer duration of depression and a higher number 
of suicide attempts than patients who had serum TSH concentrations 
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below the upper 25th percentile of the reference-range [182]. However 
in another cohort of individuals with depression, those with a high-normal 
TSH (>2.5mU/l) had lower depression as measured by Hamilton 
Depression Rating scores, fewer anxiety symptoms and less suicidal 
ideation than those with low-normal TSH (<2.5mU/l) [183].These data 
are not from the general population and observed associations may 
instead be due to selection bias, medication effects and reverse 
causation through the effects of major depression on the hypothalamic-
pituitary-thyroid axis. 
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Table 11 The effect of variation in thyroid function within the 
population reference range on neurological/psychological outcomes 
Report Study Type Outcome Comments 
Wahlin 
Sweden 
1998 
[181] 
Cross-sectional 
analysis of a non 
demented elderly 
population cohort 
(N=200) 
Memory skills TSH was positively 
related to episodic 
memory 
performance. No 
association was 
observed with FT4.  
    
Pop 
Belgium 
1999 
[176] 
 
Cohort of 
children, born to 
women with 
without thyroid 
disease 
(N=220 M:F 
1:2.35) 
Childhood 
development 
Children of mothers 
with low thyroid 
hormone  (below the 
10th centile) at 12 
weeks' gestation had 
lower scores on the 
Bayley Psychomotor 
Developmental 
Index scale at 10 
months of age.  
 
Berlin 
France 
1999 
[182] 
In-patients with 
DSM III-R criteria 
for major 
depression. 
(N=94 M:F 1:2.36)  
Depression 
status and 
duration 
Individuals who had 
serum TSH 
concentrations 
greater than the 
upper 25th 
percentile of the 
normal range were 
more likely to have 
higher number of 
episodes of major 
depression  
    
Van Boxtel 
Netherlands 
2004 
[180] 
 
Random sample 
of the Maastrict 
Aging Study 
(N=120 M:F 1:1) 
Memory 
function 
There was a modest 
negative association 
between TSH and 
memory function. 
Gussekloo 
Netherlands 
[29] 
Prospective 
cohort study of 
older individuals 
aged over 85. 
(N=559 M:F 1:2) 
Depressive 
symptoms and 
cognition 
TSH and FT4 were 
not associated with 
disability in daily 
life, depressive 
symptoms, and 
cognitive 
impairment.  
 
Eskelinen 
Finland 
2007 
Cross-sectional 
study of 
Quality of life 
scores MMSE 
There were no 
associations 
between TSH levels 
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[179] indiviuals without 
thyroid disease 
(N = 1086 M:F 
1:1.16)  
 
and self-rated 
health or life 
satisfaction,  
Alvarez-
Pedrerol 
Spain 
2007 
[177] 
Cross-sectional 
study from 2 
small population 
cohorts in 
Menorca and 
Ribera d'Ebre 
(N=342 M:F 
1:1.04) 
Attention 
deficit and 
hyperactivity 
Children in the 
highest quartile for 
TSH, had greater 
odds of having more 
than six attention 
deficit symptoms 
and 1–5 
hyperactivity or 
impulsivity 
symptoms In 
contrast, high FT4 
levels were 
associated with 
decreased odds of 
having 1-5 attention 
deficit symptoms.  
    
Joffe 
USA 
2008 
[183] 
Cross-sectional 
study of 
individuals with 
major depression 
(N=166) 
Depression Individuals with 
higher thyroid 
function were 
significantly more 
depressed, as 
measured by 
Hamilton Depression 
Rating Scale scores, 
and had more 
anxiety symptoms 
and suicidal 
tendencies than 
those with lower 
thyroid function.  
    
Panicker 
Norway 
2009 
[157] 
 
Cross-sectional 
analysis of a 
subgroup of 
individuals in the 
HUNT 2 study 
with serum TSH 
and mood scores. 
Stratified by 
those on 
(N=1,265 all 
female) and not 
on levothyroxine 
Depression 
and anxiety 
There were clear 
differences in the 
relationship 
between TSH and 
mood in males and 
females and also in 
those on 
levothyroxine.  
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(N=27,013 M:F 
1:1.90)  
    
Williams 
UK 
2009 
[156] 
 
Prospective 
cohort study of 
middle aged men 
(45-59 years) 
(N=2,269 all male 
Psychiatric 
morbidity 
(GHQ-30) over 
a mean of 
12.3 years 
follow-up. 
There was a positive 
association between 
total T(4) and 
chronic psychiatric 
morbidity  
    
Hoshiko 
USA 
2011 
[178] 
Case-control 
study of children 
with autistic 
spectrum 
disorder. (N cases 
= 554 with 
regional controls 
N = 784) 
Autistic 
spectrum 
disorder 
Infants with very 
low FT4 (lower than 
the third percentile) 
may have a higher 
risk of autism. 
OR = odds ratio, TSH = thyroid stimulating hormone 
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3.4 DISCUSSION 
We have highlighted that variation in thyroid hormone levels within the 
population reference-range is associated with a wide range of adverse 
health outcomes. Higher TSH levels are associated with worse 
cardiovascular risk factors, metabolic parameters and pregnancy 
outcomes, whereas lower TSH levels are associated with reduced BMD 
and increased risk of osteoporosis and fracture. The evidence-base for 
our findings was generally good for cardiovascular, metabolic, bone and 
pregnancy outcomes, being derived from large population cohorts; 
however high-quality data remains lacking for neurological outcomes and 
most psychological outcome studies were under-powered. 
 
A key aim in studying the relationships between thyroid function within 
the general population and health outcomes was to take advantage of 
large study populations without selection bias to inform the debate on 
thresholds for treating subclinical thyroid disease.  Hence, it might be 
expected that effects attributable to variation in thyroid function across 
the reference-range would be similar if not greater in subjects with 
thyroid function outside this range. The data collated in this report 
suggests that, at least at the population level, treatment of subclinical 
thyroid disease could potentially improve health outcomes. However, 
important limitations need to be taken into account in extrapolating data 
from the reference-range to assess risk of adverse outcomes for 
individuals with subclinical thyroid disease. Most studies in this report 
have been in individuals of white European ancestry which limits 
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generalizability. The majority of studied associations were also with TSH 
only, data are still lacking on the phenotypic consequences of variation 
in FT3 and FT4. Furthermore a substantial proportion of identified 
associations were from cross-sectional analyses, which are prone to 
unmeasured/residual confounding and reverse causation. For example, 
cigarette smoking is associated with reduced TSH concentrations; [184] 
this makes it difficult to accurately assess the effect of thyroid 
dysfunction on association studies with smoking-dependent outcomes, 
such as cardiovascular disease [141]. 
 
There may also be publication bias as negative studies assessing the 
effect of variation of thyroid function in the population reference-range 
on outcomes may be hard to publish. 
 
When considering whether to treat subclinical hypothyroidism, there also 
needs to be careful consideration of the complexities of thyroid hormone 
replacement. For instance the population reference-range by far exceeds 
the variation of the intra-individual set point [71], and although 
levothyroxine treatment will restore an individual’s TSH levels to within 
the ‘normal population range’, this may be outside their genetically 
determined set-point [185]. It is also unclear whether treatment with 
levothyroxine in individuals with subclinical hypothyroidism will 
normalize the odds of developing adverse outcomes, for instance treating 
individuals with levothyroxine will substantially reduce their T3:T4 ratio 
[186] and the long-term consequences of this in patients with subclinical 
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hypothyroidism are currently unclear. The pituitary response as 
measured by changes in TSH may not fully reflect the thyroid status in 
other key organs; for example common variation in DIO2 has been shown 
to influence mood and response to combination T3/T4 therapy [187] and 
osteoarthritis risk [188], but has no effect on serum thyroid hormone 
levels [187].  Hence it is possible, that improving outcomes for 
cardiovascular disease, may at the same time increase the risk of 
osteoporosis in the same individual and the optimal TSH (or indeed the 
premorbid TSH) may be difficult to determine.  Furthermore with current 
practice 40-48% of hypothyroid patients on levothyroxine do not achieve 
target TSH values [42, 189] with many individuals over-treated. Taken 
together, this data provides a strong rationale for the treatment of 
subclinical thyroid disease, but large, carefully designed, long-term, 
randomized clinical trials will be needed to determine the true balance 
of benefits and risks, and optimal thresholds for intervention.  
 
The continuum of effects across the reference-range of thyroid function, 
suggest that it might be more appropriate to consider thyroid hormone 
levels as “risk factors” for disease (similar to blood pressure or 
cholesterol in cardiovascular disease), rather than consider a particular 
level to be “normal” or “abnormal”. In this way of thinking, the net 
benefit of intervention at a particular TSH level, can be related to an 
individual’s comorbidities. For example, more net benefit might be 
obtained in initiating levothyroxine therapy for subclinical 
hypothyroidism in an adult with multiple cardiovascular risk factors than 
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in one with osteoporosis. This approach might then suggest that younger 
adults with cardiovascular risk factors, should be screened for thyroid 
disease, as this will increase the likelihood of identifying patients with 
subclinical disease who might benefit most from intervention [190, 191].  
 
Considering thyroid hormone levels as continuously distributed risk 
factors for different health outcomes may also help inform the debate on 
the upper limit of “normal” TSH The National Academy of Clinical 
Biochemists highlighted that 95% of individuals without evidence of 
thyroid disease or autoantibodies had TSH concentrations below 2.5mU/l 
[192] leading for calls to lower it to this level [90]. However it has been 
argued that lowering the upper TSH limit is unnecessary as treating 
individuals with high-normal TSH is unwarranted and routine 
levothyroxine treatment is not currently recommended for subclinical 
hypothyroidism [91]. Identifying TSH levels at which net benefit for 
intervention can be obtained by treatment in different patient groups by 
prospective studies may be a more relevant goal.  
 
Although no large prospective intervention studies have been performed 
in subclinical hypothyroidism, there have been cohort studies in this area. 
A large individual patient data meta-analysis (N=55,287) from 11 
population cohorts [193] identified that the impact of subclinical 
hypothyroidism on coronary heart disease event only became apparent 
between a TSH level of 7.0-9.9mU/l HR=1.17 (95%CI 0.96-1.43), with no 
clear effect observed for TSH levels between 4.50–6.99mU/l HR=1.00 
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(95%CI 0.86-1.18). However levothyroxine treatment at TSH levels lower 
than 7.00mU/l, especially in younger individuals, may still be beneficial; 
analysis from the UK General Practice Research Database identified in 
individuals under the age of 70 levothyroxine treatment at TSH levels 
between 5-10mU/l reduced the future risk of IHD events HR=0.61 (95%CI 
0.39-0.95) [191]. This is in keeping with our observed differences in the 
odds of adverse cardiovascular outcomes within even the population 
range. 
 
In summary, the data in this chapter has identified that variation in 
thyroid hormone parameters within the population reference-range 
resulted in increased odds of adverse outcomes, but this should not be 
used as justification for treating at risk individuals with thyroid hormone 
parameters within the reference-range (pregnancy aside). In particular, 
data does not support levothyroxine treatment with TSH levels within the 
reference-range for low mood. The potential benefits of treating 
individuals within the normal population range would only be modest and 
over-replacement with levothyroxine is associated with osteoporosis and 
atrial fibrillation [160].  
 
This analysis has highlighted that modest variation in thyroid hormone 
levels are associated with increased odds of developing a wide range of 
adverse health outcomes. Prospective clinical trials in subclinical 
hypothyroidism, which recognize the complexities of thyroid hormone 
replacement, are therefore urgently required. In particular, adequately 
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powered prospective, randomized, controlled, double-blinded long-term 
interventional trials will be required to fully identify the benefits and 
risks of treatment as well as determining appropriate TSH thresholds for 
intervention in different patient groups. 
 
Data here has also indicated that over treating borderline thyroid 
function with levothyroxine, may simply change adverse cardiovascular 
and metabolic risk factors for adverse bone outcomes.   
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Chapter 4 The relationship between thyroid function and body 
composition in children 
As I observed earlier in this thesis variation in TSH levels in adults even 
across the population reference-range is associated with substantial 
differences in body mass index and body composition [143, 145, 146]. 
The relationship between thyroid status and body composition is less well 
understood in children and this is the focus of the chapter. However given 
the importance of thyroid status on growth and development, an 
exploration of the longitudinal stability of TSH and thyroid hormone 
levels is also necessary. 
 
This Chapter has been separated into 3 parts; 4A where I explore the 
longitudinal stability of TSH and thyroid hormone levels in children as 
assessments of body composition were undertaken at in early and late 
puberty. In part 4B I will explore the relationship between thyroid status 
in children and body composition and in part 4C I will use instrumental 
variable analyses to help assess the relationship between FT3 levels and 
body composition as in part 4B I observed an unexpected relationship 
between FT3 and fat mass. 
 
4A.1 INTRODUCTION 
There is limited data on thyroid hormone reference ranges in children, 
particularly with regard to FT3 levels. Whilst it is well established in 
adults that there is narrow intra-individual variation in thyroid hormone 
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parameters compared to inter-individual variation [71] increased 
variance in thyroid hormone levels has been observed throughout 
childhood and adult reference intervals may not be universally applicable 
to children [74, 75, 194]. Previous cross-sectional studies from 
convenience samples have indicated that FT3 substantially falls and FT4 
rises from age 4 [55, 73, 195] but there have been no longitudinal studies 
to confirm these observations.  
 
In this original analysis, I therefore described age and sex reference-
ranges in 4,442 children at age 7 and 1,253 children at age 15 (884 
children had thyroid function measured at both time points). I also 
explored the longitudinal variability of TSH and thyroid hormone levels 
using linear mixed models by sex and pubertal status and also assessed 
the relationship between TSH and thyroid hormone at different time-
points over childhood. 
 
4A.2 METHODS 
4A.2.1 Study participants, laboratory and phenotypic measures 
The ALSPAC cohort has been described in detail in Chapter 2. Serum TSH, 
FT3 and FT4 were measured at age 7 (median age 89 months) by 
chemiluminescent emission using a photomultiplier on cobas® e601 
(Roche Diagnostics, Mannheim Germany) in 4,442 children. Thyroid 
function at age 15 was also performed in 1,253 children (median age 184 
months) using the same method and was available at both age 7 and 15 
in 884 children. Reference-ranges for adults are TSH, 0.27-4.2 mU/liter, 
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FT3 3.9-6.7pmol/liter, FT4 12-22 pmol/liter. Samples were collected 
from 1997 onwards with analysis performed in 2010-2011; it has been 
previously demonstrated that TSH and FT4 can be analyzed reliably in 
samples stored for up to 23 years [196].  
 
Standing height was measured using a wall-mounted Harpenden 
stadiometer (Holtain Ltd., Crymych, UK). Pubertal status was self-
assessed using a Tanner stage questionnaire at age 13.5 years (pubic hair 
domain) range 13.1 to 14.4 years.  Pubertal status used in this analysis 
was stage P1 - prepubertal, lanugo may be present in genital area but it 
is fine and downy. Stage P2  - sparse growth of pubic hair in the midline, 
mainly at the base of the penis or along the labia majora. Stage P3 - more 
hair grows so that it is visible from several feet, along with coarsening 
and increased pigmentation in some people. 
 
One possible confounder for TSH and thyroid hormone levels is iodine 
intake. Iodine rich foods are white fish and dairy products which may 
have a social class bias therefore  additional adjustments were made for 
home circumstances including age of mother at birth of child, parity of 
mother at birth of child (1/1-4/more than 4) maternal smoking during 
pregnancy (none/some), educational status of mother (low=no 
qualifications, certificate of secondary education, or 
vocational/medium=O level/high=A level or degree), Housing status 
(owned or mortgaged/privately rented/council rented), Family adversity 
index (see Appendix 1), Home score (1-4/4-8/9-12 -see Appendix 1). 
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4A.2.2 Statistical Analysis 
Before any analyses were conducted each variable was examined 
carefully using histogram generation and cross-tabulation to identify any 
errors, inconsistencies or grossly abnormal results. For example, males 
and females were examined to ensure they had appropriate 
corresponding pubertal measurements. To ensure the appropriateness of 
using linear regression histograms were generated to clarify whether the 
assumptions of normality of distribution were valid. 
  
Categorical variables were checked for impossible values and any 
identified were recoded as missing. Implausible TSH and thyroid hormone 
levels (> 4 SD from the mean for the sex and age-specific category) were 
considered as outliers and were recoded to missing. TSH was loge 
transformed to an approximately normal distribution. Descriptive 
statistics are presented as geometric means, standard deviations (SD), 
median and 95th centiles.  
 
A linear mixed model with random intercepts and random slopes was used 
to assess the trends of TSH and thyroid hormone parameters over 
childhood [197]. An unstructured variance-covariance matrix was 
assumed. We analyzed the baseline values at age 7, the variability at 
baseline, the longitudinal trend (slope) between age 7 and 15 and the 
variability in the slope. Analyses were performed with sex interactions 
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and sex X puberty interactions. Model simplification was undertaken 
using likelihood ratio tests. 
 
We then explored the relationship between TSH and thyroid hormone 
levels at ages 7 and 15.  Here thyroid function was standardized and 
therefore results are presented as per SD change in the outcome. 
Analyses were initially performed adjusted for age at thyroid 
measurements and sex (model 1). Three further models controlling for 
key potential confounders were undertaken; model 2 also adjusted for 
thyroid hormone parameters, model 3 also adjusted for measures of 
social class and early life environment including home ownership, 
maternal age at birth of child, maternal highest educational 
qualification, maternal smoking in pregnancy, family adversity index and 
parents and home score. Likelihood ratio tests were used to identify if 
there was any evidence of interaction by sex on the relationship between 
thyroid hormone parameters and TSH.  
4A.2.3 Funding of thyroid function performed in ALSPAC 
Thyroid function testing in ALSPAC was undertaken using 2 grants 
obtained by myself and Professor Dayan. These included a BUPA health 
research grant of £45,000 and an Above and Beyond Grant of £10,000. 
The majority of the grants were spent on performing thyroid function at 
age 7, however we had some funds to also perform thyroid function at 
age 15. Age 7 was prioritized over age 15 as data in younger children on 
the role of thyroid function was more limited and this was done to 
maximize the benefits of the grant.    
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4A.3 RESULTS 
4A.3.1 Study population and baseline characteristics 
The derivation of study participant numbers is shown in Figure 8. 
 
Figure 8 Study participants 
 
 
 
Children in our study dataset were more likely to have several higher 
markers of affluence and fewer early life events than the remainder of 
the ALSPAC cohort (Table 12). This may influence generalizability, 
although no clear relationship were seen with thyroid status and social 
class in analyses.  
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Table 12 Comparison of the study cohort to the remainder of the 
ALSPAC cohort 
Variable Study 
Cohort 
Remaining 
ALSPAC cohort† 
*p 
value 
Child Sex (% Male) 52.3 50.9 0.14 
Family Adversity Index Mean 
(SD) 
4.67 
(4.42) 
3.88  
(3.94) 
<0.001 
Home Score 
0-4 (%) 
5-8 (%) 
9-12 (%) 
 
3.39 
24.0 
72.6 
 
4.64 
24.0 
72.5 
0.003 
Housing Status 
Owned/mortgaged (%) 
Privately rented (%) 
Council rented/other (%) 
 
82.9 
13.3 
3.8 
 
69.1 
25.1 
5.8 
<0.001 
Maternal age at birth of child 
(years) Mean (SD) 
 
29.1 
(4.55) 
 
27.5  
(5.06) 
<0.001 
Maternal highest educational 
status 
Low (%) 
Middle (%) 
High (%) 
 
20.9 
35.1 
44.0 
 
34.4 
34.3 
31.3 
<0.001 
Maternal smoking in pregnancy 
None (%) 
Some (%) 
 
82.1 
17.9 
 
72.2 
27.8 
<0.001 
Parity 
0 - 1 (%) 
2 – 4 (%) 
> 5 (%) 
 
81.1 
18.7 
0.2 
 
 
79.2 
20.2 
0.7 
<0.001 
*Calculated using the Wald test 
†Remaining ALSPAC cohort defined as women who enrolled in the core 
ALSPAC sample with children surviving to 1 year (N= 14,701) p = strength 
of evidence against the null hypothesis of no difference in characteristics 
between study population and remainder of the ALSPAC cohort 
 
4A.3.2 Serum thyroid hormone levels in children at ages 7 and 15 
At age 7 years, the mean and 95% reference range values for TSH, FT3 
and FT4 were 2.26 (0.93 - 4.48) mU/l 6.29 (5.13 - 7.59) pmol/l and 15.7 
(12.7 – 19.3) pmol/l respectively (Table 13). 23.2% of children at age 7 
years had a FT3 above the adult reference range, with only 3.65% of 
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children having a TSH and 0.2% of children having FT4 values above the 
adult reference-range (Table 13 Figure 9). At age 15 years, the mean 
and 95% reference range values for TSH, FT3 and FT4 were 2.43 (0.91 – 
5.05) mU/l 5.83 (4.45 - 7.35) pmol/l and 15.5 (11.9 – 20.3) pmol/l 
respectively (Figure 10), with a marked reduction in children having FT3 
above the adult reference-range to 12.2% (Table 13).  
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Table 13 Reference-range for thyroid hormone parameters age 7 and age 15  
 Age (years) All Males   Females   
  N Mean (2.5-97.5%) 
%  
above 
ARR  
%  
below 
ARR 
N Mean (2.5-97.5%) 
 
% 
 above 
ARR  
 
 
% 
below 
ARR 
N Mean (2.5-97.5%) 
 
%  
above 
ARR 
 
% 
below 
ARR 
TSH (mU/l)  4,442 2.26 0.93 - 4.48 3.65 0 2,323 2.32 0.97 - 4.50 3.57 0 2,119 2.20 0.88 – 4.45 3.73 0 
FT3 (pmol/l) 7 4,442 6.29 5.13 – 7.59 23.2 0.09 2,323 6.23 5.07 – 7.56 19.8 0.17 2,119 6.35 5.16- 7.59 26.9 0 
FT4 (pmol/l)  4,422 15.7 12.7 – 19.3 0.20 0.70 2,323 15.6 12.7 – 19.0 0.17 0.73 2,119 15.9 12.9 – 19.6 0.24 0.66 
                 
                 
TSH (mU/l)  1,263 2.43 0.91 – 5.05 6.33 0 644 2.51 0.91- 5.17 7.92 0 619 2.34 0.87 – 5.00 4.68 0 
FT3 (pmol/l) 15 1,263 5.83 4.45 – 7.35 12.2 0.55 644 6.16 4.84 – 7.6 20.7 0 619 5.48 4.23 – 6.91 3.39 1.13 
FT4 (pmol/l)  1,263 15.5 11.9 – 20.3 0.79 2.69 644 15.5 11.8 – 20.2 0.62 2.95 619 15.5 12.0 – 20.6 0.97 2.42 
N=Number 
ARR= Adult reference range 
TSH = Thyroid stimulating hormone 
FT3 = Free tri-iodothyronine 
FT4 = Free thyroxine  
 
 
85 
Figure 9 Histograms of TSH, FT3 and FT4 levels at age 7 
 
Figure 10 Histograms of TSH, FT3 and FT4 levels at age 15 
 
Vertical bars represent the limits of reference range for adults (TSH, 0.27-4.2 mU/l, FT3 3.9-6.7pmol/l, FT4 12-22 
pmol/l) 
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4A.3.3 Linear mixed models analysis in children with thyroid function 
at age 7 and age 15 
TSH levels rose between ages 7 and 15 years whereas both FT3 and FT4 
levels fell. Strong negative correlations were observed in the models for 
TSH, FT3 and FT4 indicating that those with higher levels at age 7 years 
were more likely to have greater reductions, and those with lower levels 
at age 7 were likely to have small reductions by age 15, i.e. a 
convergence of biomarkers (Table 14). Every 2 years between ages 7 and 
15 years, TSH levels increased by 0.03 mU/l (95%CI 0.02, 0.05)  p <0.001. 
Boys had a higher baseline TSH than girls at age 7 years of 0.11mU/l 
(95%CI 0.06, 0.17) p <0.001. There was no difference in mean gain 
between boys and girls between ages 7 and 15 years b=0.0001 (95%CI -
0.001, 0.001) p=0.83 and no difference in variability at baseline -0.04 
(95%CI -0.10, 0.03) p=0.29 or in the variability of the slope b= 5.73x10-06  
(95%CI -0.0002, 0.0003) p=0.65  (Tables 15 and 16). 
 
For FT3 every 2 years between the ages of 7 and 15 years, FT3 levels fell 
0.12 pmol/l (95%CI -0.13, -0.10). Girls had a higher baseline FT3 level than 
boys 0.13pmol/l (95%CI 0.09, 0.17) p <0.001. However boys had a more 
substantial gain in FT3 than girls B=0.008 (95%CI 0.007, 0.009) p<0.001. 
There was no substantial difference by sex in variability at baseline 
B=0.02 (95%CI  -0.01, 0.05) p=0.29, or in variability in slope b = 7.85x10-
06 (95%CI -5.18x10-06, 2.01x10-05) p=0.24 (Tables 14-16). Every 2 years FT4 
levels fell 0.04 pmol/l (95%CI -0.07, -0.01) p=0.005. Girls had a higher 
baseline FT4 level than boys of 0.38pmol/l (95%CI 0.28, 0.48) p<0.001, 
however boys had a higher mean gain b =0.004 (95%CI 0.002, 0.006) 
 
 
87 
p=0.001. As a result boys had a higher FT3 than girls by age 15. Girls also 
had more variability at baseline at age 7 years b =0.38 (95%CI 0.14, 0.62) 
p=0.002 although there was no difference in variability in slope 
b=4.47x10-05 (95%CI 5.12x10-07, 0.001) p=0.33 (Tables 15 and 16).
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Table 14 Overall linear mixed models for TSH FT3 and FT4 
 Parameter       b  95% CI P-Value 
TSH 
(mU/l) All 
Main 
effects 
Age 7 years 2.27 2.24, 2.32  
Slope  0.0013 0.0007, 0.002 <0.001 
Variability 
SD@ Age 7 years 1.62 1.56 1.67  
SD Slope 0.14 0.13, 0.14  
 Correlation(int,slope) -0.87 -0.89, -0.86  
FT3 
(pmol/l) All 
Main 
effects 
Age 7 years 6.29 6.27, 6.31  
Slope  -0.005 -0.005, -0.004  
Variability 
SD@ Age 7 years 1.28 1.24, 1.32 <0.001 
SDSlope 0.12 0.11, 0.12  
 Correlation(int,slope) -0.92 -0.93, -0.91  
FT4 
(pmol/l) All 
Main 
effects 
Age 7 years 15.7 15.7, 15.8  
Slope  -0.002 -0.03, -0.0005 0.005 
Variability 
SD@ Age 7  3.03 2.92 3.14  
SDSlope 0.27 0.26, 0.28  
  Correlation(int,slope) -0.86 -0.88, -0.84  
SD = Standard Deviation 
95%CI = 95% Confidence interval 
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Table 15 Linear mixed models for TSH FT3 and FT4 in boys 
 Parameter       b  95% CI P-Value 
TSH 
(mU/l) Boys 
Main 
effects 
Age 7 2.32 2.28 2.36 <0.001 
Slope  0.001 0.0005 0.002 0.002 
Variability 
SD@ Age 7  0.9 0.87 0.92  
SDSlope 0.01 0.01 0.01  
 Correlation(int,slope) -0.46 -0.52 -0.39  
FT3 
(pmol/l) Boys 
Main 
effects 
Age 7 6.23 6.2 6.25 <0.001 
Slope  -0.0005 -0.001 0.00009 0.09 
Variability 
SD@ Age 7  0.63 0.61 0.64  
SDSlope 0.009 0.008 0.009  
 Correlation(int,slope) -0.58 -0.63 -0.53  
FT4 
(pmol/l) Boys 
Main 
effects 
Age 7 15.5 15.4 15.6 <0.001 
Slope 0.0003 -0.001 0.002 0.72 
Variability 
SD@ Age 7 1.63 1.58 1.68  
SDSlope 0.022 0.021 0.023  
 Correlation(int,slope) -0.41 -0.48 -0.34  
SD = Standard Deviation 
95%CI = 95% Confidence interval 
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Table 16 Linear mixed models for TSH FT3 and FT4 in girls 
 Parameter         b                        95% CI              P-Value 
TSH 
(mU/l) Girls 
Main effects 
Age 7 2.21 2.17 2.24 <0.001 
Slope 0.001 0.0004 0.002 <0.001 
Variability 
SD@ Age 7 0.92 0.89 0.95  
SDSlope 0.01 0.01 0.01  
 Correlation(int,slope) -0.52 -0.58 -0.46  
FT3 
(pmol/l) Girls 
Main effects 
Age 7 6.36 6.33 6.38 <0.001 
Slope -0.009 -0.01 -0.08 <0.001 
Variability 
SD@ Age 7 0.61 0.59 0.63  
SDSlope 0.009 0.008 0.009  
  Correlation(int,slope) -0.61 -0.66 -0.56  
FT4 
(pmol/l) Girls 
Main effects 
Age 7 15.9 15.8 16 <0.001 
Slope -0.004 -0.006 -0.002 <0.001 
Variability 
SD@ Age 7 1.74 1.69 1.8  
SDSlope 0.022 0.21 0.22  
  Correlation(int,slope) -0.42 -0.49 -0.35  
SD = Standard Deviation 
95%CI = 95% Confidence interval 
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4A.3.4 Relationship between pubertal status at age 13 and TSH and 
thyroid hormone parameters at aged 7 and 15 
2,702 children also had pubertal status self-assessed at age 13 years as 
well as having thyroid function measured. Pubertal status at age 13 years 
was not associated with TSH levels at age 7 in boys (p=0.89) or girls 
(p=0.31). No detectable difference in TSH slope by pubertal status was 
observed in boys (p=0.82) or girls (p=0.82). Pubertal status at age 13 years 
was not also associated with FT4 levels at age 7 years in boys (p=0.32) or 
girls (p=0.52). However, FT3 levels at age 7 years were higher in boys 
(p=0.0001) and girls (p=0.04) with more advanced puberty at age 13 years 
(Tables 17 and 18). More advanced pubertal status at age 13 years was 
however associated with a negative FT3 slope unlike early pubertal status 
which had a positive FT3 slope in both boys and girls (p=<0.001). This 
suggests that FT3 levels may peak in the very early stages of puberty as 
these changes appear to occur even before age 7. The negative slope 
indicates that FT3 falls throughout puberty after this peak. There was 
weak evidence of any difference in the variability of baseline values or 
gradients of slopes by pubertal status in either boys or girls for either FT3 
or FT4. 
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Table 17 Linear mixed models for TSH FT3 and FT4 by pubertal status in boys (Tanner pubic hair domain) at age 
13 years 
    P1 P2 P3 
 Parameter       b  95% CI P-Value b 95% CI P-Value b 95% CI P-Value 
TSH Boys 
Main effects 
Age 7 2.37 2.28 2.46 <0.001 2.4 2.3 2.51 <0.001 2.38 2.29 2.46 <0.001 
Slope  0.002 0 0.004 0.05 0.001 -0.001 0.003 0.19 0.001 -0.001 0.002 0.26 
Variability 
SD@ Age 7  0.92 0.85 0.98   0.94 0.86 1.01   0.94 0.88 1.01  
SDSlope 0.01 0.01 0.01   0.01 0.01 0.01   0.01 0.01 0.01  
 Correlation(int,slope) -0.47 -0.59 -0.34   -0.41 -0.57 -0.26   -0.46 -0.58 -0.33   
T3 Boys 
Main effects 
Age 7 6.14 6.08 6.2 <0.001 6.18 6.11 6.25 <0.001 6.32 6.26 6.38 <0.001 
Slope  0.002 0.0003 0.003 0.01 0 -0.001 0.001 0.99 -0.003 -0.004 -0.002 <0.001 
Variability 
SD@ Age 7  0.63 0.59 0.68   0.59 0.54 0.64   0.63 0.58 0.67  
SDSlope 0.008 0.007 0.009   0.01 0.008 0.01   0.009 0.008 0.01  
 Correlation(int,slope) -0.53 -0.64 -0.41   -0.66 -0.77 -0.56   -0.62 -0.71 -0.52   
T4 Boys 
Main effects 
Age 7 15.6 15.4 15.7 <0.001 15.6 15.5 15.8 <0.001 15.5 15.3 15.6 <0.001 
Slope -0.004 -0.007 -0.001 0.02 -0.004 -0.008 -0.001 0.02 0.005 0.002 0.009 0.001 
Variability 
SD@ Age 7 1.58 1.47 1.69   1.6 1.46 1.73   1.66 1.54 1.77  
SDSlope 0.02 0.02 0.03   0.02 0.02 0.03   0.02 0.02 0.03  
 Correlation(int,slope) -0.5 -0.62 -0.38   -0.5 -0.64 -0.36   -0.33 -0.47 -0.19   
              
b= Beta co-efficient, SD = Standard Deviation 
95%CI = 95% Confidence interval 
P1 = Pubertal status 1, P2= Pubertal status 2, P3 = Pubertal status 3 
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Table 18 Linear mixed models for TSH FT3 and FT4 by pubertal status in girls (Tanner pubic hair domain) at age 
13 years 
     P1    P2    P3   
Parameter    b 95%CI  P Value b 95%CI  P Value b 95%CI  P Value 
TSH Girls 
Main 
effects 
Age 7 2.16 2.04 2.28 <0.001 2.28 2.17 2.39 <0.001 2.2 2.13 2.27 <0.001 
Slope 0.0004 -0.001 0.002 0.71 0.001 -0.001 0.003 0.21 0.001 -0.003 0.002 0.15 
Variability 
SD@ Age 7 0.86 0.76 0.94   0.95 0.87 1.02   0.92 0.88 0.97  
SDSlope 0.01 0.01 0.01   0.01 0.01 0.01   0.01 0.01 0.01  
 Correlation(int,slope) -0.6 -0.74 -0.45   -0.57 -0.7 -0.45   -0.52 -0.61 -0.44   
T3 Girls 
Main 
effects 
Age 7 6.27 6.19 6.36 <0.001 6.27 6.2 6.34 <0.001 6.37 6.32 6.41 <0.001 
Slope -0.007 -0.009 -0.005 <0.001 -0.007 -0.008 -0.006 <0.001 -0.01 -0.01 -0.01 <0.001 
Variability 
SD@ Age 7 0.6 0.54 0.66   0.63 0.57 0.68   0.62 0.59 0.65  
SDSlope 0.008 0.007 0.01   0.008 0.006 0.009   0.009 0.008 0.01  
  Correlation(int,slope) -0.77 -0.86 -0.68   -0.57 -0.7 -0.44   -0.6 -0.67 -0.52   
T4 Girls 
Main 
effects 
Age 7 15.9 15.6 16.2 <0.001 15.8 15.6 16 <0.001 15.9 15.8 16 <0.001 
Slope -0.004 -0.008 0.0003 0.07 -0.002 -0.006 0.002 0.43 -0.004 -0.006 -0.001 0.005 
Variability 
SD@ Age 7 1.88 1.68 2.06   1.79 1.64 1.93   1.77 1.68 1.86  
SDSlope 0.02 0.02 0.02   0.02 0.02 0.03   0.02 0.02 0.03  
  Correlation(int,slope) -0.42 -0.61 -0.23   -0.43 -0.58 -0.27   -0.43 -0.53 -0.33   
b= Beta co-efficient, SD = Standard Deviation 
95%CI = 95% Confidence interval 
P1 = Pubertal status 1, P2= Pubertal status 2, P3 = Pubertal status 3 
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4A.3.5 Relationship between TSH and serum thyroid hormone levels 
in children at ages 7 and 15 years 
At age 7 years, TSH was weakly positively associated with FT3 after 
adjusting for age sex, FT4 and markers of social class and early life 
environment b (standardised) =0.03 (95%CI 0.001, 0.06) p=0.05 whereas 
TSH was clearly negatively associated with FT4 b (standardised) =-0.07 
(95%CI -0.10, -0.04) p=3.49x10-05 (Table 19). A similar pattern was also 
observed at age 15 years even after adjusting for pubertal status with 
TSH positively associated with FT3 b (standardised) =0.07 (95%CI 0.02, 
0.13) p=0.01 and negatively associated with FT4 b (standardised) =-0.13 
(95%CI -0.19, -0.07) p=5.16x10-06 (Table 19). FT3 and FT4 were positively 
associated with each other at age 7 years B (standardised) =0.27 (95%CI 
0.24, 0.30) p=1.12x10-14 and also at age 15 years, b (standardised) =0.19 
(95%CI 0.12, 0.26) p=4.23x10-07. 
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Table 19 Relationships between TSH and other thyroid hormone parameters (standardized) at age 7 and age 15 
Model FT3 (pmol/l) FT4 (pmol/l) 
 b (standardised) 95%CI p* b (standardised) 95%CI p* 
Age 7 (N=4,442) 
Model 1 0.01 -0.02, 0.04 0.56 -0.07 -0.10, -0.04 1.09x10-06 
Model 2 0.03 0.001, 0.06 0.05 -0.08 -0.10, -0.05 1.63x10-07 
Model 3 0.03 0.001, 0.06 0.05 -0.07 -0.10, -0.04 3.49x10-05 
Age 15 (N =1,263) 
Model 1 0.06 0.01, 0.11 0.02 -0.08 -0.14, -0.03 0.003 
Model 2 0.08 0.03, 0.12 0.002 -0.10 -0.15, -0.04 4.17x10-05 
Model 3 0.08 0.03, 0.13 0.001 -0.12 -0.17, -0.06 3.38x10-06 
Model 4 0.07 0.02, 0.13 0.01 -0.13, -0.19, -0.07 5.16x10-06 
* Calculated using the Wald test B=Beta coefficient CI = Confidence interval 
p = strength of evidence against the null hypothesis of no association 
Model 1 adjusted for age and sex 
Model 2 adjusted for Model 1 and other thyroid hormone parameters 
Model 3 adjusted for Model 2 and markers of social class and early life environment (home ownership, maternal age at birth of 
child, maternal highest educational qualification, maternal smoking in pregnancy, family adversity index and parents and home 
score)  
Model 4 adjusted for Model 3 and tanner stage 
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4A.4 DISCUSSION 
My analysis shows that there are substantial changes in the pituitary-
thyroid axis over childhood. In particular, FT3 changes much more over 
childhood than either TSH or FT4.  Levels of FT3 at age 7 are high 
compared to adult values with almost 25% of children at age 7 years have 
a FT3 level above the adult reference-range and although there is a 
substantial fall in FT3 levels between age 7 years and age 15 years, over 
10% of values at age 15 years are still above the adult reference-range. 
Of note, FT3 levels fall more rapidly in girls, so that by age 15 none are 
above the adult reference range. As a result, girls had a higher FT3 than 
boys at age 7 years, but by age 15 years this had reversed with boys now 
having higher FT3 levels. In contrast to FT3, changes in TSH and FT4 levels 
were modest: FT4 values showed almost no change and were already 
largely within the adult range at age 7; TSH values showed a small rise 
(Figures 9 and 10) 
 
In all models, there was a very strong negative correlation between 
hormone levels between age 7 and 15, this suggests that the substantial 
variability observed in childhood is reduced through puberty, with 
hormones levels converging to near adult reference values. Overall my 
data suggests that there may be higher conversion of FT4 to FT3 in younger 
children than adults. My observation that boys maintain a higher FT3 for 
longer than girls is also noteworthy and may have substantial importance 
in observed sex differences in bone development [198].   
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The reason why children have higher FT3 levels at age 7 years is unclear 
but may be due to external factors to the pituitary-thyroid axis such as 
fat mas, growth hormone and pubertal development. In this analysis I 
observed that children that reached puberty earlier (as indicated by more 
advanced self-reported pubertal stage at age 13 years) had higher FT3 
values at age 7 years and a negative FT3 slope between ages 7 and 15 
years whereas those with less advanced puberty had a positive FT3 slope 
between ages 7 and 15 years. This is also in keeping with our observation 
that girls having a higher FT3 than boys at age 7 years with a greater fall 
in between ages 7 and 15 years.  
 
These changes are more marked in girls than in boys, such that by age 
15, although girls have a higher proportion of fat mass than boys at this 
age, FT3 levels are lower. Our observed changes may also be partly due 
to thyroid derived changes in preparation for puberty, or as a 
consequence of other factors such as growth hormone, as growth 
hormone therapy has been linked to marginally increased FT3 and 
decreased FT4 levels [199]. 
 
Further changes in FT3 must occur beyond age 15 especially in boys and 
those with later puberty onset, resulting finally in values within the adult 
reference range, and indeed it appears that falls in FT3 occur even later 
in adult life [200] in males which may have implications for thyroid 
hormone replacement and treatment targets in children. 
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These findings are also clinically relevant, given the striking differences 
observed in early childhood thyroid hormone levels from adult derived 
reference-ranges. If age and sex appropriate reference ranges are not 
used, there may be substantial under-diagnosis of sub-clinical thyroid 
disease in children. In addition, the finding that children have 
substantially higher FT3 levels than adults has implications for thyroid 
hormone replacement in congenital hypothyroidism. Individuals on 
levothyroxine have a higher FT4 and a lower FT3 than euthyroid 
individuals despite having similar TSH levels [185, 186]. Children on 
levothyroxine might therefore have inadequate FT3 levels for optimal 
development and this merits further study particularly as FT3 levels may 
have a more important role in both the assessment and therapy of thyroid 
disease than previously assumed [201].  The relative lack of FT3 in these 
children may potentially be one of the reasons that optimal IQ levels are 
not reached in children with congenital hypothyroidism despite adequate 
levothyroxine therapy [202]. Taken together, there remains a pressing 
need for further study of central and peripheral determinants of thyroid 
function as well as determinants of intracellular thyroid status. 
 
Strengths of this analysis include the use of a large population birth 
cohort with detailed phenotypic and genetic data available with paired 
thyroid function in a substantial number of individuals which allows more 
robust analysis than those performed from cross-sectional convenience 
samples. The nature of the cohort means it is unlikely that interfering 
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medications or heterophilic antibodies have influenced results. 
Furthermore, our use of liner mixed models has allowed us to determine 
the change of TSH and thyroid hormone levels between ages 7 and 15, 
whilst simultaneously adjusting for an individual’s baseline hormone 
levels, indication this approach allows us to investigate how variability 
reduces as children progress into adulthood. Limitations of this analysis 
include that only 2 time points were used more thyroid function at ages 
5, 11 and 18 years might enable us to better understand the trajectory 
of thyroid function over childhood.  A higher social class bias in our 
dataset and lack of generalizability to ethnic minorities as 98% of all 
samples analyzed were in individuals of Caucasian descent. Furthermore 
all individuals were from a small region of the UK which has been shown 
to be borderline iodine deficient [203]. Pubic hair domain of the Tanner 
stage could only be used as other domains were unreliable with some 
individuals appearing to regress over puberty; this may be due to the fact 
that parents completed these pubertal assessments in a written 
questionnaire. Our findings require replication in individuals from other 
ethnic groups and using different thyroid hormone assays. Ideally TPO 
antibody levels should have been measured to perform reference range 
analysis in individuals who had no evidence of underlying autoimmune 
thyroid disease, however TPO antibodies were unavailable in this cohort 
although the number of children with substantial thyroid disease from 
TPO positivity are likely to be small. 
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In summary, this part of the chapter demonstrates that thyroid hormone 
levels change substantially during childhood, in particular FT3 which is 
substantially higher in younger children and has a different relationship 
to FT4 with TSH. This is the first analysis to utilize longitudinal data from 
a population birth cohort rather than cross-sectional convenience 
samples enabling us to explore the trends in TSH and thyroid hormone 
levels and their inter-relationships in childhood and for the first time 
study how their longitudinal stability relates to pubertal status. 
 
Taken together, these data suggests that the regulation and the role of 
FT3 may be different from that of FT4. It appears that the regulation on 
FT4 is primarily regulated by the HPT axis although FT3 appears to be 
more fluid. This FT3 fluidity is also observed in sick euthyroidism, which 
is observed in unwell individuals where FT3 levels tend to be low, with 
relative preservation of TSH and FT4. This work also raises the issue that 
the primary roles of FT3 and FT4 may be different as FT4 is tightly 
regulated by the HPT axis, whereas FT3 is influenced by other factors. 
From this analysis, it is unclear whether the FT3 rise in very early puberty 
is necessary for pubertal progression or simply a response to other factors 
such as changes in growth hormone levels. The original observation in my 
initial analyses that FT3 and FT4 had a different association with fat mass 
with FT3 being surprisingly positively associated with fat mass. Studying 
this relationship between thyroid status and body composition will be the 
focus of the next part of this chapter (4B). 
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4B.1 INTRODUCTION   
The relationship between pathological thyroid dysfunction and body 
composition is well established, with hyperthyroidism associated with 
weight loss and hypothyroidism associated with weight gain [204, 205]. 
As I observed in the meta-analysis undertaken earlier in this thesis 
(chapter 3) higher levels of TSH were associated with higher levels of BMI.  
Although this relationship has not been studied in children. Longitudinal 
studies have highlighted that weight gain is associated with an increase 
in TSH levels [145] whereas weight loss is related to decreased TSH and 
also surprisingly to decreased FT3 levels [206]. Cross-sectional studies 
have indicated that FT3 is positively associated with BMI and fat mass 
whereas FT4 is negatively associated [155, 207-209].  
 
In this section of the thesis I will explore the relationship between thyroid 
status and body composition using data from ALSPAC. 
 
4B.2 METHODS 
4B.2.1 Study participants and phenotypes 
The ALSPAC cohort has already been described in detail in chapter 2 BMI 
was calculated as weight (in kilograms) divided by height (in meters) 
squared. As a measure of adiposity BMI has several limitations [210]; in 
particular, it does not reliably distinguish between fat and lean mass. 
Therefore, total fat mass was also assessed using a Lunar Prodigy narrow 
fan beam densitometer to perform a whole-body dual-energy x-ray 
absorptiometry (DXA) scan. Additional details of these measurements, 
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including their reproducibility, are described elsewhere [211]. The fat 
mass index (FMI) was also calculated as total fat mass (in kilograms) 
divided by height (in meters) squared. Data on BMI were collected at ages 
7 and 15 years with anthropometric data from DXA performed at ages 9.9 
and 15.5 years. 
 
4B.2.2 Statistical Analysis 
Implausible height, weight, BMI, fat mass, lean mass, blood pressure and 
thyroid measurement (>4 SD from the mean for the sex and age-specific 
category) were considered as outliers and recoded to missing. TSH and 
fat mass were natural log transformed to approximate the normal 
distribution. Descriptive statistics are presented as backtransformed 
(geometric) means, standard deviations (SD), medians and lower and 
upper quartiles. All thyroid, body composition and blood pressure 
variables were standardized; analyses are therefore presented as per SD.  
 
Analyses were adjusted for several key confounders these included child 
derived variables – sex of child, age of child at assessments in months and 
thyroid. Due to the intimate relationship between social class and home 
environment on weight and body composition analyses were adjusted for 
maternal age at birth of child, parity of mother at birth of child, maternal 
smoking during pregnancy, educational status of mother, markers of 
affluence including housing status, family adversity index and HOME 
score. Further details of these confounders are available in Appendix 1.   
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Analyses were initially performed adjusted for child’s age at 
measurements and sex (model 1). Sex is likely to be associated with 
differences in thyroid function and body composition so is a key 
confounder. Age at thyroid measurements may influence thyroid status 
although little is known regarding this. Where appropriate, three further 
models controlling for key potential confounders were undertaken. These 
were selected markers of social class. The ALSPAC cohort is borderline 
iodine deficient[203], social class may influence diet particularly iodine 
in the diet and in turn has a key impact on body composition so this is 
important to include in models Model 2 also adjusted for thyroid hormone 
parameters, model 3=model 2 adjusted for height, measures of social 
class and early life environment including home ownership, maternal age 
at birth of child, maternal highest educational qualification, maternal 
smoking in pregnancy, family adversity index and parents and home score 
listed below. Height was included in model 3 as although BMI was 
designed to assess weight independently of height, it remains correlated 
with height owing to its generalized derivation. Analysis of 
anthropometric relationships with thyroid hormone status at age 15 also 
incorporated pubertal status (model 4) which was assessed using a Tanner 
stage questionnaire [198] at age 13.5 years (pubic hair domain) range 
from 13.1 to 14.4 years.   
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4B.3 RESULTS 
4B.3.1 Study population and baseline characteristics 
3,014 individuals (1,542 males, 1,472 females) had relevant thyroid, body 
composition and other phenotypic data available (Figure 11).  
Figure 11 Study participants for thyroid and body composition 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
473 (16.6%) of children in our study population were obese or overweight 
at age 7; 373 were classified as overweight with 100 classified as obese 
according to cutoffs proposed by the International Obesity Task Force 
[212]. 
 
4B.3.2 Observational analysis of baseline characteristics 
There was a good correlation between BMI at age 7 years and FMI at age 
9 years (Pearson's correlation coefficient=0.73). Height and lean mass 
were both greater in males (126.5cm vs. 125.7cm p<0.001)  (25.6Kg vs. 
14,701 children in the ALSPAC cohort 
alive at 1 year of age. 
10,268 children did not have thyroid 
function available 
 
4,433 children had full thyroid function 
available at age 7 
 1419 children did not have DXA and 
body composition available  
 
3,014 children with genetic 
data also available 
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23.7Kg p<0.001) respectively, however BMI and fat mass were greater in 
females (16.0kg/m2 vs. 16.3kg/m2 p <0.001)  (9.46kg vs. 7.10kg p<0.001).  
Baseline characteristics are shown in Table 20  
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Table 20 Baseline characteristics for body composition analysis  
1 2 children with missing data for weight at age 9, 2 323 children with missing data, 3 277 children 
with missing data, 4 215 children with missing data, 5 224 children with missing data, 6 201 children 
with missing data, 7 226 children with missing data. 
 
Variable All (N=3,014) Males (N=1,542) Females (N=1,472) 
 Mean or 
percentage 
SD Mean or 
percentage 
SD Mean or 
percentage 
SD 
BMI  age 7 (Kg/m2) 16.1 1.89 16.0 1.76 16.3 2.09 
Height age 7 (cm) 126.1 5.61 126.5 5.56 125.7 5.64 
Weight age 7 (kg) 25.8 4.34 25.7 4.16 25.9 4.51 
Fat mass measured 
by DXA (kg) 
8.26 4.77 7.10 4.53 9.46 4.71 
Body fat percentage 
[fat mass 
(kg)/weight 
(kg)]x1001 
22.6 8.69 19.4 18.26 25.9 7.87 
Lean mass measured 
by DXA (kg) 
24.7 3.11 25.6 2.89 23.7 3.05 
Age at DXA 
assessment (months) 
90.3 3.92     
Age 7 
FT3(pmol/liter) 
6.28 0.62 6.22 0.62 6.34 0.62 
Age 7 FT4 
(pmol/liter)  
15.7 1.66 15.5 1.58 15.9 1.71 
Age 7 TSH 
(mU/l) 
2.28 0.91 2.36 0.90 2.20 0.90 
Age 15 
FT3(pmol/liter) 
5.84 0.74 6.19 0.69 5.50 0.63 
Age 15 FT4 
(pmol/liter)  
15.4 1.90 15.4 1.98 15.4 1.84 
Age 15 TSH (mU/l)  2.33 1.00 2.43 1.05 2.24 0.93 
Family Adversity 
Index2  
3.71 4.45 3.73 3.87 3.69 3.80 
Home Score3 
0-4 (%) 
5-8 (%) 
9-12 (%) 
 
3.47 
23.9 
72.7 
  
2.77 
23.2 
74.1 
  
4.21 
24.6 
71.2 
 
Housing Status4 
Owned/mortgaged 
(%) 
Privately rented (%) 
Council 
rented/other (%) 
 
85.6 
11.0 
3.3 
  
85.6 
11.8 
2.7 
  
85.6 
10.2 
4.0 
 
Maternal age at 
childbirth (years) 
29.4 4.2 29.5 4.5 29.4 4.3 
Maternal highest 
educational status5 
Low (%) 
Middle (%) 
High (%) 
 
 
18.4 
34.8 
46.8 
  
 
19.3 
35.5 
45.2 
  
 
17.4 
34.1 
48.5 
 
Maternal smoking in 
pregnancy6 
None (%) 
Some (%) 
 
 
84.5 
15.5 
  
 
84.3 
15.7 
  
 
84.7 
15.2 
 
Parity7 
0 - 1 (%) 
2 – 4 (%) 
> 5 (%) 
 
82.1 
17.9 
0.2 
  
80.9 
18.7 
0.28 
  
83.4 
16.6 
0.07 
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4B.3.3 Relationship between thyroid status and body composition 
BMI at age 7 years was positively associated with FT3 at age 7 years Beta 
(β) standardized (standardised)=0.13 (95%CI 0.10, 0.16) p=5.3x10-16 and 
fat mass at age 9 β  (standardised)=0.18 (95%CI: 0.15, 0.21) p=4.3x10-25 
even after adjustment for confounders (Table 21). FT3 was also 
positively associated with lean mass β (standardised)=0.10 (95%CI: 0.06, 
0.13) p=6.6x10-09. However, adding fat mass to this model attenuated the 
association (β (standardised)=0.02, 95%CI: -0.02, 0.04 p=0.32). In 
contrast adjusting for lean mass in the relationship between FT3 and BMI 
and FT3and fat mass had no substantial effect on effect estimates β 
(standardised)=0.07 (95%CI: 0.04, 0.10) p=7.7x10-07 and β 
(standardised)=0.12 (95%CI: 0.09, 0.16) p=5.7x10-14 respectively. 
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Table 21 Associations between measures of adiposity and thyroid hormone parameters at age 7 
 
 TSH  
(mU/l) 
FT3 
pmol/liter FT4 pmol/liter FT3FT4 Ratio# 
 N b (std) 95%CI p* B (std) 95%CI p* b (std) 95%CI p* b(std) 95%CI p* 
  BMI (age 7) 
Model 
1 
3,014 0.03 0.004, 0.06 0.05 0.13 0.10, 0.16 5.3x10-16 -0.05 -0.08, -0.02 0.001 0.15 0.12, 0.18 1.4x10-20 
Model 
2 
3,014 0.02 -0.01, 0.06 0.13 0.16 0.13, 0.19 6.6x10-21 -0.10 -0.13, -0.06 1.6x10-08 - - - 
Model 
3 
3,014 
0.03 -0.004,0.07 0.09 0.12 0.08, 0.16 4.0x10-10 -0.08 -0.12, -0.04 0.00003 0.12 0.09, 0.16 5.7x10-11 
  Weight (age 7) 
Model 
1 
3,014 0.02 -0.01, 0.05 0.15 0.11 0.08, 0.14 8.1x10-17 -0.04 -0.07, 0.02 0.001 0.13 0.10, 0.15 8.4x10-22 
Model 
2 
3,014 0.01 -0.01, 0.04 0.35 0.13 0.11, 0.16 5.2x10-22 -0.08 -0.11, -0.05 6.3x10-09 - - - 
Model 
3 
3,014 
0.02 -0.001, 0.05 0.08 0.09 0.06, 0.13 5.6x10-10 -0.05 -0.08 -0.03 0.0001 0.08 0.06, 0.11 2.0x10-07 
  Fat mass (age 9)  
Model 
1 
3,014 
0.01 -0.02, 0.04 0.74 0.18 0.15, 0.21 4.3x10-25 -0.04 -0.08, -0.01 0.02 0.18 0.15, 0.21 1.8x10-25 
Model 
2 
3,014 -0.003 -0.03, 0.03 0.87 0.21 0.17, 0.24 1.1x10-30 -0.10 -0.13, -0.06 2.6x10-08 - - - 
Model 
3† 
2,538 
-0.008 -0.04, 0.03 0.64 0.12 0.09, 0.16 4.0x10-12 -0.07 -0.10, -0.03 0.002 0.11 0.08, 0.14 8.0 x10-11 
 FMI (age 9) 
Model 
1 
3,014 
0.01 -0.03, 0.04 0.75 0.17 0.13, 0.20 1.5x10-22 -0.04 -0.07, 0.002 0.04 0.17 0.14, 0.20 1.5x10-22 
Model 
2 
3,014 -0.003 -0.04, 0.03 0.84 0.19 0.16, 0.23 2.1x10-27 -0.10 -0.13, -0.06 2.4x10-07 - - - 
Model 
3† 
2,538 
-0.01 -0.04, 0.02 0.65 0.13 0.09, 017 3.9x10-12 -0.07 -0.11, -0.03 0.002 0.12 0.08, 0.15 7.9x10-11 
  Lean mass (age 9) 
Model 
1 
3,014 
0.01 -0.02, 0.06 0.18 0.10 0.06, 0.13 6.6x10-09 -0.05 -0.09, -0.02 0.002 0.12 0.09, 0.16 1.7x10-13 
Model 
2 
3,014 0.02 -0.02, 0.05 0.35 0.12 0.09, 0.15 3.4x10-12 -0.09 -0.12, -0.05 8.9x10-07 - - - 
Model 
3† 
2,538 0.02 -0.01, 0.04 0.11 0.01 -0.02, 0.03 0.56 -0.03 -0.05,-0.01 0.01 0.02 -0.0001, 0.04 0.05 
*Calculated using the Wald test † 476 individuals with missing data # Not adjusted for other thyroid hormone parameters N=Number B=Beta coefficient CI = 
Confidence interval p = strength of evidence against the null hypothesis of no association std=standardised Model 1 adjusted for age and sex Model 2 adjusted 
for Model 1 and other thyroid hormone parameters   Model 3 adjusted for Model 2 and height, markers of social class and early life environment (home 
ownership, maternal age at birth of child, maternal highest educational qualification, maternal smoking in pregnancy, family adversity index and parents and 
home score)  
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FT4 was negatively associated with fat mass β (standardised)=-0.04 
(95%CI: -0.08, -0.01) p=0.02 and lean mass β (standardised)=-0.05 (95%CI: 
-0.09, -0.02) p=0.002 as well as height and weight (Table 21). No clear 
associations between TSH and body composition were observed even 
after adjusting for confounders and other thyroid hormone parameters. 
 
Similar cross-sectional associations were also observed with thyroid 
hormone parameters at age 15 years and BMI at age 15 years for FT3and 
FT3:FT4 ratio, however effect estimates were weaker (Table 22). Much 
weaker or no associations were observed with other components of body 
composition.  Analysis revealed that for every 0.20 kg/m2 increase in FMI 
between ages 9 and 15 years there was a 0.10pmol/l increase in 
FT3(p=0.005). 
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Table 22 Relationship between thyroid hormone parameters and body composition at age 15 (N=730) 
 TSH (mU/l) FT3 pmol/liter FT4 pmol/liter FT3FT4 Ratio# 
 b (std) 95%CI p* b (std) 95%CI p* b (std) 95%CI p* b (std) 95%CI p* 
 BMI (age 15) 
Model 1 0.02 -0.05, 0.08 0.62 0.07 -0.01, 0.14 0.09 -0.05 -0.12, 0.01 0.13 0.10 0.03, 0.17 0.009 
Model 2 0.005 -0.07, 0.08 0.89 0.08 -0.001, 0.16 0.05 -0.07 -0.14, 0.01 0.07 - - - 
Model 3 0.02 -0.05, 0.09 0.64 0.07 -0.01, 0.15 0.10 -0.05 -0.12, 0.03 0.21 0.08 0.01, 0.17 0.03 
Model 4 -0.02 -0.10, 0.06 0.60 0.09 -0.001, 0.19 0.05 -0.07 -0.15, 0.01 0.08 0.11 0.02, 0.19 0.02 
 Weight (age 15) 
Model 1 0.01 -0.06, 0.07 0.85 0.02 -0.05, 0.10 0.54 -0.01 -0.08, 0.05 0.69 0.03 -0.04, 0.10 0.43 
Model 2 0.002 -0.07, 0.07 0.94 0.03 -0.05, 0.10 0.50 -0.02 -0.09, 0.05 0.62 - - - 
Model 3 0.01 -0.06, 0.07 0.79 0.03 -0.05, 0.11 0.54 -0.004 -0.07, 0.07 0.91 0.02 -0.05, 0.10 0.53 
Model 4 -0.03 -0.10, 0.05 0.46 0.06 -0.03, 0.14 0.20 -0.05 -0.13, 0.02 0.17 0.07 -0.01, 0.14 0.11 
 Height (age 15) 
Model 1 -0.01 -0.07, 0.04 0.62 -0.07 -0.13, 0.002 0.04 0.06 0.004, 0.12 0.03 -0.11 -0.17, -0.05 0.01 
Model 2 -0.001 -0.06, 0.06 0.98 -0.08 -0.14, -0.01 0.02 0.07 0.02, 0.13 0.01 - - - 
Model 3† -0.002 -0.06, 0.06 0.95 -0.07 -0.13, 0.001 0.05 0.07 0.01, 0.12 0.03 -0.10 -0.15, -0.03 0.004 
Model 4†† -0.01 -0.07, 0.06 0.84 -0.04 -0.11, 0.03 0.30 0.01 -0.06, 0.08 0.79 -0.04 -0.11, 0.03 0.26 
 Fat mass (age 15)  
Model 1 0.01 -0.05, 0.07 0.72 0.03 -0.03, 0.10 0.32 -0.03 -0.09, 0.03 0.33 0.06 -0.003, 0.12 0.06 
Model 2 0.004 -0.06, 0.07 0.89 0.04 -0.03, 0.11 0.25 -0.03 -0.09, 0.03 0.35 - - - 
Model 3† 0.01 -0.05, 0.07 0.80 0.03 -0.03, 0.10 0.38 -0.03 -0.10, 0.03 0.30 0.06 -0.01, 0.12 0.08 
Model 4†† -0.01 -0.08, 0.06 0.70 0.04 -0.05, 0.12 0.37 -0.06 -0.13, 0.01 0.10 0.07 -0.002, 0.15 0.06 
               FMI (age 15) 
Model 1 0.01 -0.04, 0.07 0.66 0.04 -0.02, 0.10 0.19 -0.04 -0.09, 0.02 0.19 0.07 0.01, 0.13 0.02 
Model 2 0.004 -0.05, 0.06 0.88 0.05 -0.01, 0.12 0.13 -0.04 -0.10, 0.01 0.13 - - - 
Model 3† 0.01 -0.05, 0.07 0.79 0.04 -0.03, 0.11 0.24 -0.04 -0.10, 0.02 0.17 0.07 0.01, 0.13 0.03 
Model 4†† -0.01 -0.08, 0.05 0.72 0.04 -0.04, 0.12 0.29 -0.06 -0.13, 0.01 0.10 0.08 0.005, 0.15 0.04 
 Lean mass (age 15) 
Model 1 -0.005 -0.05, 0.04 0.82 -0.04 -0.09, 0.01 0.09 0.02 -0.02, 0.06 0.41 -0.05 -0.10, -0.01 0.02 
Model 2 0.001 -0.04, 0.05 0.95 -0.05 -0.10, 0.003 0.07 0.02 -0.03, 0.06 0.42 - - - 
Model 3† 0.002 -0.04, 0.05 0.93 -0.04 -0.09, 0.02 0.16 0.03 -0.02, 0.07 0.21 -0.05 -0.09, -0.003 0.05 
Model 4†† -0.02 -0.07, 0.03 0.41 0.01 -0.05, 0.07 0.80 -0.01 -0.07, 0.04 0.71 -0.002 -0.06, 0.05 0.93 
† 51 individuals with missing data †† 202 individuals with missing data B=Beta coefficient CI = Confidence interval, std 
= standardized p = strength of evidence against the null hypothesis of no association Model 1 adjusted for age and sex 
Model 2 adjusted for Model 1 and other thyroid hormone parameters   Model 3 adjusted for Model 2 and height, markers 
of social class and early life environment (home ownership, maternal age at birth of child, maternal highest educational 
qualification, maternal smoking in pregnancy, family adversity index and parents and home score) Model 4 adjusted 
for Model 3 and Tanner stage  
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4B.4 DISCUSSION 
My observational analyses clearly show that FT3 and FT4 have opposing 
strong correlations with body composition in childhood; with FT3 being 
positively associated and FT4 negatively associated with fat mass and BMI. 
This effect persisted after adjusting for key confounders. Even residual 
confounding would be unlikely to explain such striking opposite 
relationships between FT3 and FT4 on body composition. Furthermore, 
this effect appeared to be more pronounced at age 7, an age when we 
also observed substantially higher FT3 levels.  
 
This finding is in keeping with other smaller recent studies have also 
shown that in healthy euthyroid adults FT3 is positively associated with 
BMI and measures of adiposity whereas FT4 is negatively associated [155, 
207-209]. It is also in keeping with the observation that obese individuals 
have higher FT3 levels [207, 213] although other studies have reported 
higher FT4 levels as well in morbidly obese patients[214]. 
 
The nature of our cross-sectional analysis is such that we cannot  
determine whether higher FT3 levels in children result in higher fat mass 
through its effect on growth or whether higher levels of fat mass either 
increase FT3 levels directly or via a response from the HPT axis. This is 
an important issue to address as the nature of the FT3 fat mass 
relationship has substantial implications for our understanding of the 
thyroid axis as well as body composition.  
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To explore this relationship further I undertook additional instrumental 
variable analyses to better clarify the relationship between FT3 and fat 
mass, this is described in the next part of the chapter (4C).   
 
  
 
 
113 
4C.1 INTRODUCTION 
My observed positive association between FT3 and BMI/fat mass were 
derived from cross-sectional analyses and therefore vulnerable to reverse 
causation and confounding. An alternative approach is to investigate the 
effect of genetic variation in levels of the exposure on the outcome of 
interest, this approach is widely known as Mendelian Randomization (MR) 
[215].  The genetic architecture of BMI is well understood [216], however 
whilst TSH and to a lesser extent FT4 have been studied there has been 
no genome-wide association studies of FT3 to date [217, 218]. Therefore 
the approach I will use is to see if genetic variation in variants associated 
with BMI is associated with changes in FT3 levels. This analytical 
approach may enable us to clarify the nature of the relationship between 
body mass index and FT3 and assess whether changes in BMI /fat mass 
causally affect thyroid status.  
 
The use of MR in analyses is based on the random allocation of genetic 
variants from parents to offspring. This random allocation means that 
these variants will generally be unrelated to other factors which affect 
the outcome  of interest [219]. The MR approach applies instrumental 
variable methods, using genetic variants as a proxy for the exposure of 
interest. In this method, the use of genetic instruments associated with 
BMI confers several advantages above traditional regression analysis [215, 
219, 220]. First, the direction of causation is from the BMI genetic 
instruments onto FT3, and cannot be due to reverse causation as FT3 
levels cannot cause genetic variation. Second, BMI is associated with a 
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wide range of behavioural, social and physiological factors that might 
confound its association with FT3. The use of genetic variants associated 
with BMI substantially reduces the risk of this confounding and they can 
be regarded as an unconfounded indicators [221]. Third, genetic variants 
and their effects are subject to relatively little measurement error or 
bias.   
 
As alleles are largely passed from parents to offspring independently of 
the environment, offspring who inherit more alleles associated with BMI 
are in effect being randomly assigned a higher BMI dosage. Several 
assumptions need to be met, firstly that the genotype is associated with 
the exposure, secondly that the genotype is associated with the outcome 
through the studied exposure only (exclusion restriction assumption), 
third that the genotype is independent of other factors which may 
influence the outcome (independence assumption). However, there are 
potential violations that can occur which can negate these 
assumptions[219]. These include i) Population stratification - the 
presence of a systematic difference in allele frequencies between 
subpopulations. ii) Linkage disequilibrium – the non-random association 
of alleles at different loci in a given population which can lead to spurious 
associations. iii) Pleiotropic effects –  where when one variant influences 
two or more seemingly unrelated phenotypic traits. iv) Canalisation -the 
ability of a population to produce the same phenotype regardless of 
variability of its environment or genotype 
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With the above caveats, MR can therefore be thought of as analogous to 
a randomized trial with randomization by genotype taking place at 
conception. A by-genotype analysis is equivalent to an intention-to-treat 
analysis in a randomized controlled trial, in which individuals are 
analysed according to the group they were randomized into, independent 
of whether they complied to the treatment regimen or not.  
 
In this section of the thesis, I now undertook MR analyses to examine the 
nature of the relationship between BMI and FT3. I used 32 independent 
genetic correlates of BMI, confirmed in a large-scale meta-analysis of 
genome-wide association studies [216], to assess whether there is a 
causal pathway between BMI and FT3 levels which would explain the 
paradoxical opposing relationship between FT3and FT4 on BMI in 
observational studies.  
4C.2. METHODS 
Details on the ALSPAC cohort have been described in chapter 2 and 
laboratory measures and DXA scans have been described in detail earlier 
in this chapter.  
4C.2.1Genotyping 
Genotyping in ALSPAC has been previously described [222]. GWAS data 
was generated by Sample Logistics and Genotyping Facilities at the 
Wellcome Trust Sanger Institute and LabCorp (Laboratory Corportation of 
America) using support from 23andMe. Single nucleotide polymorphisms 
(SNPs) were removed if the minor allele frequency (MAF) was <1%, the 
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call rate was <95% or the p-value from an exact test of Hardy-Weinberg 
equilibrium was <5.7x10-7. Individual samples were excluded on the basis 
of incorrect sex assignment, minimal or excessive heterozygosity, high 
levels of missingness and cryptic relatedness (16%). Established BMI 
variants that had not been genotyped directly were imputed with MACH 
1.0.16 Markov Chain Haplotyping software [223, 224]  using CEPH 
individuals from HapMap phase 2 (release 22) reference set. 
 
4C.2.2 Instrumental variable analysis 
Speliotes et al. previously reported 32 genetic variants to be robustlt  
associated with BMI [216]. These are shown in Table 23.  
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Table 23 Details of SNPs associated with adiposity in a large GWAS 
meta-analysis by Speliotes et al 
SNP Nearest Gene Chromosome 
Base pair 
position 
Coefficient 
from GWAS 
 for weighting 
rs1514175 TNNI3K 1 74,764,232 0.07 
rs1555543 PTBP2 1 96,717,385 0.06 
rs2815752 NEGR1 1 72,585,028 0.13 
rs543874 SEC16B 1 176,156,103 0.22 
rs2867125 TMEM18 2 612,827 0.31 
rs2890652 LRP1B 2 142,676,401 0.09 
rs713586 RBJ 2 25,011,512 0.14 
rs887912 FANCL 2 59,156,381 0.1 
rs13078807 CADM2 3 85,966,840 0.1 
rs9816226 ETV5 3 187,317,193 0.14 
rs10938397 GNPDA2 4 44,877,284 0.18 
rs13107325 SLC39A8 4 103,407,732 0.19 
rs2112347 FLJ35779 5 75,050,998 0.1 
rs4836133 ZNF608 5 124,360,002 0.07 
rs206936 NUDT3 6 34,410,847 0.06 
rs987237 TFAP2B 6 50,911,009 0.13 
rs10968576 LRRN6C 9 28,404,339 0.11 
rs10767664 BDNF 11 27,682,562 0.19 
rs3817334 MTCH2 11 47,607,569 0.06 
rs4929949 RPL27A 11 8,561,169 0.06 
rs7138803 FAIM2 12 48,533,735 0.12 
rs4771122 MTIF3 13 26,918,180 0.09 
rs10150332 NRXN3 14 79,006,717 0.13 
rs11847697 PRKD1 14 29,584,863 0.17 
rs2241423 MAP2K5 15 65,873,892 0.13 
rs12444979 GPRC5B 16 19,841,101 0.17 
rs1558902 FTO 16 52,361,075 0.39 
rs7359397 SH2B1 16 28,793,160 0.15 
rs571312 MC4R 18 55,990,749 0.23 
rs2287019 QPCTL 19 50,894,012 0.15 
rs29941 KCTD15 19 39,001,372 0.06 
rs3810291 TMEM160 19 52,260,843 0.09 
SNP = Single nucleotide polymorphism 
An ‘allelic score’ was then created by summing the dosages for BMI-
increasing alleles across all 32 SNPs [225]. Here the dose of the effect 
allele at each locus was weighted by the effect size of the variant in this 
independent meta-analysis [216]; these doses were then summed to 
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reflect the average number of effect weighted BMI increasing alleles 
carried by an individual. This combined score was able to explain a 
greater proportion of variance in BMI than single SNPs [226] and served 
as a genetic predictor in our MR analysis. This approach has previously 
been used in ALSPAC to study the relationship between adiposity and 
physical activity in children [227]. 
 
For investigating associations between the allelic score and standardized 
phenotypes, continuous effects were estimated using linear regression 
with adjustment for models as above. An additive genetic model was 
assumed since there was no evidence for interaction effects among the 
SNPs combined in the allelic score [216, 228]. Although co-variates are 
anticipated to be randomly distributed with respect to genotype [215] we 
also examined associations between confounders and genotypes to check 
the core instrumental variable assumption that the genetic instrument 
(BMI allelic score) is independent of factors that might potentially 
confound the observational association [219], and allow for comparison 
with conventional observational epidemiological models. 
 
We then performed a two-stage least squares regression using the 
weighted allelic score as an instrument for BMI/adiposity using the 
“ivreg2” command in Stata. F-statistics from the first-stage regression 
between genotype and BMI/adiposity were examined to check the 
assumption that the instrument is sufficiently associated with the 
exposure to reduce the possibility of weak instrument bias [229]. Using 
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the “ivendog’ command in Stata the Durbin-Wu-Hausman (DWH) test for 
endogeneity was performed to compare effect estimates from the second 
stage of the instrumental variable analysis and estimates from linear 
regression. Models were repeated as described above. 
4C.2.3 Sensitivity analyses 
To explore the potential distorting effects of pleiotropy in our analysis 
we repeated our analyses using two independent genetic instruments. 
Pleiotropy occurs when a genetic instrument has an effect on the 
outcome (FT3) independently of its effect on the exposure (adiposity), 
which has implications for key assumptions made in MR analyses [230]. 
Similar instrumental variable estimates acquired using two independent 
instruments would provide suggestive evidence against the existence of 
a pleiotropic effect, as it would be unlikely that both instruments had 
shared pleiotropy [230]. The two independent genetic instruments were 
rs1558902 in FTO (the individual SNP with the largest effect size on BMI 
identified by Speliotes et al. [216]), and a weighted allelic score 
constructed from the remaining 31 SNPs associated with BMI. 
 
All data analysis was performed using Stata version 12.1 (STATACORP, 
College Station, TX).  
4C.3 RESULTS 
4C.3.1 Genotypic associations 
The “allelic score” for BMI was normally distributed with a mean of 29.1 
(SD 3.87 range 15.1–45.0) and explained 2.29% of the variance in 
standardized BMI and 2.93% of the variance in standardized FMI. 
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A per allele change in allelic score was associated with a 0.04 (95%CI: 
0.03, 0.04) SD increase in BMI (p=6.41×10−17) at age 7 years, a 0.04 SD 
increase (95%CI: 0.04, 0.05) in FMI (p=4.87x10-21) at age 9 years and a 
0.05 SD increase (95%CI: 0.04, 0.06) in BMI at age 15 years (p=1.16x10-
16). In contrast to measures of adiposity, confounding factors were not 
associated with the allelic score in this cohort aside from a weak 
association for maternal smoking in pregnancy, likely representing a 
type-1 error (Table 24). 
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Table 24 Associations between the weighted allelic score for 32 SNPs 
and potential confounders at ages 7 and 15 years 
 
Confounders Per allele effects 
 b 95%CI b (std) 95%CI p* 
FT4 (age 7) 0.0003 -0.02, 0.02 0.0002 -0.01, 0.01 0.97 
TSH (age 7) -0.003 -0.01, 0.001 -0.01 -0.02, 0.001 0.15 
FT4 (age 15)
1 -0.007 -0.04, 0.03 -0.004 -0.02, 0.02 0.69 
TSH (age 15)1 -0.009 -0.02, 0.0002 -0.02 -0.04, 0.0005 0.06 
Maternal agegroup 0.01 -0.005, 0.008 - - 0.66 
Maternal education2 -0.005 -0.02, 0.07 - - 0.43 
Parity3 0.008 -0.002, 0.005 - - 0.67 
Maternal smoking4 0.004 0.001, 0.007 - - 0.04 
FAI5 -0.02 -0.05, 0.02 - - 0.38 
Own home6 0.002 -0.003, 0.006 - - 0.48 
Parents and home score7 0.004 -0.001, 0.009 - - 0.15 
*Calculated using the Wald test 
b=Beta coefficient 
CI = Confidence interval  
p = strength of evidence against the null hypothesis of no association 
1 2,279 children with missing data, 2 224 children with missing data 3 226 
children with missing data 4 201 children with missing data 5323 children 
with missing data 6 215 children with missing data 7 277 children with 
missing data  
  
4C.3.2 Mendelian Randomization 
Genetic analysis demonstrated that a higher BMI of 1 SD (1.89kg/m2) at 
age 7 years was associated with a 0.22 pmol/liter (95% CI, 0.07, 0.36) 
increase in FT3 (p=0.004) (Table 25). We did not observe strong evidence 
of a departure of instrumental-variable-derived estimates from 
observational results, as demonstrated by DWH tests (p=0.08), indicating 
similarity between observational and MR estimates in the effect of BMI 
on FT3. Point estimates for standardized effect sizes from the 
instrumental variable analysis were greater (0.30 vs. 0.13) than those 
derived from basic observational analyses. Similar results were observed 
when FMI at age 9 years was instrumented (Table 25). In contrast there 
was no substantial evidence of an association with FT4 β 
(standardised)=0.01 (95%CI: -0.23, 0.24) p=0.96 (Table 25).  The higher 
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b observed with genetic rather than traditional analysis might be 
explained by FT3 having a negative effect on fat mass (which was 
originally expected) however the effect of fat mass on FT3 is far greater 
thus resulting in a positive association. 
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Table 25 Associations between body mass index/fat mass index and FT3and FT4 levels at age 7 as tested both by 
conventional epidemiological approaches and through the application of instrumental variable analysis using a 
32-SNP weighted allelic BMI score 
 
Adiposity Model N Observational Linear Regression Instrumental Variable Regression (Weighted Allelic Score with 32 SNPs) 
   b (95% CI) b (std) (95% CI) p        F-Statistic Partial R2 b  (95% CI) B(std) (95% CI) p p (DWH) 
 FT3age 7 
BMI(kg/m2) Model 1 3,014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16) 5.3x10-16 72.4 0.009 0.22 (0.07, 0.36) 0.35 (0.11, 0.58) 0.004 0.08 
Age 7 Model 2 3,014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.6x10-21 73.7 0.009 0.22 (0.08, 0.36) 0.35 (0.143 0.57) 0.002 0.09 
 Model 3† 2,538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 4.0x10-13 56.6 0.08 0.24 (0.06, 0.42) 0.38 (0.09, 0.68) 0.01 0.06 
            
FMI(kg/m2) Model 1 3,014 0.22 (0.17, 0.26) 0.17 (0.13 0.20) 1.5x10-22 100.4 0.03 0.19 (0.07, 0.31) 0.30 (0.10, 0.50) 0.002 0.21 
Age 9 Model 2 3,014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.1x10-27 100.7 0.11 0.19 (0.08, 0.31) 0.31 (0.12, 0.50) 0.001 0.22 
 Model 3† 2,538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.9x10-12 79.5 0.09 0.20 (0.05, 0.35) 0.32 (0.08, 0.56) 0.008 0.14 
 FT4 age 7 
BMI(kg/m2) Model 1 3,014 -0.07 (-0.10, -0.03) -0.05 (-0.08, -0.02) 0.001 72.4 0.01 0.01 (-0.37, 0.40) 0.01 (-0.23, 0.24) 0.96 0.58 
Age 7 Model 2 3,014 -0.12 (-0.16, -0.08) -0.10 (-0.13, -0.06) 1.6x10-08 67.6 0.11 -0.18 (-0.56,0.20) -0.11(-0.34, 0.12) 0.35 0.92 
 Model 3† 2,538 -0.09 (-0.14, -0.05) -0.08 (-0.12, -0.04) 0.00003 46.8 0.10 -0.11 (-0.58,0.38) -0.06(-0.36, 0.23)  0.68 0.92 
            
FMI(kg/m2) Model 1 3,014 -0.01 (-0.02, -0.001) -0.04 (-0.07, -0.002) 0.04 100 0.02 -0.01 (-0.33, 0.32) -0.004 (-0.21, 0.20) 0.97 0.81 
Age 9 Model 2 3,014 -0.03 (-0.04, -0.02) -0.09 (-0.13, -0.06) 2.4x10-07 90.3 0.11 -0.18 (-0.51, 0.14) -0.11(-0.32, 0.09) 0.28 0.76 
 Model 3† 2,538 -0.02 (-0.03, -0.01) -0.07 (-0.11, -0.03) 0.002 74.1 0.11 -0.07 (-0.47, 0.34) -0.04(-0.28, 0.21) 0.75 0.76 
† 476 individuals with missing data N=Number B=Beta coefficient CI = Confidence interval std = standardized 
p = strength of evidence against the null hypothesis of no association 
p(DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from 
linear regression and instrumental variable analysis 
Model 1 adjusted for age and sex Model 2 adjusted for Model 1 and other thyroid hormone parameters 
Model 3 adjusted for Model 2 and height, markers of social class and early life environment (home ownership, maternal 
age at birth of child, maternal highest educational qualification, maternal smoking in pregnancy, family adversity index 
and parents and home score) 
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Similar results were also observed when assessing FT3 and adiposity data for 
individuals at age 15 years (Tables 26 and 27) with no evidence of difference 
in the regression estimates at ages 7 and 15 years (p=0.88).  
 
Table 26 Associations between the weighted allelic BMI score for 32 
SNPs and measures of adiposity at ages 7, 9 and 15 years.  
Measures of adiposity Per allele effects 
 b 95%CI b (std) 95%CI p* 
BMI (age 7) 0.07 0.06, 0.09 0.04 0.03, 0.04 6.41x10-17 
FMI (age 9) 0.01 0.007, 0.01 0.04 0.04, 0.05 4.87x10-21 
Fat mass age 9 (kg) 0.20 0.16, 0.25 0.04 0.03, 0.05 3.71x10-20 
BMI (age 15) 0.16 0.12, 0.19 0.05 0.04, 0.16 1.16x10-16 
FMI (age 15) 0.01 0.008, 0.01 0.04 0.03, 0.05 1.06x10-10 
Fat mass age 15 (kg) 0.03 0.02, 0.04 0.04 0.03, 0.05 1.62x10-11 
*Calculated using the Wald test  
B=Beta coefficient 
CI = Confidence interval 
p = strength of evidence against the null hypothesis of no association 
std = standardized 
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Table 27 Associations between body mass index/fat mass index and FT3levels at age 15 as tested both by conventional 
epidemiological approaches and through the application of instrumental variable analysis using a 32-SNP weighted allelic score 
 
Adiposity FT3age 15 N Linear Regression Instrumental Variable Regression (Weighted Allelic Score with 32 SNPs) 
   b (95% CI) B (std) (95% CI) p-Value F-Statistic Partial R2 b (95% CI) B(std) (95% CI) p-Value p-Value (DWH) 
BMI (kg/m2) Model 1 730 0.04 (-0.01, 0.09) 0.06 (-0.01, 0.12) 0.09 32.2 0.10 0.31 (0.05, 0.57) 0.42 (0.07, 0.77) 0.02 0.02 
Age 15 Model 2  0.05 (-0.004, 0.10) 0.07(-0.001, 0.13) 0.05 32.4 0.11 0.35 (0.09, 0.60) 0.47 (0.12, 0.81) 0.008 0.01 
 Model 3†  0.04 (-0.01, 0.09) 0.06 (-0.01, 0.12) 0.10 28.7 0.12 0.34 (0.07, 0.61) 0.46 (0.09, 0.83) 0.02 0.02 
            
FMI (kg/m2) Model 1 730 0.04 (-0.02, 0.10) 0.06 (-0.03, 0.14) 0.19 29.1 0.08 0.40 (0.07, 0.74) 0.54 (0.09, 1.00) 0.02 0.02 
Age 15 Model 2  0.05 (-0.01, 0.11) 0.06 (-0.02, 0.14) 0.13 29.3 0.08 0.45 (0.11, 0.79) 0.60 (0.15, 1.06) 0.009 0.008 
 Model 3†  0.04 (-0.02, 0.10) 0.05 (-0.03, 0.14) 0.24 27.1 0.10 0.43 (0.08, 0.78) 0.57 (0.11, 1.04) 0.02 0.01 
 
†51 children with missing details 
b=Beta coefficient 
CI = Confidence interval 
std = standardized 
p = strength of evidence against the null hypothesis of no association 
p(DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from linear regression and 
instrumental variable analysis 
 
Model 1 adjusted for age and sex 
Model 2 adjusted for Model 1 and other thyroid hormone parameters 
Model 3 adjusted for Model 2 and markers of social class and early life environment (home ownership, maternal age at birth of child, maternal 
highest educational qualification, maternal smoking in pregnancy, family adversity index and parents and home score)  
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4C.3.3 MR analysis using multiple independent instruments 
Results of genetic analysis using rs1558902 in FTO (the individual SNP with 
the largest effect size on BMI) were compared with those of a weighted 
allelic score consisting of the remaining 31 genetic variants (Tables 28 
and 29) and both revealed a positive association with individuals with a  
higher BMI having higher FT3 levels making pleiotropy unlikely. Again, no 
evidence of association was observed with FT4 levels (Tables 28 and 29). 
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Table 28 Associations between body mass index/fat mass index and FT3 and FT4 levels at age 7 as tested both by 
conventional epidemiological approaches and through 31 SNPs (excluding FTO) 
Adiposity Model N Linear Regression Instrumental Variable Regression (Weighted Allelic Score with 31 SNPs) 
   b (95% CI) b (std) (95% CI) p-Value         F-Statistic Partial R2 b (95% CI) B(std) (95% CI)a p-Value p-Value (DWH) 
 31 SNPs (all SNPs excluding FTO) 
 FT3age 7 
BMI(kg/m2) Model 1 3,014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16) 5.3x10-16 73.6 0.008 0.19 (0.04, 0.33) 0.30 (0.07, 0.53) 0.01 0.17 
Age 7 Model 2 3,014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.6x10-21 75.1 0.10 0.19 (0.05, 0.32) 0.30 (0.08, 0.52) 0.007 0.21 
 Model 3† 2,538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 3.0x10-13 57.9 0.07 0.20 (0.03, 0.38) 0.33 (0.04, 0.61) 0.02 0.14 
            
FMI(kg/m2)† Model 1 3,014 0.22 (0.17, 0.27) 0.17 (0.13, 0.20) 1.5x10-22 98.1 0.04 0.16 (0.04, 0.29) 0.26 (0.06, 0.46) 0.01 0.45 
Age 9 Model 2 3,014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.1x10-18 98.6 0.12 0.17 (0.05, 0.28) 0.27 (0.08, 0.46) 0.06 0.43 
 Model 3† 2,538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.5x10-18 77.6 0.10 0.17 (0.03, 0.32) 0.28 (0.04, 0.51) 0.02 0.26 
 FT4 age 7 
BMI(kg/m2) Model 1 3,014 -0.07 (-0.10, -0.03) -0.05 (-0.08, -0.02) 0.001 71.9 0.01 0.03 (-0.35, 0.41) 0.02 (-0.21, 0.25) 0.88 0.51 
Age 7 Model 2 3,014 -0.12 (-0.16, -0.08) -0.10 (-0.13, -0.06) 1.6x10-08 69.9 0.11 -0.14 (-0.51, 0.23) -0.09 (-0.31, 0.14) 0.46 0.90 
 Model 3† 2,538 -0.09 (-0.14, -0.05) -0.08 (-0.12, -0.04) 0.00003 48.7 0.10 -0.06 (-0.54 0.41) -0.04 (-0.33, 0.25) 0.79 0.79 
            
FMI(kg/m2)† Model 1 3,014 -0.01 (-0.02, -0.001) -0.04 (-0.07, -0.002) 0.04 105 0.01 -0.003 (-0.33, 0.32) -0.01 (-0.20, 0.20) 0.99 0.70 
Age 9 Model 2 3,014 -0.03 (-0.04, -0.02) -0.09 (-0.13, -0.06) 2.4x10-07 103 0.11 -0.16 (-0.49, 0.17) -0.10 (-0.29, 0.10) 0.35 0.99 
 Model 3† 2,538 -0.02 (-0.03, -0.01) -0.07 (-0.11, -0.03) 0.002 74.2 0.10 -0.05 (-0.45, 0.35) -0.03 (-0.27, 0.21) 0.80 0.70 
† 476 individuals with missing data 
B=Beta coefficient, CI = Confidence interval, std = Standardized, p = strength of evidence against the null hypothesis 
of no association 
P (DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from 
linear regression and instrumental variable analysis Model 1 adjusted for age and sex, Model 2 adjusted for Model 1 and 
other thyroid hormone parameters, Model 3 adjusted for Model 2 and height markers of social class and early life 
environment (home ownership, maternal age at birth of child, maternal highest educational qualification, maternal 
smoking in pregnancy, family adversity index and parents and home score)  
  
 
 
128 
Table 29 Associations between body mass index/fat mass index and FT3 and FT4 levels at age 7 as tested both by 
conventional epidemiological approaches and through the FTO SNP 
 
Adiposity Model N Linear Regression   Instrumental Variable Regression FTO 
   b (95% CI) b (std) (95% CI) p-Value         F-
Statistic 
Partial R2 b (95% CI) b (std) (95% CI) p-
Value 
p-Value (DWH) 
 FTO SNP alone 
 FT3age 7 
BMI(kg/m2) Model 1 3,014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16) 5.3x10-16 10.6 0.64 0.61 (0.12, 1.09) 0.97 (0.20, 1.75) 0.01 0.006 
Age 7 Model 2 3,014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.6x10-21 11.8 0.61 0.63 (0.15, 1.11) 1.02 (0.25, 21.80) 0.01 0.003 
 Model 3† 2,538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 3.0x10-13 9.52 0.67 0.72 (0.02, 1.43) 1.17 (0.03, 2.30) 0.04 0.007 
            
FMI(kg/m2) Model 1 3,014 0.22 (0.17, 0.27) 0.17 (0.13, 0.20) 1.5x10-22 9.87 0.31 0.48 (0.14,0.82) 0.78 (0.23, 1.32) 0.006 0.01 
Age 9 Model 2 3,014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.1x10-78 15.9 0.26 0.50 (0.17,0.84) 0.82 (0.28, 1.36) 0.003 0.008 
 Model 3† 2,538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.5x10-18 14.6 0.24 0.52 (0.10, 0.94) 0.84 (0.16, 1.52) 0.008 0.02 
 FT4 age 7 
BMI(kg/m2) Model 1 3,014 -0.07 (-0.10, -0.03) -0.05 (-0.08, -0.02) 0.001 10.6 0.01 -0.21 (-1.20, 0.79) -0.13 (-0.73, 0.47) 0.68 0.82 
Age 7 Model 2 3,014 -0.12 (-0.16, -0.08) -0.10 (-0.13, -0.06) 1.6x10-08 7.95 0.02 -0.77 (-1.96, 0.41) -0.47 (-1.18, 0.25) 0.20 0.28 
 Model 3† 2,538 -0.09 (-0.14, -0.05) -0.08 (-0.12, -0.04) 0.00003 5.27 0.01 -0.68 (-2.16, 0.83) -0.41 (-1.33, 0.50) 0.37 0.45 
            
FMI(kg/m2) Model 1 3,014 -0.01 (-0.02, -0.001) -0.04 (-0.07, -0.002) 0.04 18.1 0.01 -0.20 (-1.00, 0.60) -0.12 (-0.61, 0.31 0.63 0.74 
Age 9 Model 2 3,014 -0.03 (-0.04, -0.02) -0.09 (-0.13, -0.06) 2.4x10-07 14.2 0.03 -0.65 (-1.56, 0.26) -0.39 (-0.94, 0.16) 0.16 0.27 
 Model 3† 2,538 -0.02 (-0.03, -0.01) -0.07 (-0.11, -0.03) 0.002 11.2 0.07 -0.50 (-1.55, 0.56) -0.30 (-0.93, 0.35) 0.36 0.49 
† 476 individuals with missing data 
b=Beta coefficient, CI = Confidence interval, std = standardized, p = strength of evidence against the null hypothesis 
of no association 
P (DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from 
linear regression and instrumental variable analysis Model 1 adjusted for age and sex, Model 2 adjusted for Model 1 and 
other thyroid hormone parameters, Model 3 adjusted for Model 2 and height markers of social class and early life 
environment (home ownership, maternal age at birth of child, maternal highest educational qualification, maternal 
smoking in pregnancy, family adversity index and parents and home score) 
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The instrumented effect for FTO on FT3 showed some difference to 
observational estimates, especially for both BMI and FMI, where the 
instrumental variable analysis produced larger effect estimates than the 
observational analysis (DWH p=<0.01). There was also some evidence that 
the instrumented effects of BMI on FT3 were higher for FTO than the 
other 31 SNPs. An additional analysis identified that independent pairs of 
variants from the 32 SNPs have instrumental variable effects that are 
normally distributed (Figure 12). However pairs of variants which 
included FTO are at the upper end of this distribution, indicating that 
although variation in FTO produces a substantially higher impact on 
FT3than the average instrumental variable effect it is not an outlier.   
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Figure 12 Distribution of FT3 level for pair combinations of the 32 
SNPs in instrumental variable regressions 
 
 
Blue indicates the distribution of FT3 levels for all pair combinations of 
the 32 SNPs; red indicates the distribution of FT3 for combinations of the 
32 SNPs where one SNP was the FTO (rs1558902) variant. Variation in FTO 
clearly has the most substantial effect on body composition and was the 
first obesity marker to be identified by GWAS [231]. In keeping with this 
FTO had by far the most substantial effect of any SNP in this analysis.  
 
4C.4 DISCUSSION 
Analysis using my genetic instruments revealed that individuals with a 
genetically higher BMI/fat mass had higher FT3 levels in keeping with 
observational estimates. In contrast, there was no evidence of 
association between individuals with a genetically higher BMI/fat mass 
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and FT4 levels. Interestingly the observational positive association 
between BMI and FT3 appears to be substantially weaker at age 15, 
however IV analysis effect estimates were more comparable. 
Furthermore the effect also still appears to be present in adults as 
previous studies also identified a positive association between FT3 and 
BMI in healthy euthyroid men aged between 25-45 years [207, 209]. 
Therefore repeating this MR analysis in adults would be particularly 
informative as would further studies comparing the biology of fat in 
children and adults in this regard. 
 
Taken together, our data suggests that higher levels of BMI and adiposity 
cause an increase in serum FT3 levels but do not appear to influence FT4 
levels. This would explain the paradoxical opposing relationship of FT3 
(positive) and FT4 (negative) with BMI and fat mass in observational 
studies. It is also notable that our overall genetic effect estimates of fat 
mass on FT3 were substantially higher than the observational analysis. 
This may indicate that the higher FT3 generated from higher fat mass has 
a negative effect on fat mass, but this is a much weaker overall effect 
than the positive effect of fat mass on FT3. This is in keeping with a 
recent study which identified obese children have higher FT3 levels [232]. 
 
Whilst our genetic analyses indicate the nature of the relationship 
between fat mass and FT3 the mechanism of action for increased fat mass 
increasing FT3 remains unclear. A simplistic assumption could be that 
increased fat mass results in increased generation of FT3 from FT4 and 
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this increased FT3 production in fat leads to increased FT3 in serum. 
However, this would require increased DIO2 conversion of FT4 to FT3 in 
fat and this enzyme is expressed in brown but is not substantially 
expressed in white adipose tissue [233].  
 
Alternatively, increased fat mass may result in other alterations in the 
HPT axis as longitudinal analysis in ALSPAC has indicated that FT3 is less 
influenced by TSH levels than FT4 and has greater intra-individual 
variation (Chapter 4A). Alternatively observed changes in FT3 may relate 
in part to excess carbohydrate in the diet of obese individuals [234]. In 
addition, our analysis showed children have higher FT3 levels than adults 
with almost 25% of children having a FT3 above the adult reference-range 
(Chapter 4A). This implies that other factors influence FT3 levels in 
young children although fat mass may still have a substantial role. Further 
insight may be available from whole genome sequence analysis of body 
mass and thyroid function, however they are unlikely to substantially 
increase the variance explained at present [217]. 
 
Although the MR method is more resistant to reverse causation and 
confounding than traditional observational epidemiological studies, there 
are limitations to this approach. Polygenic score analyses for TSH and 
FT4, have not revealed a common genetic determination with metabolic 
and anthropometric measures [217] although FT3 has not been studied it 
is unlikely it shares a common genetic architecture (pleiotropy) to fat 
mass. Our use of 32 independent alleles in determining the gene score, 
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substantially reduced the risk of shared pleiotropy and linkage-
disequilibrium-induced confounding [230]. Furthermore, our use of two 
separate genetic instruments substantially reduced the risk of pleiotropy. 
Another limitation was that we did not have data on thyroid function, 
body composition or genetic architecture in a substantial number of 
children in the ALSPAC cohort. However, this would only lead to bias if 
the causal effects of higher fat mass increasing FT3 levels are different 
in the children not studied in this study. Although we cannot fully exclude 
this there was no substantial difference in our models after adjustment 
for relevant socio-economic confounders. Furthermore positive 
associations between adiposity and FT3 were also observed when using 
different instrument combinations, suggesting that there is not a 
systematic and biasing effect of pleiotropy in this case.  
 
With regard to measurement of free thyroid hormones, biases have been 
reported [235], whilst measured levels of free thyroid hormones in our 
study may not be entirely independent from thyroid binding globulin 
levels, the striking difference observed in the associations between BMI 
allelic score and FT3 and FT4 makes a substantial impact from thyroid 
binding globulin in our genetic analysis unlikely. Previous analyses have 
also identified the association between thyroid hormone parameters and 
body composition was largely independent of thyroid binding globulin 
[155]. Potentially FT3 levels may be reduced in children with recent 
illness before blood sampling but this would have likely biased our genetic 
associations to the null. 
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More recent data[236] on the genetic architecture of body composition 
than that used in our analyses[216] is now available. This new data [236] 
explains more of the variation in BMI and identified over 50 novel SNPs. 
Re-analysing using these SNPs in a future study will confirm our findings 
and may allow greater insight into the pathways through which fat mass 
increases FT3.  
 
As well as providing insight into the regulation of FT3 in children, our 
findings are potentially clinically relevant. Childhood obesity is common 
and rising [237]  and increased FT3 levels arising from increasing fat mass 
may have long-term consequences, particularly at the population-level  
as even modest variation in thyroid status within the population 
reference-range has adverse phenotypic effects (Chapter 4B).  
 
In conclusion, our analysis in this chapter has indicated that BMI and 
adiposity causally increase FT3 levels in children. More research is 
required to identify the causal mechanisms for this and the consequences 
of childhood obesity on this relationship. 
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Chapter 5 Thyroid hormone replacement in the UK 
for primary hypothyroidism. 
As we have already seen in this thesis, modest variation in thyroid status 
can have a substantial impact on key health outcomes. Given 
hypothyroidism is common and levothyroxine is being widely and 
increasingly used patterns and trends in levothyroxine prescribing may 
have important implications for adult health. There has been concern 
that individuals are being started on levothyroxine for modest elevations 
in TSH and some evidence that many individuals may end up being over-
treated. This could result in patients moving from borderline low thyroid 
function to high thyroid function, which could substantially modify the 
risks of adverse outcomes moving from cardiovascular and metabolic risk 
factors to adverse bone outcomes. In this chapter, I utilized primary care 
data of over 50,000 people started on levothyroxine for primary 
hypothyroidism and explored temporal trends in management.  
 
5.1 INTRODUCTION 
Primary hypothyroidism is one of the commonest chronic conditions with 
a prevalence between 1-2% [10, 34] and is largely managed in primary 
care [238, 239]. Recently it has been observed that levothyroxine 
prescriptions in England and Wales have increased substantially over 
recent years, rising from 17.1 million in 2006 to 23.4 million in 2010 [240], 
up from only 7 million prescriptions in 1998 [241, 242]. 
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Several factors are likely to have contributed to this rise. A proportion 
may be attributed to a fall in the average duration of prescriptions from 
60 to 45 days [242].  What is likely to have had a bigger impact is that 
thyroid function testing has also increased substantially [52, 243] and 
data from the USA has revealed that in any year 18-25% of individuals 
have their thyroid function tested [239, 243, 244]. This has therefore 
likely resulted in increased case-finding of hypothyroidism. However, an 
additional factor might be a lowering of the TSH threshold at which 
levothyroxine is initiated. This practice would be important to identify, 
as this might be associated with more marginal benefits and increased 
relative risk of patient harm. As indicated earlier in this thesis even 
variation within the population reference range might have substantial 
effects on key health outcomes (Chapter 3). Over-treatment is 
associated with an increased risk of both fractures [245] and atrial 
fibrillation [246].  As indicated earlier in this thesis, analyses from 
population-based cohorts studying the effects of variation in thyroid 
status within the normal population range might suggest that 
overtreatment of individuals with marginally elevated TSH levels might 
result in net harm. 
 
In this chapter I used a large UK population-based database to examine 
trends in TSH levels pre-and post levothyroxine initiation since 2001 up 
to 2009, to assess the potential for adverse outcomes from current 
practice in the general adult population. This will provide key data in 
determining how much our practice of managing hypothyroidism modifies 
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risk factors for adverse adult health outcomes which we observed in 
Chapter 3.    
 
5.2 METHODS  
5.2.1 Study populations 
Clinical data and dates of levothyroxine prescriptions and TSH levels were 
extracted on primary care patients from the GPRD (now called the 
Clinical Practice Research Datalink www.CPRD.com). This has been 
described already in Chapter 2. To summarize The CPRD is the largest 
computerized database of anonymized medical records from primary 
care linked with other healthcare data. It is well validated for research 
on clinical diagnoses [125, 126], drug exposure and patient safety [122-
124]. At the time of this study the GPRD contained computerized medical 
records of over 5,000,000 people from 508 primary care practices 
throughout the UK. The clinical data is entered and stored as codes. This 
enabled us to access large amounts of clinical data enabling us to 
explore both biochemical TSH levels before and after levothyroxine 
initiation, and also investigate symptoms that led to thyroid function 
testing and investigate as well as relevant comorbidities. Whilst this 
approach has key advantages, a notable limitation is it relies on data 
being entered by primary care physicians accurately and whilst entered 
data has a high positive predictive value, it may not be sensitive as 
diagnoses may not be entered.   
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Patients were included in our dataset if they were aged between 18-99 
years at their first-ever prescription of levothyroxine which occurred 
between 01/01/2001-30/10/2009. For inclusion in this analysis patients 
also needed at least 12 months of up-to-standard (data that met GPRD 
quality standards) follow-up prior to their index levothyroxine. This 
required patients to have been at the same practice, with regular 
monitoring and attendance for repeat prescriptions. Patients with a 
prescription record at any time of amiodarone, carbimazole, 
propylthiouracil, lithium, interferon, thalidomide or sunitinib were 
excluded; as were patients diagnosed with or treated for hyperthyroidism 
prior to their index levothyroxine as evidenced by medical codes (related 
to ICD-10 codes) and referral codes in the GPRD relating to Graves’ 
disease, thyrotoxicosis, hyperthyroidism, toxic multi-nodular goiter, 
toxic nodule, thyroiditis, thyroidectomy and radio-iodine. Patients with 
a documented diagnosis of thyroid cancer or a diagnosis of pituitary 
disease/pituitary surgery were excluded. Individuals with levothyroxine 
initiation related to pregnancy were also excluded. To identify 
levothyroxine prescriptions related to pregnancy, 987 medical codes 
were used to identify prescriptions motivated by pregnancy or pre-
conception planning. These pregnancy codes were provided with 
assistance from Caroline Minassian (London School of Hygiene and 
Tropical Medicine).  These codes included antenatal appointments, 
confirmation of pregnancy tests and delivery outcomes. 
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A pregnancy medical code was regarded as relevant to the prescription 
of levothyroxine if it occurred up to 365 days before or up to 40 weeks 
after levothyroxine initiation.  
 
5.2.2 Identification of TSH and FT4 results generating index 
levothyroxine prescription 
We studied incident (first) levothyroxine prescriptions. A TSH or FT4 level 
was deemed relevant if it occurred within the 90 days before 
levothyroxine initiation. If more than 1 result was available, then the 
result closest to the date of levothyroxine initiation was used. Prescribing 
rates were calculated using baseline GPRD denominator data and were 
adjusted after removing from the denominator the person-time of 
individuals prescribed levothyroxine after 2001 (from the date of their 
levothyroxine prescription until the end of the study period or their exit 
from the GPRD). Excluded individuals (e.g., those prescribed 
levothyroxine in pregnancy) were also removed from the person-years at 
risk.  
 
34,808 individuals had an interpretable FT4 level available (FT4 level with 
data of the normal assay range also available) at their index prescription.  
 
5.2.3 Identification of factors potentially relevant to prescribing 
levothyroxine at the time of initiation of treatment 
Medical codes entered within 60 days before the relevant thyroid 
function test were studied for each patient. Codes regarding symptoms, 
examination findings, diagnoses, clinic appointments, and investigations 
were grouped into categories specified a priori. For example, the atrial 
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fibrillation or tachycardia category had several medical codes, including 
atrial fibrillation, AF, and paroxysmal AF pertaining to it. Individuals 
could be assigned to more than 1 category but would only be counted 
once within a category. 
 
5.2.4 TSH levels post-levothyroxine 
Using the date of index levothyroxine as time zero, the TSH levels post-
levothyroxine therapy were studied for up to 5 years. Time bands were 
split into 6-month intervals. Individuals could only appear once in each 
time-band. If 2 or more TSH values were available for a patient in the 
same 6-month period, the later TSH level was used. We studied TSH 
values 30-36 months and 54-60 months after levothyroxine initiation. TSH 
levels below 0.5mU/l were regarded as low and values below 0.1mU/l 
were regarded as suppressed in keeping with previous regional UK studies 
[52, 246].  FT4 levels between 10-20 pmol/l were classified as within the 
normal range.  
 
5.2.5 Statistical methods for identifying differences in prescribing 
Median TSH levels at levothyroxine initiation were calculated by year 
between 2001-2009. Logistic regression was undertaken to assess the 
odds ratio of having a first levothyroxine prescription with TSH levels less 
than 10mU/l using the odds of being prescribed levothyroxine with a TSH 
lower than 10mU/l in 2001 as a baseline, with analyses adjusted for age 
at levothyroxine initiation, sex and clinical characteristics.  
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Univariable logistic regression was also used to estimate the odds of 
developing a suppressed TSH at 5 years post levothyroxine for sex, age, 
year, TSH at index levothyroxine prescription and key clinical 
characteristics prior to levothyroxine therapy. Multivariable logistic 
regression was then undertaken adjusting for sex, age, year, and TSH at 
index levothyroxine prescription. 
 
5.2.6 Regulatory approval  
Access to the GPRD dataset was obtained via the Medical Research 
Council license. The study protocol was approved by the Independent 
Scientific Advisory Group of the UK Medicines and Healthcare products 
Regulatory Agency. 
 
 
5.3 RESULTS 
5.3.1 Characteristics of individuals prescribed levothyroxine 
We identified 52,298 individuals matching our inclusion criteria who had 
a levothyroxine prescription within 90 days after a documented TSH 
level. The median age at index levothyroxine was 59 years (IQR 47-72) 
with a Male: Female ratio of 1:3.74.  
 
5.3.2 Prescribing patterns in initiating levothyroxine therapy 
Overall the median TSH prior to index levothyroxine between 2001-2009 
was 8.2mU/l (IQR 5.9–13.9) (Figure 13). The annual median TSH level fell 
over the study period, from 8.7mU/l to 7.9mU/l (Figure 14).  
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Figure 13 TSH Levels at the Time of the Index Prescription of 
Levothyroxine 
 
Dark bars represent TSH levels < 4.0 mU/l, medium bars TSH levels 4.0-
10.0 mU/l and light bars represent TSH levels > 10.0 mU/l. These cutoffs 
were used as 4.0mU/l is often the quoted upper limit of the normal range 
and TSH levels >10 are a definite indication for treatment. 
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Figure 14 Median Thyrotropin Levels at the Time of the Index 
Prescription of Levothyroxine and Rate of Index Prescriptions by 
Year 
 
 
 
This fall reflected a reduction in individuals with an initial TSH level 
greater than 10mU/l (42.1% to 35.9%) and a rise in those treated for a 
TSH in the range 4-10mU/l (49.8% to 58.1%) (Table 30).  The odds ratio 
of having an index levothyroxine prescription with a TSH level less than 
10mU/l in 2009 compared to 2001, adjusting for age at prescription, sex, 
presence of diabetes/hypertension/raised lipids, and presenting 
symptom was 1.30 (95%CI 1.19, 1.42; p=<0.001). Free thyroxine (FT4) 
levels were available in 34,808 (66.6%) subjects at index prescription. 
The odds of starting levothyroxine with a TSH of <10mU/l at the end of 
the study in the subgroup of subjects with a FT4 in the reference range 
was slightly lower OR=1.17 (95%CI 1.00, 1.36; p=0.05) than in the whole 
cohort analysis (OR=1.30). 
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Table 30 TSH levels prior to index levothyroxine prescription by year and the odds of an index prescription of 
levothyroxine arising from a TSH less than 10mU/l by year, using prescribing data of levothyroxine in 2001 as 
baseline  
Year 
 % TSH 
< 4.0mU/l 
% TSH 
4 -10mU/l 
% TSH 
> 10 mU/l 
 
Odds 
Ratio 
Model 1# 
95%CI 
 
p value*  
 
Odds 
Ratio 
Model 2# 
95%CI  
 
p value* 
 
Odds 
Ratio 
Model 3# 
95%CI  
 
p value* 
 
2001  8.08 49.8 42.1 1    1   1    
2002  5.57 53.1 41.3 1.03 0.94 - 1.12 0.49  1.02 0.94 – 1.12 0.59 1.02 0.93 - 1.11 0.68  
2003  5.51 53.3 41.2 1.04 0.95- 1.12 0.41  1.04 0.95 – 1.13 0.45 1.03 0.94 – 1.12 0.53  
2004  6.63 54.3 39.1 1.14 1.04 – 1.23 0.003  1.14 1.05 – 1.24 0.002 1.13 1.04 – 1.22 0.005  
2005  5.44 56.0 38.5 1.16 1.04 – 1.25 <0.001  1.17 1.08 – 1.27 <0.001 1.14 1.05 – 1.24 0.001  
2006  5.84 57.4 36.7 1.27 1.15– 1.35 <0.001  1.27 1.17 – 1.38 <0.001 1.24 1.14 – 1.34 <0.001  
2007  5.22 57.3 37.4 1.22 1.11 – 1.32 <0.001  1.23 1.13 – 1.34 <0.001 1.19 1.10 – 1.31 <0.001  
2008  6.67 55.8 37.5 1.18 1.11 – 1.32 <0.001  1.24 1.14 – 1.35 <0.001 1.20 1.10 – 1.31 <0.001  
2009  6.28 58.1 35.6 1.32 1.20 – 1.43 <0.001  1.34 1.23 – 1.46 <0.001 1.30 1.19 – 1.42 <0.001  
# 52,298 individuals in model * Calculated using the Wald test 
Model 1 Crude, Model 2 Adjusted for age at levothyroxine initiation, and sex, Model 3 Adjusted for age at levothyroxine 
initiation, sex diabetes prior to levothyroxine initiation, hypertension or raised lipid levels prior to levothyroxine 
initiation and presenting symptom. 
 
Between 2001-2006 there was a 1.81 fold increase in the rate of index levothyroxine prescriptions (Table 31) After this 
time the rate of new prescriptions did not substantially change despite a continuing decline in the median TSH at index 
levothyroxine (Figure 14).  Age-standardized rates comparing 2001 prescribing to 2006 prescribing revealed that there 
was still a 1.79 fold increase in the rate of index levothyroxine prescriptions after the change in age in the dataset was 
taken into account. Age-stratified rates are shown in Table 32. Levothyroxine prescriptions were usually continued 
long-term: 38,939 of the 43,057 individuals (90.4%) still in the GPRD at the end of the study received a repeat 
levothyroxine prescription during 2009. 
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Table 31 GPRD Population and prescribing patterns by year  
 
Year 
Total Population 
in GPRD 
aged 18 years + 
 
 
Person 
years 
Number of 
prescriptions 
 
Rate per 10,000 
person years 
Proportion of GPRD 
started on 
Levothyroxine 
Adjusted rate* 
per 10,000 years 
2001 3085170 2792322 3576 128.1 1.16 x10-3 129.5 
2002 3189619 2925037 4488 153.4 1.41 x10-03 155.2 
2003 3225512 2974217 5413 182.0 1.68 x10-03 184.4 
2004 3291684 3038516 6514 214.4 1.98x10-03 217.4 
2005 3341246 3095391 7005 226.3 2.10 x10-03 230.0 
2006 3415872 3131345 7226 230.8 2.12 x10-03 234.7 
2007 3451212 3165081 6512 205.7 1.89 x10-03 209.5 
2008 3430267 3140549 5985 190.6 1.74 x10-03 194.3 
2009 3400030 2518483 5539 220.0 1.96 x10-03 225.7 
*Rate adjusted for individuals no longer at risk of being prescribed levothyroxine for the first time, as a result of 
levothyroxine prescription, exclusion due to pregnancy, medication and pituitary disease from our dataset. 
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Table 32 Age stratified rates of levothyroxine prescription by year 
                           
Year 
Age-
group 2001  
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
2009 
 Prop R  Prop R  Prop R  Prop R  Prop R  Prop R  Prop R  Prop R  Prop R 
20-30 1.89 2.23  2.46 2.87  3.41 3.93  3.57 4.12  4.13 4.76  4.37 5.08  4.00 4.63  3.93 4.58  4.53 5.50 
30-40 5.06 5.69  6.41 7.10  7.28 8.03  8.61 9.50  9.36 10.3  10.2 11.3  9.75 10.8  8.65 9.68  9.42 10.8 
40-50 10.5 11.4  11.6 12.4  13.6 14.4  17.2 18.3  17.5 18.5  18.2 19.5  16.9 18.0  15.5 16.6  17.9 19.7 
50-60 16.2 17.3  18.7 19.7  21.9 23.0  25.8 27.0  28.4 29.7  28.1 29.6  26.5 28.0  23.2 24.5  26.9 29.2 
60-70 20.6 22.0  22.8 24.0  27.4 28.7  32.6 34.2  33.6 35.0  34.1 35.9  28.5 30.1  27.5 28.9  29.7 32.1 
70-80 20.9 22.5  28.4 30.1  34.8 36.9  38.9 40.9  41.7 43.6  40.3 42.7  35.1 37.2  31.6 33.4  35.0 38.0 
80-90 23.5 26.3  30.1 33.4  35.7 39.5  41.8 46.0  42.3 46.2  46.1 50.8  34.6 38.2  34.3 37.9  38.8 43.9 
90-100 18.2 22.0  30.7 37.5  36.3 43.8  39.8 48.2  51.5 61.8  41.0 49.5  38.4 46.6  42.1 51.2  40.9 50.7 
Overall 11.6 12.8  14.1 15.3  16.7 18.2  19.7 21.4  21.0 22.6  21.1 23.0  18.8 20.5  17.4 19.0  19.5 22.0 
Prop = Proportion of individuals in GPRD (x10-5) R =Rate per 10,000 patient years 
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The rate of index levothyroxine prescriptions also increased steadily with 
age (Table 32). As a proportion, of the at-risk population, the greatest 
number of new prescriptions was among those aged between 55-60 years. In 
males the median TSH at index prescription over the study period was higher 
than females (p=<0.001) 8.90mU/l (IQR 6.21–16.2) versus 8.05mU/l (IQR 
5.84-13.4) in females. There was also a surprising dip in the rate of 
levothyroxine prescribing in 2007 and 2008 followed by a recovery, although 
there was no obvious change in guideline or practice around this time. 
 
5.3.3 Clinical data in subjects prescribed levothyroxine 
The symptoms and signs recorded in the 60-day period prior to initiating 
levothyroxine are shown in Table 33. The commonest symptoms were 
tiredness (19.3%), weight gain/obesity (14.0%) and depression (5.8%). 
Individuals with recorded sleep apnea (23.1mU/l), peri-orbital oedema 
(32.7mU/l) and Addisons (21.1 mU/l), had median TSH levels substantially 
greater than 10mU/l consistent with the presence of more profound 
hypothyroidism.  
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Table 33 Relevant symptoms, signs and diagnoses prior to initiation 
of levothyroxine 
Clinical  Number of Individuals 
Median 
TSH (IQR) 
Symptom    
Cold intolerance* 43 7.05 (5.30 – 14.2) 
Loss of taste 12 7.22 (4.50 - 10.4) 
Loss of libido 51 7.36 (5.03 – 13.5) 
Depression 1462 7.60 (5.55 – 13.2) 
Tired* 4839 7.74 (5.50 - 14.5) 
Neck Pain 412 7.80 (5.59 – 12.3) 
General aches and pains 625 7.81 (5.80 – 14.9) 
Tremor 125 7.82 (5.88 – 11.2) 
Sore tongue 158 7.86 (6.15 – 13.6) 
Itch 410 7.87 (5.6 – 12.3) 
Heat intolerance 314 7.96 (5.56 -13.3) 
Disturbed Sleep 487 8.03 (5.87 – 15.0) 
Rash 589 8.12 (5.81 – 15.8) 
Menopause symptoms 546 8.22 (5.82 - 14.9) 
Weight gain/obesity 3517 8.30 (5.80 – 16.2) 
Feeling dizzy/faint 1201 8.31 (5.94 - 15.3) 
Increasing falls 265 8.41 (6.20 – 14.4) 
Weight loss 277 8.50 (5.87 – 13.8) 
Constipation* 550 8.60 (5.98 – 14.8) 
Palpitations 568 8.60 (6.43 – 14.6) 
Hoarse Voice* 157 8.70 (5.83 – 40) 
Menstrual irregularity* 1333 8.81 (6.02 – 15.9) 
General malaise 367 9.00 (5.66 – 17.6) 
Increasing frailty 19 9.08 (4.65 – 19.9) 
Fullness/constriction in neck 134 9.96 (6.40 – 18.8) 
Examination Findings    
Thyroid nodule 30 6.40 (2.51 – 11.3) 
Dry skin* 273 7.80 (5.71 – 17.2) 
Alopecia/hair loss 487 8.21 (5.78 – 13.2) 
Goitre* 531 8.28 (5.7 - 24.9) 
Atrial fibrillation/tachycardia 273 8.30 (6.08 – 13.5) 
Peripheral oedema 1363 8.40 (6.10 - 16.3) 
Bradycardia* 40 8.50 (5.38 – 17.9) 
Vitiligo 34 10.5 (6.09 – 20.0) 
Myxoedema* 202 11.3 (6.0 - 27.0) 
Gynacomastia 4 12.0 (5.12 – 20.6) 
Peri-orbital oedema 20 32.7 (6.96 – 95.0) 
Screening    
Mental health review 246 7.03 (5.36 – 12.1) 
Diabetes review 1415 7.31 (5.59 – 10.7) 
General screening 1395 8.02 (5.45 – 14.81) 
Geriatric Screen 309 8.03 (6.32 – 12.8) 
Following other diagnosis    
IGT/IFG 10 5.77 (4.79 – 8.86) 
PCOS 19 5.86 (4.15 – 9.20) 
Dementia 103 7.40 (5.53 – 12.7) 
Pernicious anaemia 62 7.77 (6.20 – 10.7) 
High lipids* 680 7.80 (5.63 – 13.7) 
Stroke 64 7.80 (6.02 - 10.9) 
Type 2 DM 367 7.85 (6.00 – 14.0) 
Coeliac 11 7.94 (6.75 – 14.0) 
Carpal Tunnel Syndrome* 243 7.97 (5.57 – 14.6) 
IHD 520 8.00 (6.14 – 13.1) 
Macrocytosis 68 8.14 (5.85 – 10.9) 
Infertility 212 8.28 (5.8 – 14.4) 
Hyponatremia 36 8.98 (5.85 - 11.9) 
Type 1 DM 19 9.70 (7.57 - 12.8) 
Sjogrens 7 10.5 (5.26 – 10.9) 
Addisons 6 21.1 (9.34 – 38.4) 
Sleep apnea* 9 23.1 (8.39 – 28.8) 
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Summary for Table 33 on previous page 
TSH – Thyroid stimulating hormone, IQR – Inter-quartile range IHD – 
Ischaemic heart disease,  DM – Diabetes Mellitus, IGT Impaired glucose 
tolerance, IFG – Impaired fasting glucose, PCOS – Polycystic ovarian 
syndrome Total Number 27,519 from 25,067 individuals (47.9%) in the 
dataset *7,410 individuals only had these “classic” signs and symptoms of 
hypothyroidism 
 
 
5.3.4 Number of thyroid function tests before index levothyroxine 
Data were available on individuals from their inclusion in GPRD and was 
therefore available for several years prior to 2001. The median number 
of thyroid function tests before index levothyroxine was 2 (IQR 1-3). 
58.2% of individuals were started on levothyroxine who had never had a 
documented TSH level greater than 10mU/l and 34.6% of individuals who 
were prescribed levothyroxine with a TSH between 4-10mU/l only had 
one value above 4.0mU/l (Table 34).   
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Table 34 Relative percentages of the number thyroid function tests 
performed prior to initiation of levothyroxine by prescription 
threshold 
 
TSH level at 
index 
prescription of 
levothyroxine 
 
Percentage of thyroid function tests performed prior to initiation 
of levothyroxine (%) 
 
1 2 >2 1* 2* >2* 
       
4 - 10 mU/l 24.8 26.3 48.9 34.6 30.8 34.7 
> 10 mU/l 47.7 23.5 17.8 65.3 23.0 11.7 
* TSH values less than 4 mU/l excluded 
 
34,808 individuals had an interpretable FT4 level available (FT4 level with 
data of the normal assay range also available) at their index prescription. 
Comparing individuals with FT4 data available to the rest of our dataset, 
there was no difference in sex (p=0.62) or age group (p=0.14), however 
TSH levels were lower at index prescription in those with FT4 available 
(p=0.01). In individuals with FT4 data available 38.8% had a TSH >10mU/l 
and 50.3 % had either a TSH >10mU/l or a low FT4.  
 
In the 34,808 individuals with a FT4 available 10, 939 (31.4%) had 
levothyroxine prescribed with a TSH level <10mU/l and a normal FT4 
despite no previous cardiovascular risk factors or classic hypothyroid 
symptoms. In addition individuals starting levothyroxine with a TSH in the 
range 4-10mU/l and a normal FT4 rather than a low FT4 were more likely 
to be older and have cardio-vascular risk-factors, but not to have 
tiredness obesity or depression at baseline (Table 35).  Individuals 
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prescribed levothyroxine with a TSH between 4-10mU/l rather than a TSH 
>10mU/l were more likely to be female, aged over 70,  prescribed 
levothyroxine after 2004, or have cardiovascular risk factors, with trends 
also observed for depression/tiredness (Table 36). 
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Table 35 Odds of having levothyroxine initiated with a normal FT4 
compared to a low FT4 in individuals with a TSH between 4-10 mU/l 
Characteristic 
CRUDE  ADJUSTED 
       
Odds 
ratio (95%CI) 
p 
value* 
 Odds 
ratio# (95%CI)# 
p 
value#
* 
Sex        
Male 1    1   
Female 0.97 0.88- 1.06 0.50  1.01 0.91 – 1.10 0.92 
Age group        
18 – 45 1    1   
45 – 70 0.97 0.88 – 1.07 <0.55  0.92 0.87 – 1.07 0.13 
70 – 99 1.18 1.06 – 1.32 <0.003  1.05 0.93 – 1.18 0.43 
Year of index 
prescription 
       
2001 -2003 1    1   
2004 – 2006 1.14 1.03 – 1.26 0.01  1.13 1.02 – 1.25 0.02 
2007 – 2009 1.04 0.94 – 1.14 0.47  1.03 0.93 – 1.14 0.54 
Classic hypothyroid sx        
No 1    1   
Yes 1.01 0.90 – 1.14 0.83  1.03 0.91, 1.16 0.63 
Presence of AF        
No 1    1   
Yes 1.70 1.50 - 1.93 <0.001  1.43 1.16 – 1.74 0.001 
Raised blood 
pressure/lipids 
       
No 1    1   
Yes 1.36 1.28 – 1.42 <0.001  1.19 1.09 – 1.30 <0.001 
Presence of Diabetes 
No 
 
1 
    
1 
  
Yes 1.27 1.10 – 1.45 0.001  1.18 1.03 – 1.35 0.02 
Clinical reasons for  
TSH measurement 
   
 
    
Depression 0.87 0.69 – 1.09 0.23  0.89 0.71 – 1.12 0.34 
Tired 1.27 0.89 – 1.81 0.19  1.34 0.92 – 1.87 0.14 
Weight gain/obesity 0.96 0.64 – 1.44 0.84  0.99 0.66 – 1.49 0.99 
Peripheral Oedema 1.07 0.83 – 1.39 0.61  0.99 0.76 – 1.28 0.94 
Menstrual irregularities 0.64 0.54 - 0.81 <0.001  0.67 0.54 – 0.85 0.001 
Diabetes review 1.04 0.82 – 1.32 0.73  0.85 0.65 – 1.11 0.23 
General Screening 0.84 0.65 – 1.08 0.17  0.82 0.63 – 1.05 0.12 
19,801 individuals in model # Adjusted for age at prescription, year at 
prescription, sex, cardiovascular risk factors and presence of classic 
symptoms 
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Table 36 Odds of having levothyroxine initiated with a TSH between 
4-10 mU/l compared to a TSH greater than 10  
Characteristic 
CRUDE ADJUSTED 
      
Odds 
ratio (95%CI) 
p 
value* 
Odds 
ratio# (95%CI)# 
p 
value#* 
Sex       
Male 1   1   
Female 1.27 1.21 – 1.32 <0.001 1.37 1.31 – 1.43 <0.001 
Age group       
18 – 45 1   1   
45 – 70 1.18 1.12 – 1.24 <0.001 1.13 1.08 – 1.19 <0.001 
70 – 99 1.35 1.28 – 1.42 <0.001 1.24 1.17 – 1.31 <0.001 
Year of index 
prescription 
      
2001 -2003 1   1   
2004 – 2006 1.16 1.11 – 1.22 <0.001 1.16 1.11 – 1.21 <0.001 
2007 – 2009 1.22 1.17 – 1.28 <0.001 1.23 1.17 – 1.29 <0.001 
Classic Symptoms       
No 1   1   
Yes 0.95 0.89 - 1.00 0.05 0.98 0.92, 1.04 0.54 
Presence of AF       
No 1   1   
Yes 1.29 1.18 – 1.41 <0.001 1.19 1.08 -1.31 <0.001 
Raised blood 
pressure/lipids 
      
No 1   1   
Yes 1.30 1.25 – 1.35  <0.001 1.19 1.14 – 1.24 <0.001 
Presence of Diabetes 
No 
 
1 
   
1 
  
Yes 1.62 1.51 – 1.74 <0.001 1.57 1.46 – 1.69 <0.001 
Clinical reasons for  
TSH measurement 
   
 
   
Depression 1.62 1.51 – 1.74 <0.001 1.11 0.99 – 1.25 0.08 
Tired 0.97 0.83 – 1.13 0.70 1.13 0.96 – 1.32 0.14 
Weight gain/obesity 0.76 0.63 – 0.90 0.002 0.80 0.67 – 0.96 0.02 
Peripheral Oedema 0.83 0.74 – 0.94 0.002 0.77 0.69 – 0.87 <0.001 
Menstrual irregularities 0.82 0.72 – 0.93 0.001 0.89 0.79 – 1.02 0.09 
Diabetes review 1.63 1.44 – 1.85 <0.001 1.20 1.05 – 1.39 0.01 
General Screening 0.87 0.77 – 0.99 0.03 0.88 0.78 – 1.00 0.06 
49,185 individuals in model (Individuals with TSH <4 mU/l excluded) 
Adjusted for age at prescription, year of prescription presence of 
cardiovascular risk factors and presence of classic symptoms 
 
5.3.5 TSH levels post-initiation of levothyroxine 
Trends are shown in TSH levels post levothyroxine (Fig 15). Not all 
individuals had TSH levels repeated regularly.  The dataset was created 
in 2010, at which time we had TSH levels at 3 year follow-up in 17,154 
individuals (51.5% of those with 3 year follow-up) and 5 year follow-up in 
9,252 individuals (39.7% of those with 5 years follow-up) During the 
period, 6 month–5 years post levothyroxine initiation the percentage of 
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those with a TSH less than 0.1mU/l increased from 2.7%–5.8% and those 
with a TSH between 0.1-0.5mU/l increased from 6.3-10.2%; this was 
accompanied by a fall in those with a TSH between 5-10 mU/l from 29.8% 
to 18.8% (Figure 15). 2.7% of individuals still had a TSH greater than 
10mU/l even 5 years after starting levothyroxine. 
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Figure 15 TSH levels after levothyroxine initiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individuals’ baseline characteristics appeared to substantially influence 
the odds of developing a suppressed TSH 5 years post-levothyroxine 
(Tables 37 and 38):  these included being female (OR=1.57, 95%CI 1.18, 
2.08 p=0.002), presenting with tiredness (OR=1.51, 95%CI 1.13, 2.01, 
p=0.005), or depression (OR=1.63, 95%CI 1.02, 2.60, p=0.04) having a TSH 
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value less than 4mU/l  (OR=1.83 95%CI 1.35, 2.47 p=<0.001) or greater 
than 10mU/l (OR= 2.68, 95%CI 2.07, 3.44, p=<0.001). Older age was a 
strong protective factor in being over-replaced and this is also a key risk 
factor for atrial fibrillation. Having cardiovascular risk-factors at baseline 
was generally associated with reduced odds of a low TSH at 5 year follow-
up, although the presence of atrial fibrillation or diabetes had wide 
confidence intervals that included equality after adjusting for 
confounding variables (Tables 37 and 38).
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Table 37 The odds of developing a suppressed TSH 5 years post levothyroxine therapy by sex, age-group, index 
TSH level, presence of cardiovascular risk-factors (N=9252) 
Characteristic 
TSH 0.1 -0.5 mU/l 
 
TSH < 0.1 mU/l 
 
Odds 
ratio (95%CI) 
p 
value* 
Odds 
ratio# (95%CI)# 
p 
value#* 
Odds 
ratio (95%CI) 
p 
value* 
Odds 
ratio# (95%CI)# 
p 
value#* 
Sex             
Male 1   1   1   1   
Female 1.40 1.19- 1.64 <0.001 1.45 1.23 – 1.73 <0.001 1.55 1.17 – 2.04 0.002 1.57 1.18 -2.08 0.002 
Age group             
18 – 45 1      1   1   
45 – 70 0.81 0.70 – 0.93 0.003 0.82 0.70 – 0.95 0.009 0.71 0.58 – 0.89 0.002 0.76 0.61 – 0.94 0.01 
70 – 99 0.52 0.44 – 0.62 <0.001 0.54 0.45 – 0.65 <0.001 0.38 0.28 – 0.51 <0.001 0.41 (0.30 - 0.55) <0.001 
Year of index 
prescription             
2001 1   1   1   1   
2002 0.95 0.80-1.14 0.64 0.97 0.80 -1.18 0.78 1.03 0.75 – 1.39 0.87 1.06 0.78 – 1.45 0.70 
2003 0.97 0.82 -1.16 0.79 0.98 0.82 – 1.18 0.86 1.30 0.98 – 1.72 0.07 1.37 1.03 – 1.82 0.03 
2004 0.75 0.63 -0.90 0.002 0.78 0.65 – 0.94 0.009 0.91 0.68 – 1.22 0.53 0.97 0.72 – 1.30 0.83 
TSH at index 
prescription             
< 4.0 mU/l 1.49 1.24 – 1.79 <0.001 1.44 1.20 – 1.72 <0.001 1.96 1.46 – 2.64 <0.001 1.83 1.35 – 2.47 <0.001 
4.0 - 7.0 mU/l 1   1   1   1   
7.0 – 10.0 mU/l 1.18 0.98 – 1.42 0.08 1.19 0.99 – 1.41 0.002 1.21 0.87 – 1.69 0.24 1.22 0.88 - 1.71 0.21 
10 + mU/l 2.54 2.19 – 2.94 <0.001 2.82 2.22– 2.99 <0.001 2.64 2.05 – 3.39 <0.001 2.68 2.07 – 3.44 <0.001 
Presence of AF 
No 
 
1      
 
1   
 
1   
Yes 0.72 0.53 – 0.98 0.04 0.87 0.63 – 1.20 0.40 0.32 0.15 – 0.68 0.003 0.42 0.20 – 0.90 0.03 
Raised blood 
pressure/lipids 
No 
Yes 
 
1 
0.70 
 
 
0.61 – 0.80 
 
 
<0.001 
 
 
0.81 
 
 
0.71- 0.94 
 
 
0.004 
 
1 
0.55 
 
 
0.44 – 0.71 
 
 
<0.001 
 
1 
0.68 
 
 
0.53 – 0.87 
 
 
0.002 
Presence of 
Diabetes 
No 
 
1   
 
1   
 
1   
 
1   
Yes 0.63 (0.48, 0.83) 0.001 0.81 (0.61 – 1.07) 0.15 0.59 0.37, 0.95 0.03 0.78 0.48 - 1.27 0.32 
T4 at levothyroxine 
initiation 
Normal 
 
1   
 
1   
 
1   
 
1   
Low 2.02 (1.73, 2.36) <0.001 1.60 1.36 – 1.89 <0.001 1.81 1.41 – 2.34 0.001 1.37 1.04 - 1.81 0.02 
              
*Calculated using the Wald test # Adjusted for sex, age group, year of index prescription, TSH at index prescription 
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Table 38 The odds of developing a suppressed TSH 5 years post levothyroxine therapy by potential motivation 
for prescription (N=9252) 
Characteristic TSH 0.1 -0.5 mU/l  
TSH < 0.1 mU/l 
 
 Odds ratio (95%CI) 
p 
value* 
Odds 
ratio# (95%CI)# 
p 
value#* 
Odds 
ratio (95%CI) 
p 
value* 
Odds 
ratio# (95%CI)# 
p 
value#* 
Clinical reasons 
for 
TSH measurement 
            
Depression 1.91 1.41 – 2.58 <0.001 1.64 1.19 - 2.27 0.003 1.86 (1.18 – 2.95) 0.008 1.63 
(1.02 – 
2.60) 0.04 
Tired 1.51 1.25 – 1.82 <0.001 1.56 1.28 – 1.89 <0.001 1.69 (1.27 – 2.24) <0.001 1.51 
(1.13 – 
2.01) 0.005 
Weight 
gain/obesity 1.31 1.05 – 1.63 0.02 1.26 1.00 -1.59 0.05 1.10 
(0.75 – 
1.62) 0.61 1.03 
(0.70 – 
1.51) 0.89 
Peripheral Oedema 0.78 0.52 -1.17 0.23 0.86 0.57 -1.30 0.49 0.50 (0.22 – 1.14) 0.10 0.57 
(0.25 – 
1.29) 0.18 
Menstrual 
irregularities 1.29 0.90 – 1.83 0.16 0.99 0.68 – 1.42 0.94 1.68 
(1.01 – 
2.80) 0.04 1.11 
(0.66 – 
1.87) 0.69 
Diabetes review 0.79 0.55 -1.15 0.23 0.90 0.61 -1.32 0.58 0.66 (0.34 – 1.29) 0.23 0.79 
(0.40 – 
1.56) 0.50 
General Screening 1.15 0.85 – 1.58 0.36 1.08 0.78 – 1.51 0.63 0.96 (0.56 – 1.66) 0.90 0.99 
(0.57 – 
1.72) 0.99 
*Calculated using the Wald test 
# Adjusted for sex, age group, year of index prescription, TSH at index prescription 9,252 individuals with 5 year follow-up
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5.4 DISCUSSION  
Our results show that the annual rate of new levothyroxine prescriptions 
increased 1.74 fold over our study period.  During this time there was a 
fall in median TSH threshold at index levothyroxine prescription from 
8.67mU/l to 7.88mU/l with a 30% increase in odds of having levothyroxine 
initiated at a TSH level <10mU/l.  
 
This increase in rate was not simply due to an ageing population as age-
adjusted and age-stratified rates also demonstrated a rise. Furthermore, 
it was not due to shorter prescriptions as we only counted the first 
(“incident”) prescription a patient ever received. An increase in case-
finding due to more thyroid tests being ordered [239, 243, 247], in 
combination with the observed fall in TSH threshold for initiating 
treatment could explain this increase. Since our dataset does not contain 
information on individuals that never received levothyroxine, we cannot 
calculate the relative contribution of these two factors.  
 
Even though it may only partly account for the overall increase in the 
number of people being started on levothyroxine, the reduction in TSH 
threshold is important as it implies the net benefits of levothyroxine 
therapy may be more marginal. For example, the highest age-adjusted 
and age- stratified rates of new levothyroxine prescribing (even with a 
normal FT4) were observed in the elderly (Table 32) who also had the 
highest odds of being prescribed levothyroxine with a TSH between 4-
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10mU/l (Table 36). This is in keeping with the highest rates of subclinical 
hypothyroidism being detected in the elderly [2]. However a substantial 
number of these prescriptions may be unwarranted as mild TSH 
elevations may be a normal manifestation of ageing [248].  Furthermore, 
there is evidence that treatment of subclinical hypothyroidism in subjects 
over the age of 70 has less cardiovascular benefit than in younger subjects 
[191]. A recent randomised clinical trial has also questioned the 
symptomatic benefits of treating older individuals with subclinical 
hypothyroidism [249].  
 
The marked increase in new levothyroxine prescriptions since 2002 may 
have been an unintended consequence of the Qualities and Outcome 
Framework [250] which required UK primary care physicians to maintain 
a database of patients with hypothyroidism and monitor TSH levels 
annually. This may have drawn more attention to thyroid function testing 
and levothyroxine replacement, resulting in increased case-finding and 
enthusiasm to initiate therapy.  New prescription rates have stabilized 
since 2007, despite a continued fall in median TSH, which may indicate 
that this enthusiasm for case-finding began to wane at this stage. 
 
The majority of patients (61%) in our dataset were initiated on 
levothyroxine with a TSH level of less than 10mU/l (Figure 13).  
Furthermore in the 34,808 individuals with a FT4 available, 31.4% had 
levothyroxine prescribed with a TSH level <10mU/l and a normal FT4 
despite no previous cardiovascular risk factors or classic hypothyroid 
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symptoms. This shows there is widespread treatment of subclinical 
hypothyroidism. However there is a challenge in fully interpreting this 
data as data on thyroid antibody status were not available and we could 
not identify symptoms relevant to hypothyroidism prior to the TSH test 
resulting in the index levothyroxine prescription in 47.9% of individuals.  
 
A summary of the guidelines for treating subclinical hypothyroidism is 
shown below in Table 39. 
 
  
 
 
163 
Table 39 International guidelines for treating subclinical 
hypothyroidism 
Guideline Subclinical Hypothyroidism 
Recommendation 
Evidence 
Grade B 
AACE[85] Treatment based on individual 
factors for patients with TSH levels 
between the upper limit of a given 
laboratory’s reference range and 
10 mIU/L should be considered 
particularly if patients have 
symptoms suggestive of 
hypothyroidism, positive TPOAb or 
evidence of atherosclerotic 
cardiovascular disease, heart 
failure  
This guideline also highlighted the 
need for prospective intervention 
studies  
 
Intermediate 
ETA[251] In younger  patients (<65 years) 
with symptoms suggestive of 
hypothyroidism, a trial of 
levothyroxine replacement therapy 
should be considered  
Age-specific reference ranges for 
serum TSH should be considered in 
order to establish a diagnosis of 
subclinical hypothyroidism in older 
people.  
The oldest old subjects (>80–85 
years) with elevated serum TSH 
≤10 mU/l should be carefully 
followed with a wait-and-see 
strategy, generally avoiding 
hormonal treatment.  
Intermediate 
 
From our data FT4 values were available in 68.3% individuals prescribed 
levothyroxine with a TSH between 4-10mU/l and 82.7% of this group had 
FT4 values within the reference range, consistent with a diagnosis of 
subclinical hypothyroidism (Table 35). The evidence for clinical benefit 
of treatment in this range outside of pregnancy is weak [85].  
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Only 39.4% of individuals prescribed levothyroxine for subclinical 
hypothyroidism had a history of hypertension, raised lipids, atrial 
fibrillation or diabetes before levothyroxine initiation with 46.9 % having 
either these cardiovascular risk-factors or documented symptoms 
consistent with hypothyroidism prior to levothyroxine. Although some 
data may be unrecorded, it suggests that up to 50% of individuals with 
subclinical hypothyroidism are treated outside of guidelines. However it 
is somewhat reassuring that individuals with cardiovascular risk-factors 
were preferentially initiated on levothyroxine in the TSH 4-10mU/l group 
compared to those without cardiovascular comorbidities.   Furthermore 
individuals over the age of 70 had high rates of being prescribed 
levothyroxine, even if they had a normal FT4 levels indicating there was 
no clear avoidance of prescribing for subclinical hypothyroidism in this 
age group contrary to ETA guidance[251]. However it should be noted 
that this guideline came out after our dataset ended. Recently a trial of 
levothyroxine therapy for subclinical hypothyroidism in  older individuals 
(age > 65 years) did not find any evidence of benefit in terms of 
hypothyroid symptoms, mood or cognition [249] 
 
Another concern is that contrary to ATA guidelines[81, 85] 34.6% of 
individuals prescribed levothyroxine with a TSH level between 4-10mU/l 
only had one abnormal TSH reading before initiating therapy. Greater use 
of confirmatory testing might reduce unnecessary prescriptions given 
that 46% of individuals with a TSH between 4.5-7.0mU/l reverted to 
normal within 2 years without treatment[252]. This is especially relevant 
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since the indication for levothyroxine is rarely reviewed once started. In 
our dataset over 90% of individuals were still being prescribed 
levothyroxine at the end of the study.  It is quite likely that a substantial 
proportion of individuals on levothyroxine, would have normal thyroid 
function if levothyroxine was stopped. The fact that levothyroxine is easy 
to prescribe and inexpensive has encouraged a low threshold for its use.  
 
Set against the uncertain potential for benefit in a large proportion of 
patients initiated on levothyroxine, it is important to examine the 
potential for harm. 5 years after levothyroxine initiation 10.2% of 
patients had a low TSH and 5.8% had a suppressed TSH.  Individuals with 
a suppressed TSH are at a potentially increased risk of developing 
osteoporotic fractures [246] and atrial fibrillation [253] and data for the 
increased risk of harm from subclinical hyperthyroidism are stronger than 
the data of potential benefit from treatment of subclinical 
hypothyroidism. However it should be highlighted that individuals on 
excess levothyroxine treatment will have relatively lower FT3 levels than 
people with subclinical hyperthyroidism, so it is difficult to draw a direct 
comparison between subclinical hyperthyroidism and excess 
levothyroxine therapy.  
 
 Individuals with cardiac risk factors had reduced odds of developing a 
suppressed TSH, suggesting that prescribers were aware of this risk, but 
10.6% of individuals treated for subclinical hypothyroidism who had 
cardiovascular risk factors ended up with a low TSH level which may have 
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actually increased their risk. Individuals with tiredness or depression at 
baseline but not those with diabetes or obesity were more likely to be 
over-replaced at 5 years (Table 38), raising the possibility that there may 
be an element of intentional increased dosing with levothyroxine rather 
than a lack of careful monitoring in these individuals.  
  
There are now 1.6 million individuals in the UK on long-term 
levothyroxine most of whom have been prescribed it for primary 
hypothyroidism [238]. If current practice continues, up to 30% of people 
on levothyroxine may have been prescribed it without an accepted 
indication, and with potential for net harm if they develop even a low 
TSH (as occurred in12.2% of individuals prescribed levothyroxine for 
subclinical hypothyroidism in our dataset). Effects may be substantial in 
the western world. In the USA the prevalence of hypothyroidism is similar 
to the UK [42] and one might therefore expect approximately 5 million 
individuals in the USA to be on long-term levothyroxine for primary 
hypothyroidism; if prescribing patterns in the USA are similar over 1.6 
million individuals may be on levothyroxine with limited evidence of 
benefit. 
 
The strengths of our study include the use of a large population-based 
dataset from many different practitioners collected over a long period. 
Detailed clinical data allowed us to ascertain cases of primary 
hypothyroidism and exclude individuals who had levothyroxine prescribed 
as a result of pregnancy or following treatment of hyperthyroidism or 
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pituitary disease. In addition, the use of electronic records by UK primary 
care physicians to issue prescriptions makes it unlikely that prescriptions 
of levothyroxine were missed. Similarly, almost all laboratories sent 
biochemical data electronically by 2000, so few TSH results were 
unavailable and transcription errors were eliminated. We also had 
substantial data on cardiovascular risk-factors and symptoms prior to 
levothyroxine initiation to enable us to investigate the appropriateness 
of levothyroxine prescriptions. 
 
Patients prescribed levothyroxine with a normal TSH level accounted for 
6% of prescriptions. As patients needed at least 12 months of up to CRPD 
standard follow-up before levothyroxine initiation to be included it 
cannot be explained by patients with established hypothyroidism on 
levothyroxine moving to a CPRD practice. A proportion of individuals 
might be planning pregnancy, but never having a pregnancy thereby being 
missed by our pregnancy CPRD codes. The majority of this prescribing 
levothyroxine with a normal TSH is likely to reflect poor practice, but 
from our data it is unclear if this was a problem in only certain parts of 
the UK. Nevertheless, retrospective studies of individuals who have been 
started on levothyroxine at a normal TSH would be important to clarify 
risk benefits of this practice and also see if there were underlying reasons 
(e.g. genetic or environmental) for hypothyroid symptoms at normal TSH 
levels.   
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Although the use of CPRD has provided substantial data there are key 
limitations of this resource. As data is routinely collected, rather than as 
part of a protocol missing data is an inevitable consequence. This is 
highlighted by the large number of individuals which did not have regular 
TSH levels measured following levothyroxine imitation. Furthermore 
absence of a read code for a disease is interpreted as absence of the 
disease itself therefore whilst the positive predictive value of a read code 
is high sensitivity is lower. Data from secondary care must be manually 
entered. Given hyperthyroidism is usually managed in secondary care, 
this may lead to people with treated hyperthyroidism, being labelled as 
primary hypothyroidism. Data on levothyroxine adherence is also not 
available. The key limitations in this study were the lack of data on 
individuals who did not receive a levothyroxine prescription and the lack 
of reliable data on thyroid peroxidase antibody titres.  Furthermore data 
on FT4 measurements were not available in all subjects, as this estimation 
is not always routine practice and follow-up TSH values were only 
available in 40% of the cohort at 5 years. Hence there is the potential for 
bias in the subsection of subjects analysed however there was no 
observed difference in sex or age-group between those with FT4 levels 
available and those without. The TSH assay used varied between 
laboratories, and we were unable to account for this, although the 
majority of assays have similar thresholds for defining low or suppressed 
TSH.  Finally, we were unable to identify and exclude from our 
denominator data individuals who were prescribed levothyroxine prior to 
2001 (and hence not at risk of receiving another first thyroxine 
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prescription) We were also not able to remove from the denominator 
person-years for individuals excluded by GPRD in the creation of our 
dataset. However we consider that the impact of this on the accuracy of 
our results is likely to be small, particularly with regard to the relative 
rate.  
 
In summary, my work suggests there is widespread prescribing of 
levothyroxine for borderline TSH levels where there is limited evidence 
of benefit. This practice may even be harmful, given the relatively high 
risk of developing a suppressed TSH after treatment. A key future study 
here would be to assess whether the potential benefits of treating 
borderline hypothyroidism in younger adults (age < 65 years) can be 
realized without over treatment.  Whilst thyroidologists are still debating 
whether subclinical hypothyroidism should be more widely treated, it is 
increasingly apparent that this is already happening in primary care. 
Randomised controlled trials with sufficient power to assess the health 
consequences of borderline/subclinical hypothyroidism and its treatment 
are urgently needed to refine current levothyroxine prescribing and 
indicate the balance of risks and benefits of current practice. There 
remains attractive potential benefit in the potential for cardiovascular 
outcome improvement in younger individuals, although neuro-
psychological benefits of treating borderline  low thyroid function are 
much less clear. Many young women are started on levothyroxine and 
they may have less cardiovascular benefit as males as they are of lower 
risk, but may be more susceptible to adverse bone outcomes. However  
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the widespread use of levothyroxine in women of child-bearing age may 
have implications for the optimal management in pregnancy, given clear 
potential benefits of optimal thyroid hormone replacement during 
pregnancy, this raises key questions regarding whether universal thyroid 
screening in pregnancy is warranted. Both of these important issues will 
be covered in the next 2 chapters.  
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Chapter 6 TSH levels and risk of miscarriage in 
women on long-term levothyroxine data from CPRD 
 
In the previous chapter I identified changing TSH thresholds for 
levothyroxine initiation for primary hypothyroidism. This has resulted in 
substantial numbers of women of child-bearing age being established on 
levothyroxine. Given the importance of thyroid status on pregnancy 
outcomes the management of women on levothyroxine during their 
pregnancy is of paramount importance. Given the UK has a high burden 
of hypothyroidism and borderline iodine sufficiency, screening and 
treating for low thyroid function may result in substantial obstetric 
benefits. It is therefore informative to study outcomes by TSH level in 
women already established on levothyroxine.  In this chapter I explore 
the adequacy of current management of women established on 
levothyroxine prior to pregnancy and how this might influence obstetric 
outcomes. Here I used primary care data to provide a substantial number 
of women established on levothyroxine who became pregnant as studies 
based on single hospital clinics have had insufficient power. 
 
6.1 INTRODUCTION 
Primary hypothyroidism affects 3-10% of women [34, 42], and is 
predominantly managed in primary care [238]. A substantial proportion 
of affected individuals are of childbearing age [34, 42] and approximately 
1-2% of women receive levothyroxine during pregnancy [4, 94]. There is 
an estimated 30-50% increase in levothyroxine requirements during 
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pregnancy [254, 255] and most hypothyroid women who become pregnant 
will require an increase in levothyroxine dose although the optimal 
magnitude and timing of this increase remains uncertain [94, 255, 256].  
 
Recent reports have highlighted that between 24–55% of women 
established on levothyroxine prior to pregnancy have an elevated thyroid 
stimulating hormone (TSH) at their first antenatal visit [257-262]. 
Suboptimal thyroid function is associated with adverse pregnancy 
outcomes including an increased risk of miscarriage, premature birth, 
gestational hypertension, placental abruption, postpartum hemorrhage 
[113, 263, 264] as well as impaired neurological development in the 
offspring [105, 265]. As would be expected these complications are more 
common and severe in overt hypothyroidism than in subclinical 
hypothyroidism [95, 266]. A recent systematic review reported that 
levothyroxine is effective at lowering the risk of preterm delivery (RR: 
0.41, 95%CI: 0.24, 0.68) and miscarriage (RR: 0.19, 95%CI: 0.08, 0.39) in 
overt hypothyroidism [267].  
 
In 2007, the Endocrine Society recommended that hypothyroid women 
contemplating pregnancy should have their levothyroxine dose adjusted 
to achieve a preconception TSH <2.5mU/L [268]. Additional monitoring 
and dose titrations are also advised to maintain a TSH between 0.2–2.5 
mU/l in the first trimester and between 0.3–3.0 mU/l in later pregnancy 
[268]. Similar targets have been endorsed by subsequent guidelines [93, 
269]. However inadequate treatment of primary hypothyroidism remains 
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a major problem with 40-48% of hypothyroid patients either over-treated 
or under-treated [42, 189, 270, 271] from large regional case series.  
 
To date there has been no population-based study of pregnancy outcomes 
in women on long-term levothyroxine. Women with thyroid function 
available in population birth cohorts are likely to be different to women 
established on levothyroxine, even if TSH levels are similar, as women on 
levothyroxine, will likely have lower FT3 levels and be much more likely 
to be TPO antibody positive. TPO positivity in particular is associated with 
an impaired thyroidal response to hCG [272]. 
 
The majority of studies in this area have been small and in groups of 
women attending specialist hospital antenatal clinics [257-259, 262].   
These hospital cohorts are less representative of the general population 
and might underestimate the incidence of early miscarriages occurring 
prior to specialist clinic enrollment. In this analysis, I addressed this topic 
using data from the CPRD as described in the previous chapter. My aim 
was to determine the adequacy of thyroid hormone replacement in 
pregnancy and to examine pregnancy outcomes in relation to TSH levels.  
 
6.2 METHODS 
6.2.1 Pregnancy Cohort  
The cohort was based on our CPRD dataset previously described in 
Chapter 2 and Chapter 5 summarized in Figure 16. This contained 
detailed primary care clinical data including patient symptoms, outcomes 
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and biochemical measures on over 50,000 patients on levothyroxine. In 
this analysis we identified 7,978 women of childbearing age (18-45 years) 
and from these we identified 1,035 pregnancies of which 1,013 were 
completed pregnancies (foetal loss or birth before the end of the dataset 
records) in women established on levothyroxine for at least 6 months.  
Figure 16 CPRD dataset of primary hypothyroidism 
 
6.2.2 Identification of pregnancies and TSH levels 
Pregnancies were identified using 987 pregnancy related codes including 
pregnancy confirmation tests, antenatal clinic appointments, and 
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delivery records provided by Caroline Minassian (London School of 
Hygiene and Tropical Medicine). Codes were used in combination to 
estimate the date of pregnancy and thereby the timing of TSH tests. For 
instance, codes pertaining to confirmation of pregnancy, early stage of 
pregnancy and morning sickness were used to identify first trimester 
dates whilst codes relating to delivery dates and antenatal clinic 
attendance from 12-40 weeks were used to confirm second and third 
trimester dates. Pregnancy dates were linked to date of first 
levothyroxine prescription and only a woman’s first pregnancy occurring 
at least six months after levothyroxine initiation was included. If 
individuals had more than one TSH level recorded in a trimester the 
highest reading was used. Individuals with evidence of a pregnancy but 
no evidence of an outcome such as delivery, miscarriage or termination 
were excluded from pregnancy outcome analysis (delivery/miscarriage), 
but not from descriptive analyses of TSH levels during pregnancy. 
Sensitivity analyses were undertaken with individuals without a delivery 
outcome (miscarriage/termination aside) recoded as a successful 
delivery. There was insufficient data on free thyroxine levels and thyroid 
peroxidase antibody titres  so these were not analysed. 
 
6.2.3 Identification of adverse pregnancy outcomes 
Adverse pregnancy outcomes were identified using medical codes 
(Appendix 2). For the primary analysis codes relating to miscarriages and 
stillbirths were used. For a secondary analysis, other adverse pregnancy 
complications were identified and grouped together using medical codes, 
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specified a priori covering emergency caesarean section, pre-eclampsia, 
post-partum hemorrhage, placental abruption, prematurity, low birth 
weight, growth restriction, need for intensive care, and neonatal death.  
 
6.2.4 Identification of diabetes and socio-economic status 
Individuals with a diagnosis of type-1diabetes, type-2 diabetes or 
gestational diabetes were identified using multiple medical codes 
pertaining to these conditions and were only included if diabetes 
preceded or occurred during the pregnancy of interest. Quintiles of socio-
economic status were calculated from the Index of Multiple Deprivation 
for the postcode of each individual’s general practice. 
 
6.2.5 Statistical analysis 
Serum TSH is presented as median (inter-quartile range). TSH was 
compared according to the year of pregnancy before and after the 
Endocrine Society guidelines [268] (2001-2007 versus 2008-2009)  and by 
pregnancy trimester (1st versus 2nd/3rd) using the Wilcoxon-rank test. 
The primary analysis assessed the odds of miscarriage/stillbirth by first 
trimester TSH level. Secondary analyses were undertaken to examine the 
odds of other pregnancy complications by first and second/third 
trimester TSH. To reflect trimester specific reference-ranges as 
recommended by current international guidelines [93, 269] first trimester 
TSH levels were split into 5 categories: i) <0.2 mU/l) ii) 0.2–2.50 mU/l iii) 
2.51–4.50 mU/l iv) 4.51–10 mU/l v) >10 mU/l. The lower three TSH level 
categories were subtly different for second/third trimester analysis, i) 
<0.3 mU/l, ii) 0.3-3.00 mU/l iii) 3.01-4.50 mU/l (26, 27. At the time of 
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this analysis the 0.2-2.5 mU/l and 0.3-3.0 mU/l categories represented 
the recommended optimal ranges for the first and second/third 
trimesters respectively and were used as the reference category for the 
multivariable model. Analyses were adjusted for age, year of pregnancy, 
social class and diabetes before or during pregnancy 
 
6.3 RESULTS 
6.3.1 TSH levels in women of child-bearing age (18-45 years) on 
levothyroxine (N=7,978). 
The CPRD dataset of 52,298 patients on levothyroxine for primary 
hypothyroidism was interrogated. 7,978 women aged 18-45 years who had 
been on levothyroxine for at least one year had a TSH level available. 
Analysis of this TSH measurement, revealed a median TSH of 2.22 mU/l 
(IQR 0.97–3.78) with 3,678 (46.1%) having a TSH > 2.5 mU/l and 364 (4.6%) 
with TSH > 10 mU/l. 1,082 women (13.6%) were over-treated with a TSH 
<0.4 mU/l and 408 women (5.11%) had a TSH < 0.1 mU/l. Data are 
summarized in Table 40. 
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Table 40 Latest TSH levels in women established on levothyroxine 
for at least one year (N=7,978) 
 
TSH  
threshold (mU/l) 
Number of 
individuals (%) 
<0.02 167 2.1 
0.02 – 0.40 915 11.5 
0.40 – 2.50 3,361 42.1 
2.50 – 4.50 2,127 26.7 
4.50 -10.0 1,044 13.1 
>10.0 364 4.56 
 
1,082 women (13.6%) of women had a TSH < 0.4 mU/l 
408 women (5.11%) of women had a TSH < 0.1 mU/l  
 
 
6.3.2 TSH levels in women who became pregnant (N=1,013) 
The median age at conception was 33 years (IQR 29-37) with a median 
duration of levothyroxine therapy prior to pregnancy of 17.5 months (IQR 
11.2–25.8). Of the 1,013 pregnancies, we identified 541 deliveries 
(53.4%), 144 miscarriages (2 were stillbirths) (14.2%), 79 terminations of 
pregnancy (7.8%), 171 pregnancies with no outcome recorded (16.9%) and 
78 pregnancies (7.7%) which were ongoing when the data were extracted 
(before the completion of pregnancy) (Figure 16). No differences were 
observed between individuals with pregnancy outcomes unaccounted for 
and those with pregnancy outcomes accounted for with regard to 
calendar year of pregnancy (p=0.18), age at pregnancy (p=0.17), first 
trimester TSH level (p=0.17) or second/third trimester TSH level (p=0.73) 
presence of diabetes (p=0.37) or social class (p=0.23). 
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Figure 17 Pregnancy outcomes and TSH measurements in CPRD 
pregnancy dataset 
 
Trim= Trimester 
 
880 women (86.9%) had a TSH level recorded during pregnancy while 769 
(75.9%) had a TSH recorded in the first trimester.  Of women with a first 
trimester TSH, 434 (56.4%) had levels that were greater than 2.5 mU/l, 
224 (29.1%) were greater than 4.50 mU/l and 57 (7.41%) were greater 
than 10 mU/l. The spread of first trimester TSH values by category is 
shown in Figure 18. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
1,013 Pregnancies 
541 Births 
(53.4%) 
144 Miscarriages 
(14.2%) 
79 Terminations 
(7.8%) 
171 Unaccounted 
(16.9%) 
78 pregnant at 
dataset extraction  
(7.7%) 
TSH recorded  
Trim. 1: 431 (79.7%) 
Trim 2/3: 441 (81.5%) 
Both 351 (64.9%) 
TSH recorded  
Trim 1: 118 (81.9%) 
Trim 2/3: 4  (2.78%) 
 
TSH recorded  
Trim 1: 36 (45.6%) 
Trim 2/3: 0 (%) 
 
TSH recorded*  
Trim 1: 121 (70.7%) 
Trim 2/3: 90  
Both 74 (43.3%)   
TSH recorded  
Trim 1: 63 
Trim 2/3: 32  
Both 27 (34.6%)  
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Figure 18 Highest recorded TSH levels during trimester 1  
 
Numbers of women in each category are shown above each bar. 
Percentages are derived from all women with a documented TSH in that 
category  
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Figure 19 Highest recorded TSH levels during trimesters 2 and 3 
 
Numbers of women in each category are shown above each bar. 
Percentages are derived from all women with a documented TSH in that 
category  
 
 
 
 
Median TSH in the first trimester was slightly lower before 2007 (2.78 
mU/, IQR 1.33-4.96) than after 2007 (2.98 mU/l, IQR 1.77-5.31) p=0.09. 
A summary of TSH levels by year-group is shown in Table 41.  
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Table 41 Gestational TSH levels by year of pregnancy in women on 
levothyroxine 
 
 
 
 
 
 
 
 
 
769 individuals with TSH measured during first trimester 
567 individuals with TSH measured during second/third trimester 
 
567 women had TSH measured in the 2nd/3rd trimester of which 348 
(61.4%) had a TSH within the trimester-specific target range of 0.30-3.0 
mU/l. In addition, 168 women (29.6%) had TSH >3.0mU/l in the 2nd/3rd 
trimester and 51 (9.0%) had a TSH <0.3 mU/l (Figure 19). Median TSH 
levels were lower in the 2nd/3rd trimester (2.10 mU/l, IQR 1.19–3.37 
mU/l) than in the first trimester (2.89 mU/l, IQR 1.50–5.0 mU/l) 
(p=<0.0001). However inadequate TSH levels persisted in a substantial 
proportion of pregnancies and 66.5% of women with TSH >2.5 mU/l in the 
first trimester who also had a TSH measured in the 2nd/ 3rd trimesters, 
had a 2nd/3rd trimester TSH greater than the target of 3.0mU/l.  133 
(13.1%) of the 1,013 pregnancies had no corresponding TSH record and 
over half of these (51.9%) ended in miscarriage or termination. A small 
number of women amounting to 20 (3.7%) out of the 541 women with a 
delivery at term recorded had no corresponding TSH measurement over 
Trimester Year group 
Number 
of women 
Median TSH 
mU/l 
IQR  
1 
2001-2003 98 2.10 0.86 - 4.33  
2004-2006 294 2.97 1.48 – 5.01  
 2007-2009 377 2.98 1.77 – 5.31  
      
2/3 
2001-2003 80 2.34 1.79 - 3.68   
2004-2006 218 2.01 0.99 - 2.05  
2007-2009 269 2.09 1.20 – 3.20  
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the entire duration of pregnancy and thus did not appear to have had 
thyroid function measured during pregnancy despite being established on 
levothyroxine.  
 
6.3.3 Delivery/Miscarriage outcomes by first trimester TSH  
We identified 431 deliveries and 118 miscarriages in the 769 pregnancies 
of women with a TSH level recorded in the first trimester. In 22 of the 
144 total miscarriages (15.3%) the miscarriage was the first GPRD record 
of a pregnancy and was not preceded by a thyroid function test in 
pregnancy.  
 
Median 1st trimester TSH was higher in women who miscarried than in 
those with a successful delivery 3.59mU/l vs. 2.80mU/l (p=0.003). After 
adjusting for maternal age, calendar year, social class and presence of 
diabetes, the odds of miscarriage rose with increasing TSH levels above 
the target TSH range of 0.2-2.5 mU/l (p for trend =0.008) with the 
greatest impact observed with TSH levels greater than 10 mU/l OR=3.95 
(95%CI 1.87, 8.37) (Table 42). An increase in the odds of miscarriage was 
also observed with TSH levels between 4.51–10 mU/l (OR=1.80, 95%CI 
1.03, 3.14). In individuals with TSH 0.2-2.5 mU/l the risk of miscarriage 
was 17%, rising to 30% at TSH >4.5 mU/l and 41.5% at TSH >10mU/l. 
Individuals with a maximum TSH <0.2 mU/l or TSH 2.51–4.5 mU/l had an 
odds ratio of miscarriage greater than 1 but this is unlikely to be of any 
clinical relevance.  
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In addition, 60 women had a recorded TSH <0.2 mU/l which did not 
persist through pregnancy. Analysis of these individuals with transient 
TSH suppression did not reveal any clear increase in the odds of 
miscarriage compared to individuals who never had had a TSH outside the 
trimester-specific target range OR=0.62 (95%CI 0.25, 1.54) p=0.30. 
Sensitivity analyses with all unidentified pregnancy outcomes recoded as 
a successful delivery revealed similar associations (Table 42).  
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Table 42 Odds of miscarriage by 1st trimester serum TSH level 
TSH 
(mU/l) 
N Foetal 
loss 
N 
Foetal 
 loss 
(%) 
Odds  
Ratio 
95%CI p OR 95%CI P 
<0.2 36 6 16.7 0.97 0.37-2.51  1.14 0.62-1.93  
0.2-2.5 199 34 17.1 1   1   
2.51-4.5 151 29 19.2 1.15 0.66-2.00 0.02 1.09 0.61-1.93 0.008 
4.51-10 122 32 26.2 1.73 1.00, 2.98  1.80 1.03-3.14  
>10 41 17 41.5 3.44 1.66, 7.08  3.95 1.87-8.37  
549 individuals in model: 431 deliveries 118 miscarriages 
*Adjusted for age, calendar year of pregnancy, diabetes during or before pregnancy, social class 
Reference category is the recommended 1st trimester TSH: 0.2-2.5 mU/L 
# Test for trend comparing the odds of miscarriage by TSH levels above 2.5 mU/l to the reference category of 0.2-2.5 mU/l. 
 
 
Table 43 Odds of miscarriage by 1st trimester serum TSH assuming all unidentified deliveries resulted in a successful 
outcome 
TSH 
(mU/l) 
Total 
 (N) 
Miscarriages 
 (N) 
Odds of 
Miscarriage 95%CI p# 
Odds of 
Miscarriage* 95%CI* p#* 
<0.2 48 6 1 0.40, 2.52  0.98 0.38, 2.55  
0.2-2.5 272 34 1  0.001 1  <0.001 
2.51-4.5 200 29 1.19 0.70, 2.02  1.09 0.63, 1.89  
4.51-10 160 32 1.75 1.03, 2.97  1.73 1.02, 2.96  
>10 53 17 3.31 1.68, 7.08  3.64 1.81, 7.32  
733 individuals in model: 615 deliveries 118 miscarriages *Adjusted for age, calendar year of pregnancy, diabetes during or before 
pregnancy, social class Reference category is the recommended 1st trimester TSH: 0.2-2.5 mU/L 
# Test for trend comparing the odds of miscarriage by TSH levels above 2.5 mU/l to the reference category of 0.2-2.5 mU/l. 
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Analyses stratified by age revealed that in women aged <35 years sub-
optimal thyroid function was associated with higher risk estimates of 
miscarriage than in women aged 35 years or older. This may also reflect 
the greater likelihood of women being TPO antibody positive being 
diagnosed at an earlier age. Alternatively, this may be related to the 
higher baseline risk of miscarriage in the older population (Table 44).  
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Table 44 Analysis of the odds of miscarriage by first trimester TSH levels stratified by age 
 Age <35 years Age 35 years and older 
TSH 
(mU/l) 
Total 
 (N) 
Miscarriages 
 (N) 
Odds of 
Miscarriage 95%CI p# 
Total 
 (N) 
Miscarriages 
 (N) 
Odds of 
Miscarriage* 95%CI* p#* 
<0.2 20 4 2.32 0.65, 8.33  16 2 0.54 0.11, 2.73  
0.2-2.5 116 12 1  <0.001 83 22 1  0.29 
2.51-5.0 90 11 1.16 0.48, 2.81  61 18 1.06 0.49, 2.29  
5.01-10 67 13 2.19 0.92, 5.21  55 19 1.50 0.71, 3.19  
>10 23 11 8.84 3.09, 25.2  18 6 1.67 0.52, 5.27  
*Adjusted for age, calendar year of pregnancy, diabetes during or before pregnancy, social class 
Reference category is the recommended 1st trimester TSH: 0.2-2.5 mU/L 
# Test for trend comparing the odds of other adverse events† by TSH levels above 2.5 mU/l to the reference category of 0.2-2.5 
mU/l. 
 
6.3.4 Odds of other adverse pregnancy outcomes by 1st trimester and 2nd/3rd trimester TSH  
Out of the 431 births with a TSH level measured in the first trimester, 29 (6.73%) had other adverse pregnancy outcomes. Of the 
441 births with a TSH level measured in the second/third trimester 31 (7.0%) had other adverse pregnancy outcomes. There was 
no clear pattern of association with adverse events around delivery and TSH level in the first trimester or second/third trimester 
(Table 45 and Table 46) although individuals with a TSH level in the target ranges had the lowest odds of a late adverse pregnancy 
outcome. 
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Table 45 Odds of other adverse obstetric outcomes by 1st trimester serum TSH level 
TSH 
(mU/l) 
Total 
(N) 
Adverse Outcomes 
(N) 
Unadjusted odds of 
late adverse outcomes 
95%CI p# 
Adjusted odds of 
late adverse outcomes* 
95%CI* p#* 
<0.2 26 4 3.47 0.95, 12.7  3.44 0.89, 13.3  
0.2-2.5 165 7 1  0.21 1  0.19 
2.51-4.5 122 8 1.58 0.56, 4.49  1.56 0.54, 4.47  
4.51-10 90 9 2.51 0.90, 6.98  2.58 0.92, 7.26  
>10 23 1 0.98 0.12, 8.34  1.05 0.12, 8.96  
426 individuals in model: 29 with adverse outcomes 
*Adjusted for age, calendar year of pregnancy, diabetes during or before pregnancy, social class 
Reference category is the recommended 1st trimester TSH: 0.2-2.5 mU/L 
# Test for trend comparing the odds of other adverse events† by TSH levels above 2.5 mU/l to the reference category of 0.2-2.5 
mU/l. 
† emergency caesarean section, pre-eclampsia, post-partum hemorrhage, placental abruption, prematurity, low birth weight, 
growth restriction, need for intensive care, and neonatal death.  
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Table 46 Odds of other adverse obstetric outcomes† by 2nd/3rd trimester serum TSH level 
TSH 
(mU/l) 
Total 
 (N) 
Adverse Outcomes 
 (N) 
Unadjusted odds of 
Adverse Outcomes 
95%CI p# 
Adjusted odds of 
Adverse Outcomes* 
95%CI* p#* 
<0.3 37 4 2.08 0.65, 6.66  2.64 0.80, 8.67  
0.3-3.0 273 15 1  0.20 1  0.11 
3.01-4.5 64 6 1.77 0.56, 4.57  1.85 0.68, 5.08  
4.51-10 59 5 1.59 0.28, 21.3  1.88 0.64, 5.54  
>10 7 1 2.45 0.65, 6.65  3.36 0.37, 30.3  
441 individuals in model: 31 with adverse outcomes 
*Adjusted for age, calendar year of pregnancy, diabetes during or before pregnancy, social class 
Reference category is the recommended 1st trimester TSH: 0.3-3.0 mU/L 
# Test for trend comparing the odds of other adverse events† by TSH levels above 3.0 mU/l to the reference category of 0.3-3.0 
mU/l. 
† emergency caesarean section, pre-eclampsia, post-partum hemorrhage, placental abruption, prematurity, low birth weight, 
growth restriction, need for intensive care, and neonatal death.  
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7.4 DISCUSSION  
This analysis of a primary care dataset studied TSH levels and birth 
outcomes during pregnancy in women established on levothyroxine for 
primary hypothyroidism. It showed that almost half of women of 
reproductive age who take levothyroxine for primary hypothyroidism 
have a thyroid status that is not optimal for pregnancy according to 
current guidelines. Furthermore, up to 60% of pregnant women have 
suboptimal TSH levels in early pregnancy. In addition, I found no evidence 
of improvement in gestational thyroid hormone replacement since the 
Endocrine Society guidelines were introduced in 2007. Our findings are in 
keeping with recent regional data from Scotland [260] and Wales [262] 
and suggest that the current problem is widespread and persistent. 
Recent ATA guidelines [93] encourage women having the confidence to 
independently increase their levothyroxine dose on confirmation of 
pregnancy. However for the UK greater awareness of this for general 
practitioners is essential as they will provide the medical input in early 
pregnancy - a time where thyroid status is particularly important. 
 
This is an important issue to address as I also observed  that TSH levels 
above 2.5 mU/l in the first trimester were associated with increased odds 
of miscarriage with levels between 4.51-10 mU/l having almost double 
and levels >10mU/l nearly a fourfold increase in the odds of subsequent 
miscarriage even after adjusting for key confounders. In effect women 
with TSH levels within the current guideline targets (0.2-2.5 mU/l) had 
the lowest miscarriage rates (17]. It would therefore seem reasonable 
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that the currently recommended preconception and early gestation TSH 
targets (<2.5 mU/l) are maintained [4].  
 
Although I observed a trend towards increasing odds of miscarriage with 
rising TSH above 2.5 mU/l I did not find a clear increase in the odds of 
miscarriage in women with TSH levels 2.51-4.5 mU/l. This finding is in 
contrast to the large (N=4,123) population based study by Negro et al 
which reported an increased risk of miscarriages at TSH levels 2.5-5.0 
mU/l [148] although these women were not on levothyroxine.  In 
addition, the miscarriage risk  in women with a TSH of 2.5-4.5 mU/l was 
higher than that observed by Negro et al in women with a comparable 
TSH of 2.5-5.0 mU/L (19% vs. 6%). The reasons for these differences are 
unclear but the higher miscarriage rates in my analysis may have arisen 
because the Negro study was restricted to antibody negative women 
while our patients were older (median age 33 years vs. 28 years) and 
more likely to be antibody positive from Hashimoto’s thyroiditis, all 
factors that are known to increase the risk of pregnancy loss [273].  
Furthermore this study may have been underpowered to detect an effect 
within this TSH category. 
 
My data also indicate the need for a more meticulous approach to thyroid 
hormone replacement in pregnancy. Around 13% of pregnant women in 
this cohort did not appear to have a TSH level measured throughout 
pregnancy highlighting the need for closer monitoring. Another important 
observation was that transient TSH suppression did not carry an increased 
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risk of miscarriage suggesting that brief periods of over-replacement 
were not detrimental to obstetric outcomes and should not deter 
judicious increases in levothyroxine dose to attain target TSH levels. 
However larger observational studies are needed to better define optimal 
TSH levels in the first trimester.  
 
I also identified a worrying discrepancy between published guidelines and 
clinical practice. The reason for this is likely to be multi-factorial 
including a lack of familiarity amongst clinicians with the current 
guidelines [93, 274], high rates of unplanned pregnancies, non-
compliance with levothyroxine [275], and inconsistencies in management 
strategies amongst endocrinologists and obstetricians [276]. Optimization 
of early gestation thyroid function in women on levothyroxine is however 
achievable. One approach is to increase the levothyroxine dose by two 
extra tablets a week on conception, representing an approximate dose 
increase of 30% [256]. This appears to be safe and effective, but requires 
wider dissemination of the guidance and a willingness on the part of 
individual women to independently adjust their doses. A second strategy 
[277] is to ensure that pre-conception TSH is maintained in the low-
normal range (<1.2 mU/l) in order to increase the likelihood of optimal 
thyroid status in early gestation [277]. However close monitoring will be 
required to prevent over-treatment which was seen in only 5.1% of our 
sample based on a TSH <0.1 mU/l according to the ATA pregnancy 
guidelines)[93] Subclinical hyperthyroidism has not been shown to be 
harmful in pregnancy [278] and the small risk of its occurrence is largely 
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outweighed by the adverse effects of suboptimal replacement due to 
insufficient or late dose increases.  Both low and high maternal FT4 levels 
may result in increased risk of lower offspring IQ which suggests that care 
must be to taken to correct low FT4 levels, but avoiding overtreatment 
is essential [76]. 
 
When compared to the risks of under-treatment, the benefits of 
levothyroxine optimization were substantial; 21 of the 49 (42.9%) 
miscarriages occurring at TSH levels >4.50 mU/l may have been 
prevented if they had the same rate of miscarriage as individuals with a 
TSH level between 0.2-2.5 mU/l. Thus my findings are also relevant to 
the current debate on universal thyroid screening. If levothyroxine 
therapy can reduce the risk of miscarriage in women with TSH levels 
above 4.5 mU/l to that observed in 0.2-2.5 mU/l, then there would be 
substantial gains at the population level from thyroid screening. 
However, clarifying treatment thresholds and implementing this policy 
would prove challenging. Furthermore, evidence from a large randomized 
controlled trial of correcting subclinical hypothyroidism and isolated 
hypothyroxinemia later in pregnancy (prior to 20 weeks) showed no 
benefit on obstetric outcomes[118] 
 
The strengths of the this analysis are the use of a large well-validated 
population-based dataset with detailed clinical and biochemical data 
collected over a long period. The widespread use of electronic 
prescriptions by UK primary care physicians makes it unlikely that 
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individuals receiving levothyroxine were missed. Similarly, almost all 
laboratories in England were issuing electronic biochemical results by the 
year 2000 thus very few TSH results would have been excluded. Compared 
to studies based on hospital clinic records our dataset included data from 
a wide variety of practitioners and is therefore representative of the 
general population. In addition, I could identify early pregnancy losses 
which would have been missed in hospital based studies since most 
pregnant women do not enrol in hospital antenatal clinics until well into 
gestation. Indeed 15.3% of our identified miscarriages were the first entry 
of that pregnancy into the GPRD record and these events would certainly 
have been missed using hospital clinic records alone. Also this analysis is 
several times larger than previous studies I was able to identify a 
substantially greater number of miscarriages enabling us to better define 
risks according to TSH thresholds. Of practical importance is the 
longitudinal nature of our study which has highlighted the persistent 
nature of the problem in spite of published guidelines [268]. Finally, the 
use of observational data has allowed us to quantify the relative risks of 
over and under-treatment of gestational hypothyroidism which could not 
have been satisfactorily addressed in a non-observational study design.  
 
Study limitations include the lack of data on some potential confounding 
factors most notably obstetric co-morbid conditions. Thus my observed 
associations between TSH levels and adverse obstetric outcomes could 
have been influenced by other undetermined obstetric factors. 
Furthermore, there be residual confounding from social class by linking 
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this to the patient’s primary care practice rather than individual 
addresses which were unavailable to us. We also lacked data on free 
thyroxine levels and thyroid peroxidase antibody titres and therefore we 
were unable to clarify the impact of hypothyroxinaemia and thyroid 
autoimmunity on the outcomes observed in this study. We were unable 
to identify 17% of pregnancy outcomes which could have potentially led 
to ascertainment bias. It is however likely that the vast majority of 
unidentified outcomes result in normal deliveries, as adverse outcomes 
are more likely to be recorded. However if there was a differential 
recording of foetal loss by TSH level then this could have a substantial 
impact on effect estimates. However a sensitivity analysis assuming all 
unidentified outcomes were normal deliveries revealed similar results. 
Another key issue is that we didn’t have data on women not on 
levothyroxine, I therefore could not assess whether results would be 
similar to those if screening on women with unknown thyroid status was 
undertaken during pregnancy. Nor could I assess differences between my 
study population and the “normal” pregnant population. 
 
In summary, in this chapter I have demonstrated that the majority of 
levothyroxine treated women in this community-based cohort have early 
gestational TSH above the currently recommended targets. The best 
pregnancy outcomes were seen in women with target TSH levels and a 
strong risk of miscarriage was present at TSH levels exceeding 4.5 mU/l. 
There is therefore a pressing need for better liaison between 
endocrinologists and primary care practitioners to improve the adequacy 
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of thyroid hormone replacement in pregnancy or preferably before 
conception. 
 
This analysis did not have any data on women who were not on 
levothyroxine, therefore other studies are needed to assess whether 
screening thyroid function is of benefit in pregnancy. This is the focus of 
my next chapter which uses trial data to ascertain if screening for and 
treating low thyroid function improves obstetric outcomes. 
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Chapter 7 Controlled Antenatal Thyroid Screening Study: 
Obstetric Outcomes 
 
In the previous chapter, I highlighted that good control of thyroid 
function in pregnancy in women established on levothyroxine appeared 
to reduce the risk of miscarriage. In this chapter I will assess whether 
screening for and treating borderline low thyroid function during 
pregnancy results in improved obstetric outcomes. This chapter will 
combine data linkage to obtain obstetric outcomes with a large 
randomized controlled trial, the controlled antenatal thyroid screening 
study [116].  
 
7.1 INTRODUCTION 
It is well established that thyroid hormone is essential for an 
uncomplicated pregnancy and optimal foetal development [4]. Maternal 
thyroid hormone levels are especially important in the first half of 
pregnancy whilst the foetal thyroid is developing [4]. Thyroid disorders 
are also common in women of child-bearing age; furthermore, pregnancy 
increases demands on the hypothalamic-pituitary-thyroid axis[4]. As I 
have shown in the previous chapter in women established on 
levothyroxine, even modest variation in TSH levels was associated with 
increased risk of foetal loss.   
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At present, it is unclear if screening for and treating abnormal thyroid 
function is of benefit. Overt maternal hypothyroidism - elevated 
concentrations of TSH and low maternal free FT4 occurs in approximately 
0.2-0.6% of pregnant women [4, 95, 96], whereas SCH (elevated TSH and 
normal FT4) can occur in up to 18% of pregnancies depending on the 
precise definition and TSH cut-point used [4, 93]. At present, all 
endocrine, thyroid, and obstetrical societies recommend initiating 
treatment for overt thyroid disease detected in pregnancy [85, 93, 269, 
279, 280].  Although there is no consensus on screening for thyroid 
disease in pregnancy. 
 
Given that SCH and isolated hypothyroxinemia (IH – FT4 below the 2.5 
centile with TSH within the normal range) are more common in pregnancy 
than overt thyroid disease, it is important to quantify the risks they pose 
and assess the potential benefits of treatment if detected during 
pregnancy. 
 
SCH is associated with similar adverse obstetric outcomes as overt 
hypothyroidism, albeit with a more modest effect [104]. Studies have 
demonstrated an increased incidence of adverse pregnancy outcomes 
with SCH including foetal loss, early pregnancy loss and admissions to the 
intensive care unit [106-110]. IH was originally considered to be a 
pregnancy specific condition possibly arising as a consequence of mild 
iodine deficiency. This concept has been more recently challenged as it 
occurs in iodine sufficient areas and does not typically resolve with iodine 
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supplementation [97, 98]. Other factors including elevated BMI, older 
age, iron status and placental angiogenic factors have all been identified 
as likely risk factors for IH [99-101]. 
 
Thyroid auto-immunity may also have a role as a meta-analysis of 19 
observational cohort studies showed more than a tripling in the odds of 
miscarriage in the presence of thyroid antibodies OR=3.9, (95%CI: 2.48 to 
6.12) [114]. This is an important observation as thyroid auto-immunity is 
a substantial risk factor for SCH [4] although there may be an important 
interactive effect with the combination of higher TSH levels and TPO 
antibody positivity resulting in substantially increased risk of adverse 
outcomes [93]. Furthermore, TPO antibody positivity may impair 
thyroidal response to hCG resulting in less responsiveness to the demands 
of pregnancy on the thyroid [272].  It is likely that thyroid hormone levels 
are not simply reflecting auto-immunity as levothyroxine in TPO antibody 
positive women may improve outcomes [273]. 
 
7.1.1 Treatment of SCH and IH detected during pregnancy 
Two large randomized controlled trials the controlled antenatal thyroid 
study (CATS)[116] and a study by Casey et al. [118] have studied the 
effects of screening and treating borderline low thyroid function in 
pregnancy. The studies are summarized in Table 47. Neither study 
showed any beneficial effects of treatment on offspring IQ [116, 118]. 
Reasons for failure to establish treatment benefit include relatively late 
initiation of treatment (particularly in the Casey study) early age of IQ 
 
 
200 
assessment (particularly in the CATS study).  Follow on analysis of the 
CATS study revealed no apparent benefit of treatment at age 9[129] 
although identified levothyroxine over-treatment may increase the risk 
of autism symptoms [281].  
 
Table 47 Summary of the CATS and Casey randomized clinical trials 
 
 
The original CATS study [116] did not collect detailed obstetric outcomes. 
Importantly, the CATS study  was substantially earlier than in the Casey 
study[118]. This presents a unique opportunity to study the potential 
benefits on obstetric outcomes with earlier initiation of levothyroxine. 
Potential advantages include additional treatment time to influence 
adverse outcomes such as early gestational age. Other outcomes such as 
foetal loss, are less common in later pregnancy, and failure to detect 
treatment benefit here may reflect lack of power. Furthermore, the 
Casey study only assessed obstetric outcomes in those with abnormal 
thyroid function, the use of data-linkage enables those with normal 
 CATS Study  
[116, 129] 
Casey Study 
[118] 
Countries UK, Italy USA 
   
Number randomised 794 1203 
   
Gestational age at recruitment 
(weeks) 
<16 <21 
   
Median TSH (mU/l) 3.8 (controls 3.2) 4.5 (controls 4.3) 
   
Placebo-controlled No Yes 
   
Offspring age at assessment 
(years) 
3, 9 5 
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thyroid function to be studied as well. A further randomized control trial 
in this area would have substantial difficulties particularly as many 
clinicians now screen for and treat SCH, therefore repeating these studies 
would be challenging. 
 
For this chapter I obtained detailed obstetric data from Welsh patients 
enrolled in the CATS study using data linkage in the Secure Anonymised 
Information linkage (SAIL) databank (described previously in the 
methods) [130]. This enabled me to assess the potential obstetric 
benefits of screening for sub-optimal maternal thyroid function in early 
pregnancy 
 
7.2 METHODS  
7.2.1 Study Cohort 
The CATS study has been previously described in detail [116, 282] and 
already introduced in Chapter 2. In brief, CATS was a large randomized 
trial of 21,846 pregnant women recruited from the UK and Italy (15,752 
from Wales).  Pregnant women were recruited prior to 16 weeks gestation 
at which time 50% had TSH and FT4 measured having been randomised to 
the screening group. The remainder (control group) had thyroid function 
measured after delivery. Women with TSH levels above the 97.5th 
percentile, and/or free T4 levels below the 2.5th percentile, were 
considered to have a positive screening result. Women with positive 
findings in the screening group received 150 mcg of levothyroxine per day 
with a median treatment initiation of 13 weeks 3 days. All patients 
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received 150mcg of levothyroxine. Thyroid function was performed 6 
weeks later with a target TSH of 0.1 to 1.0 mU/l. 
 
SAIL is a database of routinely collected health data run by the Health 
Informatics Research Unit (HIRU) at Swansea University. SAIL contains 
over two billion anonymised person-based records and is linked to other 
health and social care datasets including the Patient Episode Database 
for Wales (PEDW) [283]. PEDW is a register of all clinic and inpatient 
activity undertaken in Welsh NHS hospitals and processes over a million 
hospital episodes annually including information on diagnoses, 
admissions, hospital births, and surgical operations including Caesarean 
sections. Matching of SAIL data to CATS study data was undertaken using 
multiple approaches. These included the mother’s name, date of birth, 
hospital number, home address during the CATS study and GP practice 
during the CATS study. The matching process in SAIL is shown in Figure 
20.
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Figure 20 Data linkage in SAIL 
 
 
 
 
204 
7.2.2 CATS data and SAIL obstetric data used in analyses 
Data on maternal age, maternal weight, thyroid function (TSH and FT4), 
gestational age at recruitment, parity, trial group, whether levothyroxine 
treatment was initiated, and smoking history were all obtained from the 
CATS trial database with SAIL data providing obstetric outcomes. The pre-
specified primary outcomes of interest were foetal loss, early gestational 
age (delivery before 37 weeks, and delivery before 34 weeks), need for 
Caesarean Section (overall) and early Caesarean section (before 37 
weeks), whether the baby needed inducing, pre-eclampsia, low birth 
weight (<10th centile) macrosomia (> 90th centile) and an APGAR score <7 
at 5 minutes. 
7.2.3 Statistical analysis  
All women recruited to the CATS study from the UK were eligible, 
however as congenital abnormalities will influence the risk of adverse 
obstetric outcomes independently of thyroid function these pregnancies 
were removed from the analysis. 
 
Logistic regression was used to assess the odds of adverse outcomes. 
Analyses were performed to assess different groups 1) Those with 
abnormal thyroid function only – comparing those who were treated to 
those who were untreated. 2) Comparing those with normal thyroid 
function to those with abnormal thyroid function. 3) Comparing those 
with normal thyroid function to those who were untreated with abnormal 
thyroid function. 
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Analyses were adjusted for maternal age, maternal weight at 
recruitment, parity, smoking status, and sex of offspring. In analysis of 
just those with abnormal thyroid function analyses were also adjusted for 
maternal TSH and FT4 levels.  Maternal age was available in all 
participants there was missing data in all other co-variates in the 14,376 
individuals used in the final analysis: maternal weight at recruitment 
1,162 (8.1%), parity 119 (0.83%), smoking status 777 (5.4%), sex of 
offspring, 119 (0.83%). Missing covariates were dealt with in adjusted 
models by multiple variable imputation.  
 
Analyses were undertaken to compare outcomes with those with 
abnormal thyroid function versus those with normal thyroid function. 
Additionally, analyses were repeated by TSH level with TSH levels were 
categorized into <2.5 mU/l, 2.5-4.0 mU/l and greater than 4 mU/l in 
keeping with ATA thresholds [93]. Analyses were repeated with those who 
received treatment with levothyroxine removed to enable untreated 
individuals with low thyroid function to be compared to those with 
normal thyroid function.  
 
7.2.4 Sensitivity analyses 
As smoking during pregnancy is strongly associated with low birth weight 
and prematurity [284] this was used to confirm successful data linkage as 
smoking status was taken from the CATS study and these outcomes were 
taken from SAIL. Additionally, maternal weight is likely to be highly 
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correlated with offspring weight and this was also assessed as it used 
maternal weight from the CATS study and birthweight from SAIL.  
  
There would also be a small number of women with undiagnosed 
hyperthyroidism. Therefore, to exclude individuals with hyperthyroidism 
from the normal group, women with hyperthyroidism TSH levels below 
0.05 mU/l) and/or FT4 levels in the highest 2.5% (> 17.7 pmol/l) were 
also excluded in a sensitivity analysis.  
 
Another issue was that a reasonably large dose of levothyroxine was given 
(150 mcg). In individuals with only borderline low thyroid function, this 
dose of levothyroxine resulted in FT4 levels being higher than 17.7pmol/l 
(97.5% centile of FT4 range in the UK CATS population) at subsequent 
blood tests in pregnancy. Analyses removing individuals who were over-
replaced were also performed. Finally, to see if there was only benefit 
in early treatment we removed individuals started on levothyroxine after 
14 weeks.    
 
7.3 RESULTS 
7.3.1 Study participant flow  
In the 16,346 pregnancies from the UK in the original CATS study, birth 
outcome data were available in 15,034 (92.0%) pregnancies. In these 
there were 93 terminations and 61 foetal losses. 629 pregnancies were 
identified to have congenital abnormalities and these were excluded 
from analysis. Final outcome data were utilised in 13,650 women with 
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normal thyroid function and 726  women with abnormal thyroid function 
making 14,376 individuals used in total in the final analysis. Participant 
flow is summarized in Figure 21. 
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Figure 21 Participants of CATS study used in this analysis 
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7.3.2 TSH and FT4 Levels 
As expected, TSH was not normally distributed with a median TSH of 1.12 
mU/l (IQR 0.68 – 1.66 mU/l). The highest TSH recorded was 57.0 mU/l. 
Substantial numbers of women had modestly elevated TSH levels; 869 
(6.03%) women had a TSH level between 2.5-4.0 mU/l, 246 women 
(1.71%) women had a TSH level between 4-10 mU/l and 17 women (0.12%) 
had a TSH level greater than 10mU/l.  
 
FT4 was normally distributed (mean 14.0pmol/l SD 1.87pmol/l)) 142 
women could be classed as hyperthyroid (TSH <0.05 mU/l and FT4 > 17.7 
pmol/l). Of these 5 individuals had moderate thyrotoxicosis as evidenced 
by a FT4 > 30 pmol/l.  
 
7.3.3 Summary of women with abnormal thyroid function 
753 women had SCH and IH. Of these 726 were in the study until delivery 
or foetal loss of which 361 were treated and 365 were untreated. The 
reasons for the 27 women exiting the study before foetal loss or delivery 
are shown in Figure 21.  More women left the screening group (n=20) vs 
the control group (n=7). In the treated group, there were 7 terminations, 
7 people who did not want to take levothyroxine or attend for monitoring, 
5 missed screenings (people had abnormal thyroid function, but were in 
error not identified as requiring levothyroxine) and 1 pregnancy which 
was found to be a twin pregnancy after recruitment, but before 
treatment was commenced and therefore excluded. In the control group, 
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there were 5 people who withdrew from the study and there were 2 
terminations.   
 
7.3.4 Comparison of baseline characteristics between the treated and 
untreated groups with abnormal thyroid function 
As expected due to randomization, there was no clear difference 
between the treated and untreated groups with regard to maternal age, 
weight, previous pregnancy, smoking during pregnancy and sex off 
offspring (Table 48). However due to the nature of the original CATS 
where the threshold for treatment periodically changed to keep at the 
highest 2.5% for TSH and lowest 2.5% for FT4, TSH was higher at baseline 
in the treated group (3.76 mU/l) versus the untreated group (3.22 mU/l) 
although no significant difference was observed for FT4.   
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Table 48 Comparison of baseline characteristics in the treated and 
untreated groups (n=726) 
Factor Treated Untreated P 
value* 
Maternal age 
(years) 
30 (IQR 25-33) 30 (IQR 25-33) 0.94 
    
Maternal weight 
(Kg) 
69.9 (IQR 62-81.2) 68.5 (IQR 60.1 – 81.9) 0.50 
    
% Previous 
pregnancy 
51.6 52.7 0.79 
    
% Smoking  20.5 18.7 0.58 
    
% Male offspring 55.4 52.7 0.51 
    
TSH level (mU/l) 3.76 (IQR 1.48 – 4.61) 3.22 (IQR 1.22-4.18) 0.003 
    
FT4 level 
(pmol/l) 
11.1 (IQR 10.5 – 13.1) 11.2 (IQR 10.4 – 13.2) 0.67 
*Compared with the Wilcoxon rank sum test for continuous variables with 
non Gaussian distribution. The Chi Square test was used for categorical 
variables.   
 
Comparison of obstetric outcomes between individuals in the treated 
group and the untreated group in those with abnormal thyroid function 
A summary of TSH and FT4 and gestational age at foetal loss in women 
with abnormal thyroid function is shown in Table 49. 10 miscarriages 
occurred in women with a TSH > 2.5 mU/l. In the treated group, foetal 
loss only occurred at more profound levels of hypothyroidism.  Univariate 
analysis identified that women who did not receive levothyroxine had 
more foetal loss (12/365) than those who received treatment (3/361) 
OR=4.06 (95%CI 1.14, 15.5) p=0.03 which persisted after adjustment OR 
= 4.15 (95%CI 1.14, 15.2) p=0.03 Table 50.  
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Table 49 TSH and FT4 levels in women with abnormal thyroid 
function who had a foetal loss 
Treated Untreated 
TSH 
(mU/l) 
FT4 
(pmol/l) 
Gestational 
age at foetal 
loss (weeks) 
TSH 
(mU/l) 
FT4 
(pmol/l) 
Gestational 
age at foetal 
loss (weeks) 
9.37 13 < 24 weeks† 0.63 10.6 14.3 
12.99 11.8 <24 weeks† 0.8 10.4 13.4 
20.01 9.2 <18 weeks† 1.13 10.2 13.9 
   1.38 9.9 25.3 
   1.42 9.6 13.1 
   2.16 10.1 27.8 
   3.29 15.5 40.1 
   3.32 14.5 25.4 
   3.62 12.7 12.7 
   3.66 13.8 38.7 
   4.58 13.2 41.4 
   4.73 13.9 - 
†Exact gestational age at foetal loss unknown. 
In the 711 live births, analyses were undertaken to see if treatment with 
levothyroxine improved other obstetric outcomes. No substantial 
benefits of levothyroxine were identified (Table 50). Untreated 
individuals did not have higher odds of delivery before 37 weeks OR=0.95 
(95%CI 0.51, 1.79) p=0.88 or before 34 weeks OR=0.39 (95%CI 0.11, 1.36) 
p=0.14. Untreated individuals also did not have increased odds of 
requiring a Caesarean section OR=0.83 (95%CI 0.59, 1.17) p=0.28 or an 
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early Caesarean section (before 37 weeks) OR=1.03 (95%CI 0.42, 2.55) 
p=0.94 or having labour induced OR =1.29 (95%CI 0.93, 1.80) p=0.12. 
There was also no difference in odds in untreated individuals for offspring 
outcomes including low birth weight OR = 1.39 (95%CI 0.77, 2.51) p=0.28, 
macrosomia OR=1.03 (95%CI 0.58, 1.82) p=0.92 and APGAR score <7 
OR=1.21 (95%CI 0.10, 15.6) p=0.88.  
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Table 50 Obstetric outcomes in individuals with abnormal thyroid function by treatment status 
Outcome Treated Untreated   Untreated # 
 N OR N OR 95%CI p   OR 95%CI p 
Still birth 3/358 1 12/353 4.06  1.14, 14.5 0.03   4.15 1.14, 15.1 0.03 
711 live births            
Delivery <37 week1 22/357 1 21/352 0.97 0.52, 1.79 0.91   0.95 0.51, 1.79 0.88 
Delivery <34 week1 9/357 1 4/352 0.44 0.14, 1.46 0.18   0.39 0.11, 1.36 0.14 
Caesarean Section2 98/355 1 86/353 0.84 0.60, 1.18 0.33   0.83 0.59, 1.17 0.28 
Caesarean Section2  
<37 weeks 
10/355 1 11/353 1.11 0.47, 2.65 0.82   1.03 0.42, 2.55 0.94 
Induced3 235/352 1 252/349 1.29 0.94, 1.79 0.12   1.29 0.93, 1.80 0.12 
Pre-eclampsia            
Birth weight centile <104 23/295 1 32/303 1.40 0.80, 2.85 0.24   1.39 0.77, 2.51 0.28 
Birth weight centile >904 29/295 1 30/303 1.01 0.59, 1.73 0.98   1.03 0.58, 1.82 0.92 
Apgar <7 at 5 mins5 1/265 1 2/265 2.01 0.18, 22.3 0.57   1.21 0.10, 15.6 0.88 
12 individuals with missing data 
23 individuals with missing data 
3 10 individuals with missing data 
4 113 individuals with missing data 
5 181 individuals with missing data 
# Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring, TSH level, FT4 
level  
N=number. OR = odds ratio, CI = confidence interval p = p value against the null hypothesis of no association.   
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7.3.5 Comparing outcomes women with abnormal (low) thyroid 
function to the rest of the cohort 
Women older than 30 years OR = 1.28 (95%CI 1.10, 1.49) p=0.001 and 
women heavier than 90 Kg OR =1.51 (95%CI 1.21, 1.88) p<0.001 were 
more likely to have abnormal thyroid function. No substantial difference 
in odds of abnormal thyroid function was observed for smokers OR =0.87 
(95%CI 0.71, 1.08) p=0.20, foetal female sex OR =0.88 (95%CI 0.75, 1.04) 
p=0.13 or previous childbirth OR =0.95 (95%CI 0.80, 1.12) p=0.55.  
 
Women with abnormal thyroid function were more likely to suffer from 
foetal loss than those with normal thyroid function OR =5.85 (95%CI 3.24, 
10.6) p<0.001. No clear difference was observed for any other obstetric 
outcomes (Table 51). 
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Table 51 Comparing outcomes in women with normal thyroid function to those with abnormal thyroid function 
1 2 people with missing data 
2 425 people with missing data 
3 545 people with missing data 
4 232 people with missing data 
5 1,643 people with missing data 
N=number. OR = odds ratio, CI = confidence interval p = p value against the null hypothesis of no association 
# Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring 
Outcome Normal Abnormal   Abnormal # 
  N Effect N OR 95%CI p   OR 95%CI p 
Foetal loss 46/13,650 1 15/726 6.23 3.46, 11.2 <0.001   5.85 3.24, 10.6 <0.001 
14,315 live births           
<37 weeks1 763/13,604 1 43/709 1.09 0.79, 1.49 0.61   1.08 0.79, 1.49 0.63 
<34 weeks1 201/13,604 1 13/709 1.25 0.71, 2.19 0.45   1.26 0.71, 2.22 0.43 
Caesarean 
Section2 
3,181/13,182 1 184/708 1.10 0.93, 1.31 0.26   1.02 0.85, 1.21 0.81 
Caesarean 
Section  
<37 weeks2 
269/13,182 1 21/708 1.47 0.94, 2.30 0.10   1.42 0.91, 2.23 0.13 
Pre-eclampsia3 571/13,178 1 21/567 0.82 0.52, 1.27 0.38   0.74 0.47, 1.16 0.19 
Birth weight 
centile <104 
1395/13,485 1 55/598 0.88 0.66, 1.16 0.37   0.94 0.70, 1.25 0.67 
Birth weight 
centile >904 
1047/13,485 1 59/598 1.30 0.99, 1.71 0.06   1.19 0.90, 1.58 0.22 
Apgar <7 at 5 
mins5 
105/12,142 1 3/530 0.65 0.21, 2.06 0.47   0.62 0.19, 1.97 0.42 
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Removing individuals who received treatment revealed no substantial 
differences in obstetric outcomes, aside from foetal loss. The effect 
estimate was higher OR=9.61 (95%CI 5.03, 18.4) p<0.001 (Table 52). 
Analyses of odds of adverse outcomes by TSH thresholds as recommended 
by the American Thyroid Association[93] were performed. Removing 
individuals who received treatment, higher TSH levels were associated 
with increased odds of fetal loss, but this was only apparent at TSH levels 
>4.0 mU/l - OR=5.85 (95%CI 1.29, 26.5) but no substantial differences 
were observed for other obstetric outcomes (Table 53).  Including 
individuals who were treated did attenuate the association with higher 
TSH and fetal loss OR= 4.82 (95%CI 1.90, 12.2) but had no apparent effect 
on other obstetric outcomes (Table 54).   
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Table 52 Comparing obstetric outcomes in women with normal thyroid function to those with abnormal thyroid function who 
were untreated 
 
 
 
 
 
 
 
 
# Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring, 
1  1 person with missing data 
2 422 people with missing data 
3 477 people with missing data 
4 169 people with missing data 
5 1,550 people with missing data 
 
 
 
 
 
 
 
Outcome Normal Abnormal   Abnormal # 
  N Effect N OR 95%CI p   OR 95%CI P 
Fetal loss 46/13,650 1 12/365 10.1 5.27, 19.1 <0.001   9.61 5.03, 18.4 <0.001 
13,957 live births           
Delivery <37 week1 763/13,604 1 21/352 1.07 0.68, 1.67 0.77   1.07 0.69, 1.69 0.76 
Delivery <34 week1 201/13,604 1 4/352 0.77 0.28, 2.07 0.60   0.78 0.28, 2.12 0.63 
Caesarean Section2 3,181/13,182 1 86/353 1.01 0.79, 1.30 0.92   0.95 0.74, 1.22 0.67 
Caesarean Section  
<37 weeks2 
269/13,182 1 11/353 1.54 0.84, 2.85 0.16   1.52 0.83, 2.81 0.18 
Pre-eclampsia3 571/13,178 1 10/298 0.77 0.41, 1.45 0.41   0.71 0.38, 1.35 0.30 
Birth weight centile <104 1395/13,485 1 32/303 1.02 0.71, 1.48 0.90   1.09 0.75, 1.60 0.64 
Birth weight centile >904 1047/13,485 1 30/303 1.31 0.89, 1.91 0.17   1.22 0.82, 1.80 0.33 
Apgar <7 at 5 mins5 105/12,142 1 2/265 0.87 0.21, 3.55 0.85   0.85 0.21, 3.46 0.82 
 
 
219 
 
   Table 53 Comparison of obstetric outcomes by ATA TSH thresholds with treated individuals excluded 
Outcome   TSH Level   TSH level # 
 N  TSH 
Level 
(mU/l) 
 OR 95%CI p   OR 95%CI p 
Foetal loss 52/13,094  <2.5  1        
 4/757  2.5-4  1.22 0.44, 3.39 0.06   1.16 0.38, 3.51 0.12 
 2/106  >4  6.88 1.65, 28.8    5.85 1.29 26.5  
13,957 live births             
Birth <37 weeks1 739/13,094  <2.5  1     1   
 37/756  2.5-4  0.86 0.61, 1.21 0.86   0.86 0.61, 1.20 0.86 
 8/106  >4  1.36 0.66, 2.82    1.38 0.67, 2.86  
             
Birth < 34 weeks1 194/13,094  <2.5  1     1   
 10/756  2.5-4  0.89 0.47, 1.69 0.58   0.91 0.48, 1.73 0.65 
 1/106  >4  0.63 0.09, 4.56    0.67 0.09, 4.86  
             
Caesarean Section2 3,035/12,692  <2.5  1        
 211/737  2.5-4  1.28 1.08, 1.51 0.09   1.18 1.00, 1.39 0.56 
 21/106  >4  0.77 0.49, 1.27    0.69 0.42, 1.11  
             
Caesarean Section<37 weeks2 259/12,692  <2.5  1        
 17/737  2.5-4  1.13 0.69, 1.86 0.26   1.12 0.68, 1.85 0.27 
 4/106  >4  1.88 0.69, 5.15    1.88 0.69, 5.17  
             
Pre-eclampsia3 550/12,118  <2.5  1     1   
 29/720  2.5-4  0.92 0.63, 1.35 0.36   0.80 0.54, 1.17 0.11 
 2/92  >4  0.49 0.12, 1.99    0.43 0.11, 1.77  
             
Birth Weight Centile <104 1,330/12,954  <2.5  1     1   
 88/741  2.5-4  1.17 0.94, 1.48 0.30   1.26 1.00, 1.54 0.08 
 9/93  >4  0.94 0.47, 1.87    1.08 0.54, 2.19  
             
Birth  Weight Centile >904 1,003/12,954  <2.5  1     1   
 65/741  2.5-4  1.15 0.88, 1.49 0.22   1.10 0.84, 1.44 0.47 
 9/93  >4  1.28 0.64, 2.55    1.11 0.55, 2.25  
   # Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring, 
1 1 person with missing data 2 422 people with missing data,3 477 people with missing data 4 169 people with missing data 
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   Table 54 Comparison of obstetric outcomes by ATA TSH thresholds 
Outcome   TSH Level   TSH level # 
 N  TSH 
Level 
(mU/l) 
 OR 95%CI p   OR 95%CI p 
Foetal loss 52/13,234  <2.5  1     1   
 4/834  2.5-4  1.18 0.43, 3.28 0.002   1.14 0.41, 3.18 0.002 
 5/247  >4  5.15 2.04, 13.0    4.82 1.90, 12.2  
14,315 live births             
Birth <37 weeks1 747/13,233  <2.5  1     1   
 43/833  2.5-4  0.91 0.66, 1.25 0.97   0.91 0.66, 1.24 0.98 
 16/247  >4  1.16 0.69, 1.93    1.16 0.69, 1.93  
             
Birth < 34 weeks1 199/13,233  <2.5  1     1   
 12/833  2.5-4  0.96 0.53, 1.72 0.71   0.98 0.54, 1.75 0.79 
 3/247  >4  0.81 0.26, 2.53    0.84 0.27, 2.65  
             
Caesarean Section2 3,075/12,831  <2.5  1     1   
 234/814  2.5-4  1.28 1.09, 1.50 0.09   1.18 1.00, 1.38 0.66 
 56/245  >4  0.94 0.70, 1.27    0.83 0.61, 1.13  
             
Caesarean Section<37 weeks2 263/12,831  <2.5  1     1   
 19/814  2.5-4  1.14 0.71, 1.83 0.18   1.12 0.70, 1.80 0.20  
 8/245  >4  1.61 0.79, 3.30    1.61 0.78, 3.29  
             
Pre-eclampsia3 551/12,774  <2.5  1     1   
 33/784  2.5-4  0.97 0.68, 1.40 0.71   0.84 0.58, 1.20 0.24 
 8/212  >4  0.87 0.43, 1.77    0.76 0.37, 1.57  
             
Birth Weight Centile <104 1,337/13,062  <2.5  1     1   
 92/805  2.5-4  1.13 0.90, 1.42 0.58   1.22 0.97, 1.54 0.18 
 21/216  >4  0.94 0.60, 1.49    1.06 0.67, 1.68  
             
Birth  Weight Centile >904 1,012, 13,062  <2.5  1     1   
 73/805  2.5-4  1.19 0.93, 1.52 0.09   1.12 0.87, 1.44 0.27 
 21/206  >4  1.28 0.81, 2.02    1.18 0.74, 1.88  
   # Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring, 
   1 2 people with missing data, 2 425 people with missing data 
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7.3.6 Sensitivity analyses  
Sensitivity analysis – matching  
Data matching appears to be robust. Smokers were more likely to have 
children with low birthweight (less than 10th centile) than non-smokers 
OR=2.70 (95%CI 2.40, 3.04) p=<0.001. Smokers were also more likely to 
have children born before 37 weeks OR=1.44 (95%CI 1.23, 1.70) p<0.001 
and before 34 weeks OR =1.86 (95%CI 1.41, 2.46) p<0.001.  Variation in 
maternal weight in pregnancy explained 56% of the variation in offspring 
birthweight and was strongly associated with it (p<0.001). 
 
Sensitivity analysis: Removing women who were over-treated from the 
analysis 
As a substantial dose of levothyroxine was given to all individuals, 97 of 
the 358 women who were treated were identified as being over-replaced 
with a subsequent FT4 greater than 17.7 pmol/l.  Given over-treatment 
might negate some of the treatment benefits analyses were repeated 
excluding these 97 individuals. Removing these individuals did not appear 
to have a substantial effect on effect estimates. (Table 55).  
 
Sensitivity analysis: Removing women who were commenced on 
treatment after 13 weeks 
117 women were started on levothyroxine after 13 weeks. They were 
removed from analysis. No substantial effect was seen on obstetric 
outcomes (Table 56) indicating no additional benefit at treating at a 
slightly earlier time point.      
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Table 55 Obstetric outcomes in women with abnormal thyroid function with over-treated individuals removed from 
analysis 
Outcome Treated Untreated   Untreated # 
 N Effect N OR 95%CI P   OR 95%CI p 
Still birth 3/261 1 12/353 2.96  0.83, 10.6 0.10   2.91 0.78, 10.8 0.11 
614 live births            
Odds <37 week1 16/260 1 21/352 0.97 0.49, 1.83 0.92   0.93 0.46, 1.87 0.84 
Odds <34 week1 9/260 1 4/352 0.32 0.10, 1.05 0.06   0.28 0.08, 0.99 0.05 
Caesarean Section2 70/258 1 86/353 0.85 0.59, 1.22 0.39   0.85 0.58, 1.25 0.42 
Caesarean Section <37 
weeks2 
7/258 1 11/353 1.16 0.44, 3.03 0.77   1.11 0.40, 3.04 0.84 
Induced3 173/255 1 252/349 1.23 0.87, 1.75 0.25   1.23 0.86,1.77 0.26 
Pre-eclampsia4 7/195 1 10/298 1.10 0.43, 2.85 0.84   1.26 0.46, 3.40 0.65 
Birth weight centile 
<105 
13/199 1 32/303 1.70 0.87, 3.32 0.12   1.58 0.77, 3.22 0.22 
Birth weight centile 
>905 
20/199 1 30/303 0.99 0.54, 1.80 0.97   1.17 0.62, 2.22 0.63 
Apgar <7 at 5 mins6 1/183 1 2/265 1.39 0.13, 15.5 0.79   - - - 
# Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring, TSH and FT4 
1 2 individuals with missing data 
2 3 individuals with missing data 
3 10 individuals with missing data 
4 130 individuals with missing data 
5 112 individuals with missing data 
6 166 individuals with missing data 
APGAR <7 at 5 mins could not be calculated in adjusted models due to colinearity 
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Table 56 Obstetric outcomes in women with abnormal thyroid function and removing all individuals who started treatment 
after 13 weeks 
 
Outcome Treated Untreated   Untreated # 
 N Effect N OR 95%CI p   OR 95%CI p 
Still birth  3/255 1 12/365 2.86  0.80, 10.2 0.11   2.87 0.78, 10.5 0.11 
602 live births            
Odds <37 week1 19/247 1 22/353 0.80 0.42, 1.51 0.49   0.83 0.43, 1.60 0.58 
Odds <34 week1 7/247 1 5/353 0.49 0.15, 1.57 0.23   0.55 0.16, 1.82 0.33 
Caesarean Section2 69/246 1 86/353 0.83 0.57, 1.20 0.31   0.85 0.58, 1.24 0.39 
Caesarean Section2  
<37 weeks 
9/246 1 11/353 0.85 0.35, 2.08 0.72   0.91 0.36, 2.30 0.83 
Induced3 165/245 1 252/349 1.26 0.88, 1.80 0.20   1.23 0.84, 1.80 0.30 
Pre-eclampsia4 10/199 1 10/298 0.66 0.27, 1.61 0.36   0.69 0.27, 1.77 0.44 
Birth weight centile 
<105 
16/204 1 32/303 1.39 0.74, 2.60 0.31   1.36 0.70, 2.65  0.36 
Birth weight centile 
>905 
20/204 1 30/303 1.01 0.56, 1.83 0.97   1.11 0.59, 2.11 0.74 
Apgar <7 at 5 mins6 1/189 1 2/265 1.43 0.13, 15.9 0.77      
# Adjusted for maternal age, maternal weight at recruitment, parity, smoking status, sex of offspring TSH and FT4 level 
1 2 people with missing data 
2 3 people with missing data 
3 8 people with missing data 
4 105 people with missing data 
5 95 people with missing data 
6 148 people with missing data 
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Screening of women to determine if they had abnormal thyroid function 
Screening for women on the basis of age and weight may be practical in 
that data are readily available to healthcare practitioners. Screening 
women aged greater than 30 years would involve screening 46.5% of the 
population and would detect 52.5% of those with abnormal thyroid 
results. Increasing the age to greater than 35 years would results in 12.2 
% of the population being screened and 14.1% of those with abnormal 
thyroid function being detected.  Screening women with a weight greater 
than 90 kg would involve screening 9.74% of the population and detect 
13.8% of those with abnormal thyroid function. 
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7.4 DISCUSSION 
My results show that sub-optimal maternal thyroid function is associated 
with increased odds of foetal loss compared to women with normal 
thyroid function. This effect is reduced in women who receive 
levothyroxine who had a fourfold reduction (3 vs 12) in foetal loss 
compared to those who were untreated. Women who were untreated had 
a tenfold increased risk of foetal loss compared to those with normal 
thyroid function. Screening and treating for low thyroid function could 
potentially reduce 18 of the 64 foetal losses identified in the study 
(28.1%). Whilst the number needed to screen to potentially prevent 1 
miscarriage is quite high - 18 foetal losses potentially prevented by 
screening 15,034 women; giving a number needed to screen of 835 to 
prevent 1 foetal loss. The number needed to treat is substantially lower 
at 40 women to be treated to prevent 1 foetal loss. This finding would 
lend strong support to implementing universal thyroid screening in 
pregnancy with the aim of reducing foetal loss. 
   
My results are at first inspection are in conflict with a recent large 
randomized controlled trial by Casey at al. which used a similar study 
design, but found no benefit in terms of obstetric outcomes [118].  Two 
key differences in the trial and its analysis are noteworthy. The Casey 
trial recruited later in pregnancy and the Casey trial analysed SCH and IH 
separately, whereas in the original CATS study, both were analysed 
together [116]. Intriguingly in the Casey study there were more foetal 
losses in women with abnormal thyroid function who did not receive 
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levothyroxine - there were 18 foetal losses in total with 6 foetal losses in 
the treated group, and 12 in the untreated group [117]. As in the Casey 
study we observed no benefit of levothyroxine therapy with other 
obstetric outcomes, however it remains to be seen if initiating 
levothyroxine even earlier than the CATS study might improve other 
obstetric outcomes.  Although our observation that neither SCH or IH 
were associated with substantially earlier gestational age is in keeping 
with a recent meta-analysis [285]. 
 
My foetal loss data however, is of potentially substantial importance to 
universal thyroid screening in pregnancy a key debate in thyroidology. 
The criteria for undertaking screening programs as laid down by Wilson 
and Jungner is shown in the box on the next page. 
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Adapted from Wilson J, Jungner G: Principles and practice of screening 
for disease. Geneva: World Health Organization, 1968. Public health 
papers 34, (2011)[286]  
 
It is already clear that thyroid dysfunction is an important health problem 
(criteria 1), resulting in adverse obstetric and offspring outcomes [4]. 
This still holds true even if only overt hypothyroidism and overt 
hyperthyroidism are considered. However, this analysis has indicated 
potential benefits of treating borderline thyroid function. Furthermore, 
almost 2% of women had a TSH level above 4.0 mU/l and over 8% had a 
TSH level greater than 2.5 mU/l.  Treatment of both overt 
Considerations when deciding on implementing screening 
1.   Is the condition an important health problem? 
2.  Does the condition have an accepted treatment? 
3.   Are facilities for both diagnosis and treatment readily available ?. 
4.   Is there a recognizable latent or asymptomatic stage? 
5.   Is there a suitable screening test or examination? 
6.   Is the screening test acceptable to the population? 
7.  Is the natural history of the condition, including development from 
latent to declared disease adequately understood? 
8.   Is there an agreed policy on whom to treat ? 
9.  Is the cost of case-finding (including diagnosis and treatment of 
patients diagnosed) economically viable? 
10.  Case-finding should be a continuing process. 
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hypothyroidism and hyperthyroidism results in improved outcomes and is 
cost-effective and acceptable to patients (criteria 2), however the TSH 
and FT4 threshold for initiation of levothyroxine during pregnancy is less 
clear. Data from this work has indicated benefits at modest TSH and FT4 
levels.  
 
Facilities for both diagnosis and treatment are readily available (criteria 
3) and there is also a well-recognized asymptomatic stage (criteria 4). 
Clinical assessment of thyroid status and thyroid function testing are both 
commonplace and are already readily acceptable to the general 
population (criteria 5 and 6). The natural history of subclinical thyroid 
dysfunction leading to overt hypothyroidism/hyperthyroidism is well 
understood, however it needs highlighting that many women with 
subclinical hypothyroidism would not progress to overt hypothyroidism if 
left untreated (criteria 7). The costs of case finding are also economically 
balanced even if only overt thyroid disease is considered [287] (criteria 
9). The nature of thyroid screening in pregnancy ensures a continuing 
process and not a “once and for all” project (criteria 10).  
 
Realistically only criteria 8 “there should be an agreed policy on whom 
to treat as patients” is not satisfied as more data on the benefits of 
levothyroxine therapy in women with subclinical hypothyroidism, 
isolated hypothyroxinaemia, and euthyroid autoimmunity are needed. 
Given there is widespread variation in current practice at present, this 
criteria alone should not prevent the implementation of universal 
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screening. Furthermore, this data largely supports current ATA TSH 
thresholds for initiation of levothyroxine in pregnancy [93]. A key feature 
of this guidance is that levothyroxine treatment should definitely be 
initiated at TSH levels greater than 10mU/l if TPO antibody negative and 
at greater than 4.0 mU/l if TPO antibody positive.  The guidance also 
proposes that levothyroxine treatment can be considered at TSH levels 
greater than 2.5 mU/l if TPO antibody positive. TPO antibody levels were 
unfortunately not measured routinely in CATS, however I observed that 
greater risk of foetal loss became apparent at TSH levels greater 3.0mU/l 
with a substantial increase above 4.0 mU/l. Thus, it appears current ATA 
guidance is broadly correct (Table 52). 
 
These considerations notwithstanding, we still found that some women 
with profoundly elevated TSH had normal obstetric outcomes, a finding 
which has previously been reported [288]. Women found to have 
profoundly abnormal thyroid function during pregnancy can be reassured 
that obstetric outcomes do appear to be reasonable, particularly if 
treated. 
 
The strength of this study is the linkage of a large and unique randomized 
controlled trial in pregnancy with multiple obstetric outcomes through a 
nationwide linked database. The high capture rate (92.9%) of pregnancy 
outcomes and expected findings from smoking confirms the robust data 
linkage in our study. Furthermore, we have used obstetric outcomes that 
are of key importance. One limitation of our study is that we were unable 
 
 
230 
to include the entire CATS cohort as we could not identify outcomes for 
all women in the CATS study. Adverse outcomes were more identifiable 
in those with abnormal thyroid function as they were more closely 
followed up (100% capture). There were also more terminations in the 
screening group versus the control group (7 vs 2) although the reason for 
this discrepancy is unclear and may be due to random error. There was a 
higher withdrawal rate in the treated group, but this is largely due to 
more terminations and that some women refused to take levothyroxine. 
Owing to the original design of the study, which had changes in TSH 
thresholds over the course of the study women in the treated group were 
more likely to have a higher TSH at baseline however this would likely 
bias our results towards the null. The number of statistical tests 
performed in this analysis, especially including the sensitivity analyses 
was substantial  and has increased the risk of type-1 error. 
 
The use of routinely collected data raises additional issues as routinely 
collected data tends to have high positive predictive values but may have 
lower sensitivity. However obstetric outcomes are well recorded on 
patient episode statistics as hospitals are incentivised to return accurate 
and routinely validated records. Although the use of this approach may 
be less robust than in the data collection of highly focused clinical trials 
it has enabled us to also explore outcomes in those with normal thyroid 
function.  
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Overall my results are supportive for identifying and correcting low 
thyroid function in pregnancy given the substantial benefits of reducing 
the risk of foetal loss. Replication is necessary, particularly using lower 
initial levothyroxine doses and in iodine sufficient areas. The use of a 
high levothyroxine doses does not appear to have been harmful in terms 
of obstetric outcomes, but however may have adverse effects on 
offspring. Recent data from a prospective population based pregnancy 
cohort, the Generation R study, indicates that the relationship between 
maternal FT4 levels and IQ is U shaped and therefore high or high-normal 
FT4 levels may potentially negatively impact on offspring neurological 
development [76] and follow-up data from the CATS study has indicated 
that higher ADHD scores were recorded in offspring in women who were 
untreated. Therefore more cautious levothyroxine dosing is required in 
pregnancy to offset against potentially deleterious effects on offspring 
IQ. Clarification is also needed as to whether substantial additional 
benefits might be obtained with preconception or even earlier pregnancy 
levothyroxine initiation and this should be the focus of future studies.  
 
  
 
 
232 
Chapter 8 Thesis Discussion 
In this thesis, I have explored the relationship between common variation 
in thyroid status and adult health. I have demonstrated that even modest 
variation in thyroid status is associated with a key range of health 
outcomes. Pregnancy in particular, places additional demands on the 
thyroid and is a critical period, where even borderline low thyroid 
function is associated with an increased risk of foetal loss.  
 
I have also observed the HPT axis is more complex than previously 
envisaged, with FT3 being less regulated by the HPT axis than FT4 and 
influenced by external factors including body composition and pubertal 
status. FT3 is also more variable over childhood and children appear to 
have different thyroid reference ranges to adults with a substantial 
proportion of children at age 7 having a FT3 above the adult reference 
range. FT3 may also be a reflection of nutritional status pre-puberty 
rather than simply being a mediator of thyroid status.  We also appear to 
frequently modify the HPT axis in adults by routinely treating fairly 
modest low thyroid function with a high likelihood of subsequent over-
treatment, and many individuals are also undertreated, which is of 
particular relevance in women of child-bearing age.   
 
Therefore, two clear important themes from this thesis emerge. The first 
theme is that I have shown that even modest variation thyroid status is a 
modifiable risk factor for adverse outcomes. This was demonstrated in 
pregnancy where I have demonstrated that screening and treating for low 
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thyroid function is associated with reduced odds of foetal loss and women 
established on levothyroxine also have lower odds of foetal loss if well 
controlled. Preliminary data from the follow up to the CATS study, has 
also demonstrated that thyroxine treatment in pregnancy results in a 
reduction in maternal weight gain post-pregnancy indicating maternal as 
well as offspring benefits. The second theme is confirmation that 
assessment of thyroid function status is more complex than anticipated 
with serum FT3 likely being a poor marker of intracellular T3 status.  
 
To extend the first theme, we see that variation of TSH within the 
population reference range is associated with a range of key health 
outcomes, although both higher and lower levels are associated with 
adverse outcomes. This U shaped curve indicates there may be an optimal 
zone of thyroid status as observed for instance with maternal FT4 and 
offspring IQ [289].  Earlier screening and intervention in pregnancy may 
produce even more profound benefits on foetal loss, and should assess 
whether it may influence other pregnancy outcomes including gestational 
age at delivery and low birth weight. 
 
My pregnancy findings may also provide insight into variation in thyroid 
status in the general adult population. Whilst pregnancy may be a 
particularly critical time for optimal thyroid levels the sudden increased 
demands on the thyroid may cause a substantial change in intracellular 
thyroid levels especially in TPO positive individuals. It may be that tissues 
adapt to their prevailing thyroid function, and respond poorly to changes. 
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If there is an adaptation to a prevailing thyroid state minor variation 
within the reference range, can have important health consequences for 
an individual as it is a level of thyroid function their tissues are not 
prepared for.  
 
For instance, treatment of borderline low thyroid function in adults 
younger than 65 years may reduce adverse cardiovascular outcomes  
[191].  The recent thyroid hormone therapy trial for older adults with 
subclinical hypothyroidism did not find benefits of correcting low thyroid 
function on mood or tiredness but was underpowered for cardiovascular 
outcomes  [249]. Prospective trials of younger adults with subclinical 
hypothyroidism with a longer follow-up to properly explore 
cardiovascular outcomes are still urgently needed. 
 
Given the potential importance of even minor variation in thyroid status 
data shows that our management of hypothyroidism in adults and 
particularly in women of child-bearing age could be substantially 
improved. Widespread thyroid function testing has resulted in few 
individuals with overt thyroid disease being undiagnosed [30]. However, 
the current UK approach to managing hypothyroidism results in many 
individuals having borderline low thyroid function corrected, but due to 
inadequate monitoring, many of them are converted to borderline high 
thyroid function whilst some remain inadequately treated. At 5 years post 
levothyroxine initiation 16% of patients had a TSH less than 0.5 mU/l and 
21.5% had a TSH greater than 5.0 mU/l.  The risk benefit of this practice 
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is unclear, and is likely to vary between body systems, but as we have 
observed in pregnancy modest differences may have substantial adverse 
outcomes, with prolonged sub-optimal treatment. Our widespread over-
treatment of young women could substantially increase the risk of 
osteoporosis. Overtreatment is associated with increased fracture risk 
and adverse cardiovascular outcomes in small cohorts [246]. 
 
The second theme to emerge is that assessment of thyroid function status 
is more complex than anticipated. Our data from epidemiological cohorts 
and in pregnancy shows that high TSH and low FT4, which might be 
expected to have similar outcomes as both indicate low thyroid function, 
in fact have separate and distinct outcomes. This is shown most clearly 
in pregnancy where SCH and IH are associated with distinct and disparate 
outcomes [4]. Recent ATA guidance [93] also modifies the recommend 
TSH level for intervention with levothyroxine based on TPO antibody 
status. This reflects that TSH does not capture all of the variation in 
thyroid status with regard to adverse outcomes. The differing 
relationship of FT3 and FT4 to TSH over childhood also demonstrates the 
HPT axis is not as straightforward as we think and FT3 is more fluid.  FT3 
although a reliable sign of thyrotoxicosis is not a reliable marker of 
hypothyroidism and is likely a poor indicator of tissue FT3 [2]. 
 
As a result, an alternative means of assessing thyroid status may be 
desirable as while serum TSH, FT3 and FT4 also do not fully incorporate 
the extent of peripheral and intracellular regulation. An extreme 
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example of this is reflected in Allan-Herndon-Dudley syndrome which is 
a rare disorder of brain development that causes moderate to severe 
intellectual disability due to intracellular hypothyroidism from failure of 
MCT8 receptors to transport T3 into nerve cells effectively [290]. Excess 
amounts of T3 circulate in the bloodstream resulting in some tissues such 
as the liver and heart becoming hyperthyroid. Peripheral regulation of 
thyroid status may be more important when considering health outcomes 
than previously realised. The deiodinases, particularly DIO2 which 
converts intracellular FT4 to FT3 [291] may have a more substantial 
impact on intracellular FT3 than serum FT3 levels.  This may be a key 
issue for the brain in particular as animal studies have indicated that 
serum tri-iodothyronine (T3) contributes just 20% of intracellular T3 in the 
cerebral cortex, the remainder coming from local deiodination of serum 
thyroxine (T4) by deiodonase-2 [291, 292]. Genetic variation in the 
deiodinases have been associated with a wide range of phenotypes 
including patient satisfaction with thyroid hormone replacement [187].  
 
Taken together, there is a compelling case for a better tissue specific 
marker for thyroid status  NMR tissue spectroscopy would be on option 
which has considerable potential for non-invasive characterisation of 
tissue biochemistry and the diagnosis of tissue abnormalities. Another 
approach is to study metabolomics – the systematic study of the unique 
chemical fingerprints that specific cellular processes leave behind. Given 
the importance of thyroid hormone on intracellular processes it is highly 
likely metabolic signatures of intracellular hypothyroidism and 
 
 
237 
hyperthyroidism or “thyroid stress” can be identified. Metabolomic 
differences within the population reference range of thyroid status have 
already been identified [293]. Serum FT4 concentrations are strongly 
linked to serum acylcarnitines and phosphatidylcholines, indicating 
enhanced transport of fatty acids to mitochondrion and subsequent β-
oxidation [293]. Metabolomic signatures are also heritable which will 
allow the use of genetics to study causality of the metabolomic 
signatures.  
 
 Analysis of the metabolomics of individuals with overt and subclinical 
thyroid disease would be particularly instructive. The key test then will 
then be to see whether a metabolomics signature of thyroid stress is 
better correlated with adverse outcomes.  In turn having better tissue 
markers may enable us to have greater insight into the patient’s true 
thyroid status and lead to better prescribing practice. This may 
potentially allow better targeting of individuals who might benefit from 
treatment particularly in those with borderline TSH levels for 
hypothyroidism. A metabolomic signature of hypothyroidism may be more 
indicative of intracellular thyroid dysfunction than TSH and may provide 
clearer data in epidemiological studies as potentially this approach may 
be more resistant to confounding. Furthermore, this approach may be 
able to distinguish between higher TSH levels that are a response to low 
thyroid hormone status rather than common genetic variants which do 
not appear to have an appreciable effect on FT4 levels. This discrepancy 
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might be a potential explanation for the differing trial outcomes in 
subclinical thyroid disease.  
 
It will also be informative to assess whether there is a different 
metabolomic signature in hypothyroid patients on levothyroxine vs those 
taking combination T3 and T4 therapy or those on other preparations such 
as Armour. It is well established that individuals on levothyroxine have a 
relatively high FT4 level but a relatively low FT3 despite a normal TSH 
[186]. Assessment of the effect of the different thyroid hormone 
replacements on metabolomic signature would be a clearer way of 
demonstrating whether there is any role for alternatives to the standard 
thyroid hormone replacement of levothyroxine. The role could be 
extended to iodine deficiency which still occurs in the UK [294] maternal 
iodine deficiency in pregnancy  is associated with reduced offspring IQ 
[203] due to its effects on the maternal and foetal thyroid. Iodine 
deficiency is measured by urinary iodine, but this is an imperfect measure 
heavily influenced by recent diet and is not a good guide of long term 
iodine status [7]. Metabolomics may allow a better understanding of 
iodine deficiency and its diagnosis.   
 
8.1 CONCLUSION 
As has been highlighted in the discussion of each research chapter in the 
thesis we have observed that common variation in thyroid hormone has 
substantial effects on key health outcomes. In this final synthesis of the 
thesis we see that these effects may be particularly profound during key 
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periods in life such as pregnancy. What is also readily apparent, is that 
our current management of hypothyroidism is sub-optimal. Patients are 
increasingly being started at more modestly elevated TSH levels and are 
frequently over-treated, the risk benefits of this practice are not fully 
understood, but our tendency to over-treat young women may result in 
excess cases of osteoporosis in later life and failure to maintain optimal 
TSH levels during pregnancy is associated with foetal loss. The 
management of hypothyroidism could however be extended into 
screening for sub-optimal thyroid function in pregnancy in an effort to 
reduce foetal loss.  
 
This thesis has also identified that identifying treatment thresholds from 
serum thyroid function tests is not straightforward. Rather than defining 
individuals statistically as having abnormal thyroid function by being 
outside the 95% reference range an epidemiological approach is more 
meaningful where abnormal thyroid function is classified as having 
adverse outcomes that treatment would attenuate or prevent. This may 
be possible by defining sub-groups based on TPO antibody positivity as in 
ATA pregnancy guidelines [93] but developing alternative strategies such 
as the use of metabolomics may yield more valuable insights and the 
potential for a much greater benefit to risk ratio.  
 
Key advances in thyroid epidemiology have also been made by the 
Rotterdam group. In particular, their work in pregnancy and also in the 
elderly has substantially changed our understanding of the field. Work 
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between our group and the Rotterdam group is becoming increasingly 
collaborative [295] and will enable with other large meta-analyses of the 
consequences of variation in thyroid status during pregnancy. Endeavors 
here could include work on iodine sufficiency and endocrine disruptors in 
pregnancy [296]. More trial work is needed also to see if very early 
screening and treating of low thyroid function in pregnancy also improves 
other obstetric outcomes as well as foetal loss. Data from my CATS and 
CPRD work have revealed that fetal loss, may be substantially reduced 
by optimizing thyroid status in early pregnancy. A trial of screening for 
thyroid dysfunction (subclinical hypothyroidism and isolated 
hypothyroxinemia) in early pregnancy, taking into account TPO antibody 
status may reveal substantial benefit in reducing fetal loss. Furthermore 
additionally measuring beta hCG may help differentiate between a high 
TSH secondary to thyroid failure versus a high TSH due to low hCG status 
as seen in a failing placenta. This work may reveal additional benefits of 
screening and treating for thyroid disease in other areas aside from fetal 
loss including low birth weight as treatment is likely to be beneficial in 
mild thyroid failure but unlikely to be beneficial in those with low beta 
hCG secondary to placental dysfunction.  More appropriately powered 
long-term follow-up trials are needed in subclinical hypothyroidism 
especially in adults under the age of 70. The work in this thesis has 
identified that such endeavors are clinically relevant, theoretically 
possible and urgently needed. 
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Appendix 1 Details of socio-economic and early life scores 
used in the analysis in Chapter 4. 
 
ALSPAC Family Adversity Index 
A measure of hardship during pregnancy and early life 
Sum of (1 point given for each applicable item): 
Demographics 
- Mother younger than 20 years at first pregnancy 
Housing 
- Housing inadequacy (crowding and periods of homelessness) 
- Basic living conditions (no availability of hot water, 
no indoor toilet, bath or shower, or no kitchen) 
- Major defects in housing or infestation 
Education 
- No educational qualifications (mother or father) 
Financial status 
- Financial difficulties 
Relationship with partner 
- Single status 
- Low affection and aggression 
- Physical/emotional cruelty 
- No social support 
- Family 
- Family size >4 children 
- Caregiving problems (on social services risk register, 
child in care/not with natural mother) 
Social network - No emotional support - No practical/financial support 
Maternal emotional status 
- Depression, anxiety or suicide attempts 
- Substance abuse 
Drugs or alcohol use 
- Crime 
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- In trouble with police 
- Actual convictions 
 
• Mother’s parenting score 
Assessed at six months postpartum 
Variable derived from responses as to how often mother: 
- Plays with child 
- Sings to child 
- Shows child pictures in books 
- Plays with toys 
- Cuddles child 
- Physically plays with child 
- Takes child for walks 
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Home observation for measurement of environment (HOME) score 
Assessed at six months postpartum and a measure of the emotional and 
cognitive environment 
 
Variable derived from responses to: 
- Child has cuddly toys 
- Child has push/pull toys 
- Child has co-ordination toys 
- Number of books child has of their own 
- Mother teaches child 
- Mother talks to child when working 
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Appendix 2 Pregnancy Read Codes  
 
Read code Outcome 
13H7.00 Unwanted pregnancy 
13H8.00 Illegitimate pregnancy 
13Hd.00 Teenage pregnancy 
13S..00 Pregnancy benefits 
13SZ.00 Pregnancy benefit NOS 
1514.11 Due to deliver - EDC 
1514.12 Estimated date of delivery 
250 PG DIABETES PREGNANCY 
2722.00 O/E - breech presentation 
275..00 O/E - fetal movements 
2752.00 O/E - fetal movements seen 
2753.00 O/E - fetal movements felt 
275Z.00 O/E - fetal movements NOS 
3004B PREGNANCY DEPRESSION 
3049TA CANNABIS INGESTION IN PREGNANCY 
4453.00 Serum pregnancy test positive 
44B2.00 Alpha-feto protein normal 
4654.00 Urine pregnancy test positive 
584..00 Ultrasound in obstetric diagn. 
584..11 Fetal U-S scan 
584..12 U-S scan - obstetric, diagn. 
584..13 Ultra-sound scan - obstetric 
5841.00 U-S obstetric scan requested 
5842.00 U-S obstetric scan normal 
5843.00 U-S obstetric scan abnormal 
5844.00 U-S scan -placental localisatn 
5844.11 Placenta U-S scan 
5845.00 U-S scan - fetal cephalometry 
5846.00 U-S scan - fetal maturity 
5847.00 U-S scan - fetal abnormality 
5848.00 U-S scan - multiple fetus 
5849.00 U-S scan - fetal presentation 
584B.00 Viability US scan 
584C.00 Antenatal ultrasound result received 
584D.00 
Antenatal ultrasound confirms intra-uterine 
pregnancy 
584G.00 Nuchal scan 
584Z.00 U-S obstetric diagn. scan NOS 
615C.00 IUD failure - pregnant 
615C.11 Pregnant, IUD failure 
6166.00 Pregnant, diaphragm failure 
6174.00 Pregnant, sheath failure 
62...00 Patient pregnant 
62...11 Antenatal care 
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62...12 Maternity care 
62...13 Pregnancy care 
621..00 Patient currently pregnant 
621..11 Pregnancy confirmed 
6211.00 Pregnant - urine test confirms 
6212.00 Pregnant - blood test confirms 
6213.00 Pregnant - V.E. confirms 
6215.00 Pregnant - on abdom. palpation 
6216.00 Pregnant - planned 
6217.00 Pregnant - unplanned - wanted 
6218.00 Pregnant -unplanned-not wanted 
621A.00 Pregnancy unplanned ? wanted 
621B.00 Pregnant - ? planned 
621C.00 Unplanned pregnancy 
621Z.00 Patient pregnant NOS 
622..00 Antenatal care: gravida No. 
6221.00 Antenatal care: primigravida 
6222.00 Antenatal care: 2nd pregnancy 
6223.00 Antenatal care: 3rd pregnancy 
6224.00 Antenatal care: multip 
622Z.00 Antenatal care: gravida NOS 
623..00 A/N care: obstetric risk 
6231.00 A/N care: uncertain dates 
6232.00 A/N care: recurrent aborter 
6233.00 A/N care: grand multip 
6234.00 A/N care: H/O stillbirth 
6235.00 A/N care: H/O perinatal death 
6236.00 A/N care: poor obstetr history 
6237.00 A/N care: H/O trophoblast.dis. 
623Z.00 A/N care: obstetric risk NOS 
624..00 A/N care: precious pregnancy 
6241.00 A/N care: elderly primip. 
6242.00 A/N care: H/O infertility 
624Z.00 A/N care: precious preg. NOS 
625..00 A/N care: social risk 
6251.00 A/N care: poor home conditions 
6252.00 A/N care: poor A/N attender 
6253.00 A/N care: late booker 
6254.00 A/N care: H/O child abuse 
625Z.00 A/N care: social risk NOS 
626..00 A/N care: medical risk 
627..00 A/N care: gynae. risk 
628..00 A/N care: risk NOS 
6281.00 A/N care: under 5ft tall 
6282.00 A/N care:10yrs+since last preg 
6283.00 A/N care: primip. < 17 years 
6284.00 A/N care: primip. > 30 years 
6285.00 A/N care: multip. > 35 years 
628Z.00 A/N risk NOS 
629..00 No ante-natal care 
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6291.00 Ante-natal care: not offered 
6292.00 Ante-natal care: not wanted 
6293.00 Ante-natal care: not attended 
6294.00 No A/N care: not known preg. 
629Z.00 No ante-natal care NOS 
62A..00 A/N care provider 
62A1.00 A/N care from G.P. 
62A2.00 A/N care from consultant 
62A3.00 A/N - shared care 
62A4.00 A/N care midwifery led 
62AZ.00 A/N care provider NOS 
62B..00 Delivery booking place 
62B1.00 Delivery: no place booked 
62B2.00 Home delivery booked 
62B3.00 G.P. unit delivery booking 
62B4.00 Consultant unit booking 
62B5.00 Private home delivery booking 
62B6.00 Delivery booking place changed 
62B8.00 Midwife unit delivery booking 
62BZ.00 Delivery booking - place NOS 
62C..00 Deliv.booking - length of stay 
62C1.00 Short stay delivery booking 
62C2.00 Full stay delivery booking 
62CZ.00 Delivery booking - stay NOS 
62F..00 Antenatal amniocentesis 
62F1.00 A/N amniocentesis -not offered 
62F2.00 A/N amniocentesis - offered 
62F3.00 A/N amniocentesis - not wanted 
62F4.00 A/N amniocentesis wanted 
62F5.00 A/N amniocentesis - awaited 
62F6.00 A/N amniocentesis - normal 
62F7.00 A/N amniocentesis - abnormal 
62F8.00 A/N amnio. for ? chrom.abnorm. 
62F9.00 A/N amnio. for ? neural tube 
62FZ.00 Antenatal amniocentesis NOS 
62G..00 Antenatal ultrasound scan 
62G1.00 A/N U/S scan not offered 
62G2.00 A/N U/S scan offered 
62G3.00 A/N U/S scan not wanted 
62G4.00 A/N U/S scan wanted 
62G5.00 A/N U/S scan awaited 
62G6.00 A/N U/S scan normal += dates 
62G7.00 A/N U/S scan normal +? dates 
62G8.00 A/N U/S scan abnormal 
62G9.00 A/N U/S scan for ? abnormality 
62GA.00 A/N U/S scan for slow growth 
62GB.00 Antenatal ultrasounds scan at 4-8 weeks 
62GC.00 Antenatal ultrasound scan at 9-16 weeks 
62GD.00 Antenatal ultrasound scan at 17-22 weeks 
62GE.00 Antenatal ultrasound scan at 22-40 weeks 
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62GZ.00 Antenatal ultrasound scan NOS 
62H..00 A/N Rh antibody screen 
62H1.00 A/N Rh screen not offered 
62H2.00 A/N Rh screen offered 
62H3.00 Rh screen - 1st preg. sample 
62H4.00 Rh screen - 2nd preg. sample 
62H5.00 Rh screen - 3rd preg. sample 
62HZ.00 A/N Rh antibody screen NOS 
62I..00 Alpha-feto protein blood test 
62I..11 AFP test - antenatal 
62I..12 Alpha-feto protein test - A/N 
62I1.00 AFP blood test offered 
62I2.00 AFP blood test not offered 
62I3.00 AFP blood test wanted 
62I4.00 AFP blood test not wanted 
62I5.00 AFP - blood sent 
62IZ.00 AFP blood test NOS 
62K..00 Antenatal syphilis screen 
62K1.00 A/N syphilis screen not done 
62K2.00 A/N syphilis screen-blood sent 
62KZ.00 Antenatal syphilis screen NOS 
62L..00 Antenatal blood group screen 
62L1.00 A/N blood gp screen not done 
62L2.00 A/N blood group screen done 
62LZ.00 A/N blood group screen NOS 
62M..00 Antenatal sickle cell screen 
62M1.00 A/N sickle screen not done 
62M2.00 A/N sickle cell screen done 
62MZ.00 A/N sickle cell screen NOS 
62N..00 Antenatal examinations 
62N1.00 A/N booking examination 
62N2.00 A/N 12 weeks examination 
62N3.00 A/N 16 week examination 
62N4.00 A/N 20 week examination 
62N5.00 A/N 24 week examination 
62N6.00 A/N 28 week examination 
62N7.00 A/N 30 week examination 
62N8.00 A/N 32 week examination 
62N9.00 A/N 34 week examination 
62NA.00 A/N 35 week examination 
62NB.00 A/N 36 week examination 
62NC.00 A/N 37 week examination 
62ND.00 A/N 38 week examination 
62NE.00 A/N 39 week examination 
62NF.00 A/N 40 week examination 
62NG.00 A/N 41 week examination 
62NH.00 A/N 42 week examination 
62NZ.00 Antenatal examination NOS 
62O..00 Misc. antenatal data 
62O..11 Fetal maturity - A/N 
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62O..12 Static weight gain pregnancy 
62O1.00 Fetal movements felt 
62O1.11 Quickening 
62O2.00 Fetal movements seen 
62O3.00 Fetal maturity: dates = size 
62O4.00 Fetal maturity: dates not=size 
62O6.00 Vaginal 'show' 
62O6.11 Vaginal 'show' - A/N 
62O7.00 Pregnancy prolonged - 41 weeks 
62O8.00 Pregnancy prolonged - 42 weeks 
62OZ.00 Misc. antenatal data NOS 
62U..00 Downs screen - blood test 
62U..11 Barts test 
62U..12 Triple test 
62U..13 Double test 
62U0.00 Triple test offered 
62U1.00 Double test offered 
62U2.00 Triple test not offered 
62U3.00 Double test not offered 
62U4.00 Triple test wanted 
62U5.00 Double test wanted 
62U6.00 Triple test not wanted 
62U7.00 Double test not wanted 
62U8.00 Downs screening - blood sent 
62U9.00 Downs screen blood test normal 
62UA.00 Downs screen blood test abnormal 
62Uz.00 Downs screening blood test NOS 
62V..00 Delivery place planned 
62V0.00 Home delivery planned 
62W..00 Antenatal blood tests 
62X..00 Length of gestation 
62X0.00 Gestation <24 weeks 
62X1.00 Gestation = 24 weeks 
62X2.00 Gestation >24 weeks 
62X3.00 Full term gestation - 40 weeks 
62Y..00 Routine antenatal care 
62Z..00 Maternal care NOS 
62a..00 Pregnancy review 
62b..00 Antenatal HIV screening 
62c..00 Antenatal screening 
62u6.00 Triple test not wanted 
630 PREGNANCY GENITAL INFECTION 
630 B VAGINITIS PREGNANCY 
6320 PREGNANCY PLACENTA PRAEVIA 
6320A PRAEVIA PLACENTA 
6320C PLACENTA PRAEVIA CENTRAL 
6320D PLACENTA PRAEVIA LATERAL 
6320E PLACENTA PRAEVIA MARGINAL 
6320F PLACENTA PRAEVIA PARTIAL 
6321BR PLACENTA ABRUPTIO 
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6323 THREATENED MISCARRAGE 
6329A PREGNANCY HAEMORRHAGE 
6329AB PREGNANCY BLEEDING 
6330 PREGNANCY MACROCYTIC ANAEMIA 
6330B PREGNANCY ANAEMIA MEGALOBLASTIC 
6330H HYPERCHROMIC ANAEMIA PREGNANCY 
6331 PREGNANCY IRON-DEFICIENCY ANAEMIA 
6331H PREGNANCY ANAEMIA HYPOCHROMIC 
6339 PREGNANCY ANAEMIA 
6340 PREGNANCY MALPOSITION FOETUS 
6349 PREGNANCY COMPLICATION 
6349AA CONCEALED PREGNANCY 
6349AB PREGNANCY PELVIS BONY ABNORMAL 
6349AD INTRAUTERINE DEATH 
6349AP PREGNANCY ABNORMAL 
6349B TWIN PREGNANCY 
6349BM PREGNANCY MULTIPLE 
6349BT TRIPLET PREGNANCY 
6349BV PREGNANCY BICORNATE UTERUS 
6349D PREGNANCY DISPROPORTION 
6349EP PRIMIGRAVIDA ELDERLY 
6349F VARICOSE VEINS PREGNANCY 
6349LF LABOUR FALSE 
6349LG BRAXTON HICKS CONTRACTIONS 
6349LH FALSE UTERINE CONTRACTIONS 
6349LI HICK'S CONTRACTIONS 
6349LP POSSIBLE LABOUR 
6349NF PREGNANCY INFECTION DURING 
6349P PREGNANCY PHLEBITIS 
6349PP PREGNANCY PHLEBOTHROMBOSIS 
6349PT THROMBOSIS PREGNANCY 
6349PV VARIX COMPLICATING PREGNANCY 
6349PW PREGNANCY MILK LEG 
6349SD SMALL FOR DATES (FOETUS) 
6349SR INTRAUTERINE GROWTH RETARDATION 
6349TP PROLAPSED UTERUS PREGNANCY 
6349WE PREGNANCY WEIGHT GAIN EXCESSIVE 
6349WT STATIC WEIGHT GAIN PREGNANCY 
6350CG PYELOCYSTITIS PREGNANCY 
6350G PYELITIS PREGNANCY 
6359A PREGNANCY CYSTITIS 
6359G URINARY INFECTION PREGNANCY 
636 GA PREGNANCY ALBUMINURIA 
636 GM SYNDROME NEPHROTIC PREGNANCY 
636 GN PREGNANCY NEPHRITIS 
6361PG PREGNANCY GLYCOSURIA 
6370 PREGNANCY PRE-ECLAMPSIA 
6370A TOXAEMIA PRE-ECLAMPTIC 
6370H PREGNANCY HYPERTENSION 
6370HE PREGNANCY BP RAISED AT END OF 
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6371 PREGNANCY ECLAMPSIA 
6379 TOXAEMIA PREGNANCY 
6389C PREGNANCY HYPEREMESIS 
6389CD PREGNANCY NAUSEA & VOMITING 
6389CK SICKNESS PREGNANCY 
6389CM PREGNANCY MORNING SICKNESS 
6389CP VOMITING PERNICIOUS PREGNANCY 
6389CV VOMITING PREGNANCY 
6389D PREGNANCY NAUSEA 
63C5.00 Maternal tobacco abuse 
63C6.00 Maternal drug abuse 
6409TR TERMINATION OF PREGNANCY REQUESTED 
651 G PREMATURE SEPARATION PLACENTA 
655 C DISPROPORTION CEPHALOPELVIC 
656 BP PRESENTATION BREECH (MOTHER) 
6600C UTERINE PERFORATION OBSTETRICAL 
661 K LABOUR PREMATURE WITH COMPLICATIONS 
66AX.00 
Diabetes: shared care in pregnancy - diabetol and 
obstet 
6776.00 Preg. termination counselling 
679E.00 Antenatal education 
67A2.00 Diet in pregnancy advice 
67A3.00 Pregnancy smoking advice 
67A4.00 Pregnancy exercise advice 
67A5.00 Pregnancy alcohol advice 
67A6.00 Drugs in pregnancy advice 
67A7.00 Pregnancy dental advice 
67A7.11 Care of teeth advice -in preg. 
67A8.00 Maternity grant advice 
67AA.00 Maternity milk/vits advice 
67AB.00 Preg. prescription exempt adv. 
67B..00 Ante-natal relaxation classes 
6981BP PRURITUS OF PREGNANCY 
7615 PREGNANCY ACCIDENT AFFECTING BABY 
7763 FOETAL DISTRESS 
7763A ASPHYXIA ANTENATAL 
7763DM DECREASED FOETAL MOVEMENTS 
7763FM FOETAL MOVEMENTS NOT FELT 
7763MD FOETAL MOVEMENTS DECREASED 
7789C ACCIDENT INTRAUTERINE FOETUS/NEWBORN 
7E06000 
Open removal of products of conception from 
uterus NEC 
7F...00 Obstetric operations 
7F...12 Pregnancy operations 
7F0..00 Fetus and gravid uterus operations 
7F0..11 Fetus operations 
7F0..12 Fetus & gravid uterus ops 
7F00.00 Therapeutic fetoscopic operations on fetus 
7F00.11 Therapeutic endoscopic operations on fetus 
7F00.12 Therapeutic foetoscopic operations on fetus 
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7F00000 Fetoscopic blood transfusion of fetus 
7F00y00 Other specified therapeutic fetoscopic operation 
7F00z00 Therapeutic fetoscopic operation NOS 
7F01.00 
Diagnostic endoscopic examination of fetus using 
fetoscope 
7F01.11 
Diagnostic endoscopic examination of foetus using 
fetoscope 
7F01000 Fetoscopic examination of fetus and biopsy of fetus 
7F01100 
Fetoscopic examination of fetus and sampling of 
fetal blood 
7F01111 
Foetoscopic examination foetus and sampling of 
foetal blood 
7F01y00 
Diagnostic endoscopic examination fetus using 
fetoscope OS 
7F01z00 
Diagnostic endoscopic examination fetus using 
fetoscope NOS 
7F01z11 
Diagnost endoscopic examination foetus using 
foetoscope NOS 
7F01z12 Fetoscopy NEC 
7F03.00 Therapeutic percutaneous operations on fetus 
7F03000 
Percutaneous insertion of fetal vesicoamniotic 
shunt 
7F03100 
Percutaneous insertion of fetal pleuroamniotic 
shunt 
7F03200 Percutaneous blood transfusion of fetus 
7F03y00 
Other specified therapeutic percutaneous 
operation on fetus 
7F03z00 Therapeutic percutaneous operation on fetus NOS 
7F04.00 Diagnostic percutaneous examination of fetus 
7F04.11 Diagnostic percutaneous examination of placenta 
7F04000 Percutaneous biopsy of fetus 
7F04100 Percutaneous sampling of fetal blood 
7F04111 Percutaneous sampling of foetal blood 
7F04200 Percutaneous sampling of chorionic villus 
7F04y00 
Other specified diagnostic percutaneous 
examination of fetus 
7F04z00 Diagnostic percutaneous examination of fetus NOS 
7F05.00 Other operations on amniotic cavity 
7F05000 Drainage of amniotic cavity 
7F05100 Diagnostic amniocentesis 
7F05111 Amniocentesis NEC 
7F05200 Amnioscopy 
7F05300 Sampling of chorionic villus NEC 
7F05y00 Other specified other operation on amniotic cavity 
7F05z00 Other operation on amniotic cavity NOS 
7F06.00 Operations on gravid uterus 
7F06000 Cerclage of cervix of gravid uterus 
7F06011 McDonald cerclage of cervix 
7F06012 Shirodkar suture in pregnancy 
7F06100 Removal of cerclage from cervix of gravid uterus 
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7F06111 Removal of Shirodkar suture 
7F06200 Repositioning of retroverted gravid uterus 
7F06300 External version of breech 
7F06y00 Other specified operation on gravid uterus 
7F06z00 Operation on gravid uterus NOS 
7F0y.00 Other specified operations on fetus or gravid uterus 
7F0z.00 Fetus and gravid uterus operations NOS 
7F1A300 
Drainage of hydrocephalus of fetus to facilitate 
delivery 
7F1Bz00 Other operation to facilitate delivery NOS 
7F2..00 Other obstetric operations 
7F24.00 Other obstetric operations 
7F24y00 Other specified other obstetric operation 
7F24z00 Other obstetric operation NOS 
7F25.00 Obstetric monitoring 
7F25.11 Fetal monitoring 
7F25.12 Foetal monitoring 
7F25000 Fetal heart monitoring NEC 
7F25z00 Obstetric monitoring NOS 
7F2y.00 Other specified obstetric operations 
7F2z.00 Other obstetric operations NOS 
7Fy..00 Other specified obstetric operations 
8B68.00 Pregnancy prophylactic therapy 
8B7..11 Pregnancy vitamin/iron prophyl 
8B74.00 Iron supplement in pregnancy 
8B75.00 Vitamin supplement - pregnancy 
8E96.00 Ante-natal exercises 
8H7W.00 Refer to TOP counselling 
8HHV.00 Referral for termination of pregnancy 
8HHf.00 Refer to early pregnancy unit 
8HT9.00 Referral to antenatal clinic 
8HV6.00 Private referral to obstetrician 
8M6..00 Requests pregnancy termination 
95...00 Maternity services admin. 
951..00 FP24 maternity claim status 
9Ea..00 Reason for termination of pregnancy 
9Ea0.00 
Risk life pregnant woman greater than if pregnancy 
terminatd 
9Ea1.00 
To prevent grave permnt inj physic/mental health 
preg woman 
9Ea2.00 
Less 24 wk involv risk injury physic/mentl health 
preg woman 
9Ea3.00 
Lss 24 wk inv risk inj phys/men hlth ext child preg 
wom fmly 
9Ea4.00 
Unborn child at risk physi/ment abnormal serious 
handicap 
9N1N.00 Seen in antenatal clinic 
K7071AB SUTURE SHIRODKAR 
K744 PREGNANT HYSTERECTOMY 
K746 AMNIOCENTESIS 
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K7461CV CHORIONIC VILLOUS SAMPLING 
K748 AP ANTENATAL OPERATION 
K752 AA REPOSITIONING FOETUS 
K759 ANTEPARTUM OPERATION 
K965 ME VERSION EXTERNAL 
L 115H ALPHA-FETO PROTEIN HIGH 
L 115L ALPHA-FETO PROTEIN LOW 
L 115N ALPHA-FETO PROTEIN NORMAL 
L 134C AZ TEST POSITIVE 
L 134DA HUMAN PLACENTAL LACTOGEN LEVEL ABNORMAL 
L 134DN HUMAN PLACENTAL LACTOGEN LEVEL NORMAL 
L 134FA PLACENTAL FUNCTION TEST 
L 134FB PLACENTAL FUNCTION TEST NORMAL 
L 134FC PLACENTAL FUNCTION TEST ABNORMAL 
L 134P PREGNANCY TEST POSITIVE 
L0010BE SEEN IN ANTENATAL CLINIC 
L0010FE REFERRED TO ANTENATAL CLINIC 
L01z.00 Other abnormal product of conception NOS 
L031100 Gravid fallopian tube rupture 
L03y000 Cervical pregnancy 
L03y100 Cornual pregnancy 
L03y200 Membranous pregnancy 
L03y300 Combined or heterotopic pregnancy 
L03y400 Mural pregnancy 
L03y500 Intraligamentous pregnancy 
L03y600 Mesenteric pregnancy 
L03y700 Angular pregnancy 
L03y800 Mesometric pregnancy 
L08..00 Failed attempted abortion 
L080.00 
Failed attempted abortion + genital tract/pelvic 
infection 
L081.00 
Failed attempted abortion + delayed or excessive 
haemorrhage 
L082.00 
Failed attempted abortion + damage to pelvic 
organs/tissues 
L083.00 Failed attempted abortion with renal failure 
L084.00 Failed attempted abortion with metabolic disorder 
L085.00 Failed attempted abortion with shock 
L086.00 Failed attempted abortion with embolism 
L08w.00 
Failed attempted abortion with other specified 
complication 
L08x.00 Failed attempted abortion with complication NOS 
L08y.00 
Failed attempted abortion with no mention of 
complication 
L08z.00 Failed attempted abortion NOS 
L0A..00 Failed attempted abortion 
L0A1.00 
Failed medical abortion complic by genital 
tract/pelvic infn 
L0A2.00 
Failed medical abortion comp by delayed/excessive 
haem'ge 
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L0A3.00 Failed medical abortion, complicated by embolism 
L0A4.00 Failed medical abortion, without complication 
L1...00 Pregnancy complications 
L10..00 Haemorrhage in early pregnancy 
L100.00 Threatened abortion 
L100000 Threatened abortion unspecified 
L100200 Threatened abortion - not delivered 
L100z00 Threatened abortion NOS 
L10y.00 Other haemorrhage in early pregnancy 
L10y.11 Bleeding in early pregnancy 
L10y000 Other haemorrhage in early pregnancy unspecified 
L10y200 
Other haemorrhage in early pregnancy - not 
delivered 
L10yz00 Other haemorrhage in early pregnancy NOS 
L10z.00 Early pregnancy haemorrhage NOS 
L10z000 Early pregnancy haemorrhage NOS unspecified 
L10z200 Early pregnancy haemorrhage NOS - not delivered 
L10zz00 Early pregnancy haemorrhage NOS 
L11..00 
Antepartum haemorrhage, abruptio placentae, 
placenta praevia 
L11..11 Antepartum haemorrhage 
L11..12 Antepartum bleeding 
L110.00 Placenta praevia without haemorrhage 
L110000 Placenta praevia without haemorrhage unspecified 
L110200 
Placenta praevia without haemorrhage - not 
delivered 
L110z00 Placenta praevia without haemorrhage NOS 
L111.00 Placenta praevia with haemorrhage 
L111000 Placenta praevia with haemorrhage unspecified 
L111200 Placenta praevia with haemorrhage - not delivered 
L111z00 Placenta praevia with haemorrhage NOS 
L112.00 Placental abruption 
L112.11 Ablatio placentae 
L112.12 Couvelaire uterus 
L112000 Placental abruption unspecified 
L112200 Placental abruption - not delivered 
L112300 
Premature separation of placenta with coagulation 
defect 
L112z00 Placental abruption NOS 
L113.00 Antepartum haemorrhage with coagulation defect 
L113.11 Antepartum haemorrhage with afibrinogenaemia 
L113.12 Antepartum haemorrhage with hyperfibrinolysis 
L113.13 
Antepartum haemorrhage with 
hypofibrinogenaemia 
L113000 
Antepartum haemorrhage with coagulation defect 
unspecified 
L113200 
Antepartum haemorrhage with coagulation defect - 
not deliv 
L113z00 
Antepartum haemorrhage with coagulation defect 
NOS 
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L114.00 Antepartum haemorrhage with trauma 
L114000 Antepartum haemorrhage with trauma unspecified 
L114200 
Antepartum haemorrhage with trauma - not 
delivered 
L114z00 Antepartum haemorrhage with trauma NOS 
L115.00 Antepartum haemorrhage with uterine leiomyoma 
L115.11 Antepartum haemorrhage with fibroid 
L115.12 Antepartum haemorrhage with uterine fibroid 
L115000 
Antepartum haemorrhage with uterine leiomyoma 
unspecified 
L115200 
Antepartum haemorrhage with uterine leiomyoma - 
not deliv 
L115z00 
Antepartum haemorrhage with uterine leiomyoma 
NOS 
L116.00 Placenta praevia 
L11y.00 Other antepartum haemorrhage 
L11y000 Other antepartum haemorrhage unspecified 
L11y200 Other antepartum haemorrhage - not delivered 
L11yz00 Other antepartum haemorrhage NOS 
L11z.00 Antepartum haemorrhage NOS 
L11z000 Antepartum haemorrhage NOS, unspecified 
L11z200 Antepartum haemorrhage NOS - not deliv 
L11zz00 Antepartum haemorrhage NOS 
L120300 
Benign essential hypertension in 
preg/childb/puerp-not deliv 
L121300 
Renal hypertension in preg/childbirth/puerp - not 
delivered 
L122300 
Other pre-exist hypertension in preg/childb/puerp-
not deliv 
L123.00 Transient hypertension of pregnancy 
L123000 Transient hypertension of pregnancy unspecified 
L123300 Transient hypertension of pregnancy - not delivered 
L123500 Gestational hypertension 
L123600 Transient hypertension of pregnancy 
L123z00 Transient hypertension of pregnancy NOS 
L124.00 Mild or unspecified pre-eclampsia 
L124.11 Mild pre-eclampsia 
L124.12 Toxaemia NOS 
L124000 Mild or unspecified pre-eclampsia unspecified 
L124300 Mild or unspecified pre-eclampsia - not delivered 
L124500 Mild pre-eclampsia 
L124600 Pre-eclampsia, unspecified 
L124z00 Mild or unspecified pre-eclampsia NOS 
L125.00 Severe pre-eclampsia 
L125000 Severe pre-eclampsia unspecified 
L125300 Severe pre-eclampsia - not delivered 
L125z00 Severe pre-eclampsia NOS 
L126.00 Eclampsia 
L126000 Eclampsia unspecified 
L126300 Eclampsia - not delivered 
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L126500 Eclampsia in pregnancy 
L126z00 Eclampsia NOS 
L127.00 
Pre-eclampsia or eclampsia with pre-existing 
hypertension 
L127000 
Pre-eclampsia or eclampsia with hypertension 
unspecified 
L127300 
Pre-eclampsia or eclampsia with hypertension - not 
delivered 
L127z00 
Pre-eclampsia or eclampsia + pre-existing 
hypertension NOS 
L129.00 Moderate pre-eclampsia 
L12A.00 
HELLP - Syndrome haemolysis, elev liver enzyme 
low platelets 
L12B.00 Proteinuric hypertension of pregnancy 
L13..00 Excessive pregnancy vomiting 
L13..11 Hyperemesis gravidarum 
L13..12 Hyperemesis of pregnancy 
L130.00 Mild hyperemesis gravidarum 
L130.11 Morning sickness 
L130000 Mild hyperemesis unspecified 
L130200 Mild hyperemesis-not delivered 
L130z00 Mild hyperemesis gravidarum NOS 
L131.00 
Hyperemesis gravidarum with metabolic 
disturbance 
L131000 
Hyperemesis gravidarum with metabolic 
disturbance unsp 
L131200 
Hyperemesis gravidarum with metabolic 
disturbance - not del 
L131z00 
Hyperemesis gravidarum with metabolic 
disturbance NOS 
L132.00 Late vomiting of pregnancy 
L132000 Late pregnancy vomiting unspecified 
L132200 Late pregnancy vomiting - not delivered 
L132z00 Late pregnancy vomiting NOS 
L13y.00 Other pregnancy vomiting 
L13y000 Other pregnancy vomiting unspecified 
L13y200 Other pregnancy vomiting - not delivered 
L13yz00 Other pregnancy vomiting NOS 
L13z.00 Unspecified pregnancy vomiting 
L13z000 Unspecified pregnancy vomiting unspecified 
L13z200 Unspecified pregnancy vomiting - not delivered 
L13zz00 Unspecified pregnancy vomiting NOS 
L14..00 Early or threatened labour 
L140.00 Threatened premature labour 
L140.11 False labour 
L140000 Threatened premature labour unspecified 
L140100 Threatened premature labour - not delivered 
L140200 
False labour at or after 37 completed weeks of 
gestation 
L140z00 Threatened premature labour NOS 
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L141.00 Other threatened labour 
L141000 Other threatened labour unspecified 
L141100 Other threatened labour - not delivered 
L141z00 Other threatened labour NOS 
L14z.00 Early or threatened labour NOS 
L15..00 Prolonged or post-term pregnancy 
L15..11 Post-term pregnancy 
L150.00 Post-term pregnancy 
L150000 Post-term pregnancy unspecified 
L150200 Post-term pregnancy - not delivered 
L150z00 Post-term pregnancy NOS 
L15z.00 Prolonged pregnancy NOS 
L16..00 Other pregnancy complication NEC 
L160.00 Papyraceous fetus 
L160000 Papyraceous fetus unspecified 
L160200 Papyraceous fetus - not delivered 
L160z00 Papyraceous fetus NOS 
L161.00 
Oedema or excessive weight gain in pregnancy no 
hypertension 
L161.11 Excessive weight gain in pregnancy 
L161.12 Maternal obesity syndrome 
L161.13 Gestational oedema 
L161000 
Oedema or excessive weight gain in pregnancy, 
unspecified 
L161300 
Oedema or excessive weight gain in pregnancy - not 
delivered 
L161z00 Oedema or excessive weight gain in pregnancy NOS 
L162.00 Unspecified renal disease in pregnancy 
L162.11 Albuminuria in pregnancy without hypertension 
L162.12 
Nephropathy NOS in pregnancy without 
hypertension 
L162.13 Uraemia in pregnancy without hypertension 
L162000 Unspecified renal disease in pregnancy unspecified 
L162300 
Unspecified renal disease in pregnancy - not 
delivered 
L162z00 Unspecified renal disease in pregnancy NOS 
L163200 Habitual aborter - not delivered 
L163300 Pregnancy care of habitual aborter 
L164.00 Peripheral neuritis in pregnancy 
L164000 Peripheral neuritis in pregnancy unspecified 
L164300 Peripheral neuritis in pregnancy - not delivered 
L164z00 Peripheral neuritis in pregnancy NOS 
L165.00 Asymptomatic bacteriuria in pregnancy 
L165000 Asymptomatic bacteriuria in pregnancy unspecified 
L165300 
Asymptomatic bacteriuria in pregnancy - not 
delivered 
L165z00 Asymptomatic bacteriuria in pregnancy NOS 
L166.00 Genitourinary tract infections in pregnancy 
L166.11 Cystitis of pregnancy 
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L166000 
Genitourinary tract infection in pregnancy 
unspecified 
L166300 
Genitourinary tract infection in pregnancy - not 
delivered 
L166500 Infections of kidney in pregnancy 
L166700 Infections of the genital tract in pregnancy 
L166800 Urinary tract infection complicating pregnancy 
L166z00 Genitourinary tract infection in pregnancy NOS 
L166z11 UTI - urinary tract infection in pregnancy 
L167.00 Liver disorder in pregnancy 
L167000 Liver disorder in pregnancy unspecified 
L167200 Liver disorder in pregnancy - not delivered 
L167z00 Liver disorder in pregnancy NOS 
L168.00 Fatigue during pregnancy 
L168000 Fatigue during pregnancy unspecified 
L168300 Fatigue during pregnancy - not delivered 
L168z00 Fatigue during pregnancy NOS 
L169300 Herpes gestationis - not delivered 
L16A.00 Glycosuria during pregnancy 
L16A000 Glycosuria during pregnancy unspecified 
L16A300 Glycosuria during pregnancy - not delivered 
L16Az00 Glycosuria during pregnancy NOS 
L16B.00 Braxton-Hicks contractions 
L16C.00 
Pregnancy induced oedema+proteinuria without 
hypertension 
L16C000 Gestational proteinuria 
L16C100 Gestational oedema with proteinuria 
L16D.00 Excessive weight gain in pregnancy 
L16E.00 Pregnancy pruritus 
L16y.00 Other pregnancy complications 
L16y000 Other pregnancy complication unspecified 
L16y300 Other pregnancy complication - not delivered 
L16y500 Abdominal pain in pregnancy 
L16yz00 Other pregnancy complication NOS 
L16z.00 Pregnancy complication NOS 
L170300 
Maternal syphilis during pregnancy - baby not yet 
delivered 
L171300 
Maternal gonorrhoea in pregnancy - baby not yet 
delivered 
L172300 
Other maternal venereal dis. in pregnancy-baby not 
delivered 
L173300 
Maternal tuberculosis in pregnancy - baby not yet 
delivered 
L174300 
Maternal malaria during pregnancy - baby not yet 
delivered 
L175.11 Rubella contact in pregnancy 
L175300 
Maternal rubella during pregnancy - baby not yet 
delivered 
L176300 
Other maternal viral dis.in pregnancy-baby not yet 
delivered 
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L177.00 Infections of bladder in pregnancy 
L178.00 Infections of urethra in pregnancy 
L17y300 
Other mat infective/parasit dis in pregnancy - not 
delivered 
L17z300 
Mat infect/parasitic dis NOS in pregnancy-baby not 
delivered 
L180300 
Diabetes mellitus during pregnancy - baby not yet 
delivered 
L180800 Diabetes mellitus arising in pregnancy 
L180811 Gestational diabetes mellitus 
L180900 Gestational diabetes mellitus 
L181300 
Thyroid dysfunction in pregnancy - baby not yet 
delivered 
L182300 Anaemia during pregnancy - baby not yet delivered 
L182500 Iron deficiency anaemia of pregnancy 
L183.11 Pregnancy and drug dependence 
L183300 
Drug dependence during pregnancy - baby not yet 
delivered 
L184300 
Mental disorder during pregnancy - baby not yet 
delivered 
L185.11 Congenital heart disease in pregnancy 
L185300 
Congenital cardiovasc dis in pregnancy - baby not 
delivered 
L186.11 Heart disease during pregnancy 
L186300 
Other cardiovascular dis in pregnancy - baby not 
delivered 
L187300 
Orthopaedic disorder in pregnancy - baby not yet 
delivered 
L188300 
Abnormal GTT during pregnancy - baby not yet 
delivered 
L18A000 Cholestasis of pregnancy 
L18z300 
Medical condition NOS in pregnancy - baby not yet 
delivered 
L19..00 Complications specific to multiple gestation 
L191.00 
Continuing pregnancy after abortion of one fetus or 
more 
L192.00 
Continuing preg after intrauterine death one fetus 
or more 
L2...00 Risk factors in pregnancy 
L21..00 Multiple pregnancy 
L21..11 Gestation - multiple 
L210.00 Twin pregnancy 
L210000 Twin pregnancy unspecified 
L210200 Twin pregnancy with antenatal problem 
L210z00 Twin pregnancy NOS 
L211.00 Triplet pregnancy 
L211000 Triplet pregnancy unspecified 
L211200 Triplet pregnancy with antenatal problem 
L211z00 Triplet pregnancy NOS 
L212.00 Quadruplet pregnancy 
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L212000 Quadruplet pregnancy unspecified 
L212200 Quadruplet pregnancy with antenatal problem 
L212z00 Quadruplet pregnancy NOS 
L21y.00 Other multiple pregnancy 
L21y000 Other multiple pregnancy unspecified 
L21y200 Other multiple pregnancy with antenatal problem 
L21yz00 Other multiple pregnancy NOS 
L21z.00 Multiple pregnancy NOS 
L21z000 Multiple pregnancy NOS, unspecified 
L21z200 Multiple pregnancy NOS with antenatal problem 
L21zz00 Multiple pregnancy NOS 
L22..00 Malposition and malpresentation of fetus 
L22..11 Malpresentation of fetus 
L220.00 Fetus - unstable lie 
L220000 Unstable lie unspecified 
L220200 Unstable lie with antenatal problem 
L220z00 Unstable lie NOS 
L221.00 Cephalic version NOS 
L221000 Cephalic version NOS, unspecified 
L221200 Cephalic version NOS with antenatal problem 
L221z00 Cephalic version NOS 
L222.00 Breech presentation 
L222000 Breech presentation unspecified 
L222200 Breech presentation with antenatal problem 
L222z00 Breech presentation NOS 
L223.00 Oblique presentation 
L223000 Oblique lie unspecified 
L223200 Oblique lie with antenatal problem 
L223z00 Oblique lie NOS 
L224.00 Transverse presentation 
L224000 Transverse lie unspecified 
L224200 Transverse lie with antenatal problem 
L224z00 Transverse lie NOS 
L227.00 High head at term 
L227000 High head at term unspecified 
L227200 High head at term with antenatal problem 
L227z00 High head at term NOS 
L228.00 Multiple pregnancy with malpresentation 
L228000 
Multiple pregnancy with malpresentation 
unspecified 
L228200 
Multiple pregnancy with malpresentation with 
antenatal prob 
L228z00 Multiple pregnancy with malpresentation NOS 
L22y.00 Other fetal malposition and malpresentation 
L22y000 
Other fetal malposition and malpresentation 
unspecified 
L22y200 
Other fetal malposition and malpresentation with 
a/n prob 
L22yz00 Other fetal malposition and malpresentation NOS 
L22z.00 Fetal malposition and malpresentation NOS 
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L22z000 
Fetal malposition and malpresentation NOS, 
unspecified 
L22z200 
Fetal malposition and malpresentation NOS with 
a/n problem 
L22zz00 Fetal malposition and malpresentation NOS 
L23..00 Cephalo-pelvic disproportion 
L230.00 Disproportion - major pelvic abnormality 
L230000 
Disproportion - major pelvic abnormality 
unspecified 
L230200 
Disproportion - major pelvic abnormality with 
antenatal prob 
L230z00 Disproportion - major pelvic abnormality NOS 
L231.00 Generally contracted pelvis 
L231000 Generally contracted pelvis unspecified 
L231200 Generally contracted pelvis with antenatal problem 
L231z00 Generally contracted pelvis NOS 
L232.00 Inlet pelvic contraction 
L232000 Inlet pelvic contraction unspecified 
L232200 Inlet pelvic contraction with antenatal problem 
L232z00 Inlet pelvic contraction NOS 
L233.00 Outlet pelvic contraction 
L233000 Outlet pelvic contraction unspecified 
L233200 Outlet pelvic contraction with antenatal problem 
L233z00 Outlet pelvic contraction NOS 
L234.00 Mixed feto-pelvic disproportion 
L234000 Mixed feto-pelvic disproportion unspecified 
L234200 
Mixed feto-pelvic disproportion with antenatal 
problem 
L234z00 Mixed feto-pelvic disproportion NOS 
L235.00 Large fetus causing disproportion 
L235000 Large fetus causing disproportion unspecified 
L235200 
Large fetus causing disproportion with antenatal 
problem 
L235z00 Large fetus causing disproportion NOS 
L236.00 Hydrocephalic disproportion 
L236000 Hydrocephalic disproportion unspecified 
L236200 
Hydrocephalic disproportion with antenatal 
problem 
L236z00 Hydrocephalic disproportion NOS 
L237.00 Other fetal abnormality causing disproportion 
L237.11 Conjoined twins causing disproportion 
L237000 
Other fetal abnormality causing disproportion 
unspecified 
L237200 
Other fetal abnormality causing disproportion with 
a/n prob 
L237z00 Other fetal abnormality causing disproportion NOS 
L23y.00 Other disproportion 
L23y000 Other disproportion unspecified 
L23y200 Other disproportion with antenatal problem 
L23yz00 Other disproportion NOS 
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L23z.00 Disproportion NOS 
L23z000 Disproportion NOS, unspecified 
L23z200 Disproportion NOS with antenatal problem 
L23zz00 Disproportion NOS 
L240000 
Congenital abnormality of uterus affecting 
obstetric care 
L240011 Bicornuate uterus affecting obstetric care 
L240300 
Cong abnorm uterus complicating a/n care, baby 
not delivered 
L240311 
Bicornuate uterus complicating a/n care, baby not 
delivered 
L241000 Tumour of uterine body affecting obstetric care 
L241011 Uterine fibroid affecting obstetric care 
L241300 
Tumour of uterine body complicating a/n care, 
baby not deliv 
L241311 
Uterine fibroid complicating a/n care, baby not 
delivered 
L243.00 Retroverted incarcerated gravid uterus 
L243000 Retroverted incarcerated gravid uterus unspecified 
L243300 
Retroverted incarcerated gravid uterus with 
antenatal prob 
L243z00 Retroverted incarcerated gravid uterus NOS 
L244011 Cystocele affecting obstetric care 
L244300 
Other uterine/pelvic floor abnormal - baby not yet 
delivered 
L244311 
Cystocele complicating antenatal care - baby not 
delivered 
L244312 
Rectocele complicating antenatal care - baby not 
delivered 
L245.00 Cervical incompetence 
L245.11 Shirodkar suture present 
L245000 Cervical incompetence unspecified 
L245300 Cervical incompetence with antenatal problem 
L245z00 Cervical incompetence NOS 
L246000 Other cervical abnormality affecting obstetric care 
L246300 
Other cervical abn complicating a/n care- baby not 
delivered 
L246311 
Polyp of cervix complicating a/n care- baby not 
delivered 
L246312 
Stenosis of cervix complicating a/n care- baby not 
delivered 
L247300 
Vaginal abnormality complicating a/n care-baby 
not delivered 
L247311 
Septate vagina complicating a/n care- baby not yet 
delivered 
L247312 
Stenosis of vagina complicating a/n care- baby not 
delivered 
L248012 Rigid perineum affecting obstetric care 
L248300 
Vulval abn complicating a/n care - baby not yet 
delivered 
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L248311 
Persistent hymen complicating a/n care - baby not 
delivered 
L248312 
Rigid perineum complicating a/n care - baby not 
delivered 
L248z12 
Rigid perineum in 
pregnancy/childbirth/puerperium NOS 
L25..00 Known or suspected fetal abnormality 
L250.00 Fetus with central nervous system malformation 
L250.11 Suspect fetal anencephaly 
L250.12 Suspect fetal hydrocephaly 
L250.13 Suspect fetal spina bifida 
L250000 
Fetus with central nervous system malformation 
unspecified 
L250200 
Fetus with central nervous system malformation + 
a/n problem 
L250300 
Maternal care for suspected CNS malformation in 
fetus 
L250400 Maternal care for CNS malformation in fetus 
L250z00 
Fetus with central nervous system malformation 
NOS 
L251.00 Fetus with chromosomal abnormality 
L251.11 Suspect cystic fibrosis fetus 
L251.12 Suspect mongol fetus 
L251000 Fetus with chromosomal abnormality unspecified 
L251200 
Fetus with chromosomal abnormality with 
antenatal problem 
L251300 
Maternal care for suspected chromosomal 
abnormality in fetus 
L251400 Maternal care for chromosomal abnormality in fetus 
L251z00 Fetus with chromosomal abnormality NOS 
L252.00 Fetus with hereditary disease 
L252000 Fetus with hereditary disease unspecified 
L252200 
Fetus with hereditary disease with antenatal 
problem 
L252z00 Fetus with hereditary disease NOS 
L253.00 Fetus with viral damage via mother 
L253.11 Fetus with suspected rubella damage via mother 
L253000 Fetus with viral damage via mother unspecified 
L253200 
Fetus with viral damage via mother with antenatal 
problem 
L253300 
Maternal care for damage to fetus from maternal 
rubella 
L253z00 Fetus with viral damage via mother NOS 
L254.00 Fetus with damage due to other maternal disease 
L254.11 Suspect fetal damage from maternal alcohol 
L254.12 Suspect fetal damage from maternal toxoplasmosis 
L254000 
Fetus with damage due to other maternal disease 
unspecified 
L254200 
Fetus with damage due to other maternal disease + 
a/n prob 
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L254z00 
Fetus with damage due to other maternal disease 
NOS 
L255.00 Fetus with drug damage 
L255000 Fetus with drug damage unspecified 
L255200 Fetus with drug damage with antenatal problem 
L255300 
Maternal care for (suspected) damage to fetus from 
alcohol 
L255z00 Fetus with drug damage NOS 
L256.00 Fetus with radiation damage 
L256000 Fetus with radiation damage unspecified 
L256200 
Fetus with radiation damage with antenatal 
problem 
L256z00 Fetus with radiation damage NOS 
L257.00 
Fetus with damage due to intra-uterine 
contraceptive device 
L257.11 Fetus with damage due to coil 
L257.12 
Fetus with damage due to intra-uterine 
contraceptive device 
L257000 Fetus with damage due to IUCD unspecified 
L257200 
Fetus with damage due to IUCD with antenatal 
problem 
L257z00 Fetus with damage due to IUCD NOS 
L25y.00 Fetus with other damage NEC 
L25y000 Fetus with other damage NEC, unspecified 
L25y200 
Fetus with other damage NEC with antenatal 
problem 
L25yz00 Fetus with other damage NEC NOS 
L25z.00 Fetus with damage NOS 
L25z000 Fetus with damage NOS, unspecified 
L25z200 Fetus with damage NOS with antenatal problem 
L25z300 
Maternal care for suspect fetal abnormal and 
damage, unspec 
L25z400 
Maternal care for fetal abnormality and damage, 
unspecified 
L25zz00 Fetus with damage NOS 
L26..00 Other fetal and placental problems 
L260.00 Fetal-maternal haemorrhage 
L260000 Fetal-maternal haemorrhage unspecified 
L260200 
Fetal-maternal haemorrhage with antenatal 
problem 
L260z00 Fetal-maternal haemorrhage NOS 
L261200 Rhesus isoimmunisation with antenatal problem 
L262200 
Other blood-group isoimmunisation with antenatal 
problem 
L263.00 Fetal distress - affecting management 
L263.11 Fetal acidosis 
L263.12 Fetal bradycardia 
L263.13 Fetal tachycardia 
L263000 Fetal distress unspecified 
L263200 Fetal distress with antenatal problem 
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L263311 Maternal care for fetal hypoxia 
L263700 Maternal care for fetal hypoxia 
L263900 
Maternal care for fetal tachycardia during 
pregnancy 
L263A00 
Maternal care for fetal bradycardia during 
pregnancy 
L263A11 
Maternal care for reduced fetal heart rate during 
pregnancy 
L263B00 Maternal care for fetal acidosis during pregnancy 
L263z00 Fetal distress NOS 
L264.00 Intrauterine death 
L264.11 Fetal death in utero 
L264000 Intrauterine death unspecified 
L264200 Intrauterine death with antenatal problem 
L264z00 Intrauterine death NOS 
L265.00 Small-for-dates fetus in pregnancy 
L265.11 Placental insufficiency 
L265200 Small-for-dates with antenatal problem 
L265300 Maternal care for poor fetal growth 
L265311 Maternal care for intrauterine growth retardation 
L266.00 Large-for-dates fetus in pregnancy 
L266200 Large-for-dates with antenatal problem 
L266300 Suspected macroscopic fetus 
L267300 Placental transfusion syndromes 
L267500 Other fetal problems 
L268.00 Other fetal problems 
L268000 Reduced fetal movements 
L26y.00 Other feto-placental problems 
L26y000 Other feto-placental problems unspecified 
L26y200 
Other feto-placental problems with antenatal 
problem 
L26yz00 Other feto-placental problems NOS 
L26z.00 Feto-placental problems NOS 
L26z000 Feto-placental problems NOS, unspecified 
L26z200 
Feto-placental problems NOS with antenatal 
problem 
L26zz00 Feto-placental problems NOS 
L27..00 Polyhydramnios and hydramnios 
L27..11 Hydramnios 
L270.00 Polyhydramnios 
L270000 Polyhydramnios unspecified 
L270200 Polyhydramnios with antenatal problem 
L270z00 Polyhydramnios NOS 
L27z.00 Polyhydramnios NOS 
L28..00 Other problems of amniotic cavity and membranes 
L280.00 Oligohydramnios 
L280000 Oligohydramnios unspecified 
L280200 Oligohydramnios with antenatal problem 
L280300 Anhydramnios 
L280z00 Oligohydramnios NOS 
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L284.00 Amniotic cavity infection 
L284.11 Amnionitis 
L284.13 Membranitis 
L284.14 Placentitis 
L284000 Amniotic cavity infection unspecified 
L284200 Amniotic cavity infection with antenatal problem 
L284z00 Amniotic cavity infection NOS 
L28y.00 Other problems of amniotic cavity and membranes 
L28y.11 Amnion nodosum 
L28y.12 Amniotic cyst 
L28y000 
Other problem of amniotic cavity and membranes 
unspecified 
L28y200 
Other amniotic/membrane problem with antenatal 
problem 
L28yz00 
Other problem of amniotic cavity and membranes 
NOS 
L28z.00 Amniotic cavity and membrane problems NOS 
L28z000 
Amniotic cavity and membrane problem NOS, 
unspecified 
L28z200 
Amniotic cavity and membrane problem NOS with 
a/n problem 
L28zz00 Amniotic cavity and membrane problem NOS 
L295.00 Elderly primigravida 
L295000 Elderly primigravida unspecified 
L295200 Elderly primigravida with antenatal problem 
L295z00 Elderly primigravida NOS 
L2A..00 Abnormal findings on antenatal screening of mother 
L2A0.00 
Abnormal haematologic find on antenatal screening 
of mother 
L2A1.00 
Abnormal biochemical finding on antenatal screen 
of mother 
L2A2.00 
Abnormal cytological finding on antenatal screen of 
mother 
L2A3.00 
Abnormal ultrasonic finding on antenatal screening 
of mother 
L2A4.00 
Abnormal radiological finding on antenatal screen 
of mother 
L2A5.00 
Abnormal chromosomal and genet find/antenat 
screen of mother 
L2AX.00 Abnormal finding on antenatal screening of mother 
L2B..00 Low weight gain in pregnancy 
L2C..00 Malnutrition in pregnancy 
L2D..00 
Retained intrauterine contraceptive device in 
pregnancy 
L2y..00 Other specified risk factors in pregnancy 
L2z..00 Risk factors in pregnancy NOS 
L304.00 
Persistent occipitoposterior or occipitoanterior 
position 
L304000 
Persistent occipitopost/occipitoant position, 
unspecified 
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L3210CF CONTRACEPTION CAP FAILURE 
L3241SF CONTRACEPTION SHEATH FAILURE 
L33..00 Umbilical cord complications 
L335.00 Vasa praevia 
L335.11 Velamentous insertion of cord 
L335000 Vasa praevia unspecified 
L335200 Vasa praevia with antenatal problem 
L335z00 Vasa praevia NOS 
L336.00 Vascular lesions of cord 
L336000 Vascular lesions of cord unspecified 
L336200 Vascular lesions of cord with antenatal problem 
L336z00 Vascular lesions of cord NOS 
L33y.00 Other umbilical cord complications 
L33y000 Other umbilical cord complications unspecified 
L33y200 
Other umbilical cord complications with antenatal 
problem 
L33yz00 Other umbilical cord complications NOS 
L33z.00 Umbilical cord complications NOS 
L33z000 Umbilical cord complications NOS, unspecified 
L33z200 
Umbilical cord complications NOS with antenatal 
problem 
L33zz00 Umbilical cord complications NOS 
L370.11 Placenta accreta without haemorrhage 
L385.00 Failed or difficult intubation during pregnancy 
L390.00 Maternal distress 
L390000 Maternal distress unspecified 
L390300 Maternal distress with antenatal problem 
L390z00 Maternal distress NOS 
L392.00 Maternal hypotension syndrome 
L392000 Maternal hypotension syndrome unspecified 
L392300 
Maternal hypotension syndrome with antenatal 
problem 
L392z00 Maternal hypotension syndrome NOS 
L394.00 Other complications of obstetric procedures 
L394000 
Other complications of obstetric procedures 
unspecified 
L394z00 Other complications of obstetric procedures NOS 
L410500 Varicose veins of legs in pregnancy 
L411500 Genital varices in pregnancy 
L411511 Perineal varices in pregnancy 
L411512 Vaginal varices in pregnancy 
L411513 Vulval varices in pregnancy 
L412500 Superficial thrombophlebitis in pregnancy 
L412511 Thrombophlebitis of legs in pregnancy 
L413.00 Antenatal deep vein thrombosis 
L413.11 DVT - deep venous thrombosis, antenatal 
L413000 Antenatal deep vein thrombosis unspecified 
L413200 
Antenatal deep vein thrombosis with antenatal 
complication 
L413z00 Antenatal deep vein thrombosis NOS 
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L414.12 Phlegmasia alba dolens - obstetric 
L415500 Other phlebitis in pregnancy 
L416600 Haemorrhoids in pregnancy 
L417000 Cerebral venous thrombosis in pregnancy 
L41z500 Venous complication of pregnancy, unspecified 
L431300 
Amniotic fluid pulmonary embolism with a/n 
complication 
L43y.11 Fat embolism - obstetric 
L43y300 
Other obstetric pulmonary embolism with antenatal 
comp 
L4500F CONTRACEPTION I U C D FAILURE 
L465300 Suppressed lactation with antenatal complication 
L46z300 
Disorder of lactation NOS with antenatal 
complication 
L5...00 Maternal care for fetus 
L51..00 
Maternal care for other known or suspected fetal 
problems 
L510.00 Maternal care for hydrops fetalis 
L511.00 
Maternal care for viable fetus in abdominal 
pregnancy 
L512.00 Maternal care for diminished fetal movements 
L514.00 Maternal care for poor fetal growth 
L51X.00 
Maternal care/known or suspected fetal 
problem,unspecifd 
L6000UP PREGNANCY UNPLANNED 
L9610UP PREGNANCY UNWANTED 
Lyu0100 [X]Other specified abnormal products of conception 
Lyu0400 
[X]Oth+unspcf failed inducd abort,complct gen 
tract+pelv inf 
Lyu0500 
[X]Oth+unspc fail induc 
abortn,complict/delay/exces h'morrhg 
Lyu0600 
[X]Other+unspcf failed induced 
abortion,complicated/embolism 
Lyu0700 
[X]Oth+unspcf failed inducd abortn,wth oth+unspcf 
complicatn 
Lyu0800 
[X]Other+unspcf failed induced abortion,without 
complication 
Lyu2.00 
[X]Other maternal disorders predominant related to 
pregnancy 
Lyu2000 [X]Other haemorrhage in early pregnancy 
Lyu2100 [X]Other vomiting complicating pregnancy 
Lyu2200 [X]Other venous complications in pregnancy 
Lyu2300 
[X]Infections of other parts of urinary tract in 
pregnancy 
Lyu2400 
[X]Other+unspcf genitourinary tract infection in 
pregnancy 
Lyu2500 [X]Other specified pregnancy-related conditions 
Lyu2600 
[X]Other abnormal findings on antenatal screening 
of mother 
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Lyu2A00 
[X]Abnormal finding on antenatal screening of 
mother 
Lyu3000 [X]Other multiple gestation 
Lyu3100 
[X]Other complications specific to multiple 
gestation 
Lyu3300 [X]Maternal care for other abnormalities of cervix 
Lyu3400 
[X]Maternal care for other abnormalities of gravid 
uterus 
Lyu3500 
[X]Maternal care for other abnormalities of pelvic 
organs 
Lyu3600 
[X]Maternal care/(suspected)damage/fetus/oth 
medicl procedur 
Lyu3700 
[X]Maternal care/other(suspected)fetal 
abnormality+damage 
Lyu3800 [X]Maternal care for other isoimmunization 
Lyu3900 
[X]Maternal care/oth spcf known or suspected fetal 
problems 
Lyu3A00 
[X]Maternal care/known or suspected fetal 
problem,unspecifd 
Lyu3B00 [X]Other disorders of amniotic fluid and membranes 
Lyu3C00 [X]Other placental disorders 
Lyu3D00 [X]Other premature separation of placenta 
Lyu3E00 [X]Other antepartum haemorrhage 
M240500 Alopecia of pregnancy 
Q000.11 Fetus affected by maternal toxaemia 
Q007111 Fetal alcohol syndrome 
Q013.11 Fetus affected by hydramnios 
Q014100 
Fetus or neonate affected by abdominal ectopic 
pregnancy 
Q015100 Fetus or neonate affected by twin pregnancy 
Q016.11 Fetus affected by maternal death 
Q017.11 Fetus affected by malpresentation 
Q02..00 
Fetus/neonate affected by complic of 
placenta/cord/membrane 
Q021000 
Fetus/neonate affected by antepartum 
haemorrhage unspecified 
Q021011 Fetus affected by APH - antepartum haemorrhage 
Q021111 Fetus affected by placental abruption 
Q021200 
Fetus/neonate affected by placental damage-
amniocentesis 
Q021500 
Fetus or neonate affected by premature placental 
separation 
Q021511 
Fetus/neonate affected-prem placental 
separation+acc haem'ge 
Q021y00 
Fetus/neonate affected placental 
separation/haemorrhage OS 
Q021z00 
Fetus/neonate affected placental 
separation/haemorrhage NOS 
Q022.11 Fetus affected by placental insufficiency 
Q026.11 Fetus affected by cord problems 
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Q10..00 Slow fetal growth and fetal malnutrition 
Q10..11 Fetal malnutrition 
Q100.00 
Fetus small-for-dates, without mention of 
malnutrition 
Q100.11 
Fetus small-for-dates (SFD), without mention of 
malnutrition 
Q101.00 Fetus small-for-dates with signs of malnutrition 
Q101.11 
Fetus small-for-dates (SFD) with signs of 
malnutrition 
Q102.00 
Fetal malnutrition, no mention light or small for 
gest age 
Q102.11 
Fetal malnutrition without mention of 'light for 
dates' 
Q10z.00 Fetal growth retardation NOS 
Q10z.11 Intrauterine growth retardation 
Q21..11 Intrauterine hypoxia 
Q210.00 Fetal death due to prelabour anoxia 
Q408.00 Intra-amniotic fetal infection 
Q408000 Intra-amniotic fetal infection, unspecified 
Q408100 Clostridial intra-amniotic fetal infection 
Q408200 Eschericha coli intra-amniotic fetal infection 
Q408300 Staphylococcal intra-amniotic infection NEC 
Q408500 
Group B haemolytic streptococcal intra-amniotic 
infect. NEC 
Q408z00 Intra-amniotic fetal infection NOS 
Q40y000 Intrauterine fetal sepsis, unspecified 
Q410.00 Fetal blood loss 
Q410000 Fetal blood loss, unspecified 
Q410200 Fetal placental blood loss 
Q410400 Fetal blood loss from vasa praevia 
Q410500 Fetal haemorrhage into co-twin 
Q410600 Fetal haemorrhage into mother's circulation 
Q410700 Fetal exsanguination 
Q410y00 Other specified fetal blood loss 
Q410z00 Fetal blood loss NOS 
Q423.00 Hydrops fetalis due to isoimmunisation 
Q42X.00 
Hydrops fetalis due to other+unspcfd haemolytic 
disease 
Q436.00 Fetal and neonatal jaundice, unspecified 
Q454100 Polycythaemia due to maternal fetal transfusion 
Q470.00 Idiopathic hydrops fetalis 
Q479.00 Non-immune hydrops fetalis 
Qyu0400 
[X]Fetus+newbrn affect/oth forms/placental 
separatn+h'morrhg 
Qyu0700 
[X]Fetus+newborn affectd/oth+unspcfd 
conditns/umbilical cord 
Qyu5000 [X]Other fetal blood loss 
Qyu5600 
[X]Hydrops fetalis due to other+unspcfd haemolytic 
disease 
QyuA500 [X]Complications of intrauterine procedures NEC 
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T182 PREGNANCY HIGH RISK 
T347 ADVICE GIVEN ON ABORTION 
T349 REQUESTS ABORTION 
T800 PREGNANCY OPERATION DURING 
T901 PREGNANCY WITH I U D IN PLACE 
T9011 IUCD FAILED 
T961 AA PREGNANCY UNMARRIED 
T961 AC PROBLEM PREGNANCY UNMARRIED 
T961 AD PROBLEM UNMARRIED PREGNANCY 
T961 AE PREGNANCY OUT OF WEDLOCK 
T967 PROBLEM PREGNANCY 
T976 TERMINATION REFUSED PREGNANCY 
T9761 DECIDED AGAINST TERMINATION PREGNANCY 
Y409 D RUBELLA CONTACT IN PREGNANCY 
Y409 DA RUBELLA CONTACT IN EARLY PREGNANCY 
Y60 PREGNANCY 
Y60  A PREGNANCY NORMAL 
Y60  AA PREGNANT 
Y60  AM INSTRUCTION ANTENATAL GIVEN 
Y60  AN INSTRUCTION ANTENATAL 
Y60  B PROPHYLACTIC THERAPY PREGNANCY 
Y60  BA PREGNANCY PROPHYLACTIC THERAPY PRESCRIBE 
Y60  CA PREGNANCY PRENATAL CARE 
Y60  CB PREGNANCY PRENATAL CARE NORMAL 
Y60  EL MEDICAL EXAMINATION ANTENATAL 
Y60  EM MEDICAL EXAMINATION PREGNANCY 
Y60  EN PREGNANCY BOOKING CONSULTATION 
Y60  EP PRENATAL EXAMINATION 
Y60  EQ PREGNANCY EXAMINATION NORMAL 
Y60  ER EXAMINATION PRENATAL 
Y60  NA ANTENATAL CARE 
Y60  NB ANTENATAL BOOKING 
Y60  NC BOOKING ANTENATAL 
Y60  NP PRENATAL CARE NORMAL PREGNANCY 
Y60  NQ PRENATAL CARE REGULARLY ATTENDED 
Y60  NR PREGNANCY ANTENATAL CARE NORMAL 
Y60  NS NORMAL PREGNANCY PRENATAL CARE THROUGHOU 
Y601 HH FOETAL HEART HEARD 
Y601 HN FOETAL HEART NORMAL 
Y601 MF FOETAL MOVEMENTS FELT 
Y601 MN FOETAL MOVEMENTS NORMAL 
Y601 MS FOETAL MOVEMENTS STOPPED 
Z212.00 Antenatal care 
Z212.11 Pregnancy care 
Z212100 Delivery place planned 
Z212200 Home delivery planned 
Z212300 Delivery place booked 
Z22..00 Pregnancy observations 
Z221.00 Primigravida 
Z222.00 Multigravida 
 
 
291 
Z225.00 Normal pregnancy 
Z226.00 Pregnancy problem 
Z227.00 Confirmation of pregnancy 
Z229.00 Observation of position of pregnancy 
Z229100 Intrauterine pregnancy 
Z22A.00 Observation of pattern of pregnancy 
Z22A100 Low risk pregnancy 
Z22A200 High risk pregnancy 
Z22A300 Concealed pregnancy 
Z22A400 Early stage of pregnancy 
Z22A500 Biochemical pregnancy 
Z22A600 Teenage pregnancy 
Z22A700 Surrogate pregnancy 
Z22A800 Undiagnosed pregnancy 
Z22A900 Unwanted pregnancy 
Z22AA00 Wanted pregnancy 
Z22AB00 Unplanned pregnancy 
Z22AB11 Accidental pregnancy 
Z22AC00 Pregnancy with uncertain dates 
Z22AD00 Presentation of pregnancy 
Z22AD11 Reported conception - pregnancy 
Z22AE00 Baby overdue 
Z22B.00 Observation of quantity of pregnancy 
Z22B100 Single pregnancy 
Z22B900 Continuing pregnancy after abortion of sibling fetus 
Z22BA00 
Contin pregnancy after intrauterine death of sibling 
fetus 
Z22C.00 Observation of measures of pregnancy 
Z22C100 Estimated date of delivery from last period 
Z22C200 Estimated date of delivery from last normal period 
Z22C300 Length of gestation 
Z22C311 Pregnancy duration 
Z22C312 Duration of gestation 
Z22C313 Duration of pregnancy 
Z22C314 Weeks pregnant 
Z22C500 Estimated date of conception 
Z22C511 EDC - Estimated date of conception 
Z22CF00 Date symptom of pregnancy first noted 
Z22D.00 Observation of viability of pregnancy 
Z22D100 Viable pregnancy 
Z22D200 Non-viable pregnancy 
Z22D300 Uncertain viability of pregnancy 
Z22D311 Query viability of pregnancy 
Z23..00 Observation of gravid uterus 
Z231.00 Gravid uterus present 
Z234.00 Observation of size of gravid uterus 
Z234100 Gravid uterus large-for-dates 
Z234200 Gravid uterus small-for-dates 
Z234300 Observation of height of gravid uterus 
Z234400 Fundal height high for dates 
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Z234500 Fundal height equal to dates 
Z234600 Fundal height low for dates 
Z235.00 Observation of shape of pregnant abdomen 
Z235300 Transversely enlarged pregnant abdomen 
Z235400 Pendulous pregnant abdomen 
Z236100 Normal position of gravid uterus 
Z237.00 Observation of sensation of gravid uterus 
Z237200 Tender scar of gravid uterus 
Z238112 Fundus firm 
Z239200 Uterine contractions absent 
Z239300 Uterine contractions ceased 
Z239800 Uterine activity 
Z23A100 Intermittent uterine contractions 
Z23A200 Occasional uterine tightenings 
Z23A400 Irregular uterine contractions 
Z23A700 Niggling uterine contractions 
Z23A800 Mild uterine contractions 
Z23AO00 Irritable uterus 
Z23AP00 Premature uterine contraction 
Z23B100 Date false contractions first detected 
Z23D100 Girth of pregnant abdomen 
Z23D200 Pregnant abdomen observation 
Z23E.00 Gravid uterus normal 
Z23F.00 Gravid uterus problem 
Z242.00 Labour not established 
Z243200 First stage of labour not established 
Z245100 Maternal blood loss minimal 
Z245400 Maternal blood loss heavy 
Z246500 Time vaginal show detected 
Z252.00 Mother not delivered 
Z26..00 Observation of structures of conception 
Z261.00 Observation of gestational sac 
Z261100 Gestational sac present 
Z261200 Gestational sac absent 
Z262C00 Retroplacental clot 
Z262D00 Fresh retroplacental clot 
Z262E00 Old retroplacental clot 
Z262E11 Stale retroplacental clot 
Z262J11 Placental infection 
Z262R00 Placenta problem 
Z263.00 Uterine membrane observations 
Z263900 Number of chorions in membranes 
Z263C00 Intact membranes 
Z264100 Observation of quantity of liquor 
Z264111 Quantity of liquor 
Z264112 Amount of liquor 
Z264400 Normal liquor volume 
Z264500 Reduced amniotic fluid 
Z264600 Excessive amniotic fluid 
Z265.00 Umbilical cord observations 
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Z265200 Umbilical cord problem 
Z265A00 Number of blood vessels in umbilical cord 
Z265A11 Number of vessels entering umbilical cord 
Z265B00 Number of umbilical arteries 
Z265C00 Number of umbilical veins 
Z271.00 Cardiotochogram observation 
Z271.11 CTG observations 
Z271100 Fetal heart acceleration 
Z271200 Normal CTG tracing 
Z271400 Unsatisfactory CTG tracing 
Z271411 Technically poor CTG 
Z271500 CTG reactivity 
Z271600 Reactive CTG tracing 
Z271900 Fetal heart rate variability 
Z271912 FHRV - Fetal heart rate variability 
Z271C00 Fetal heart baseline pattern 
Z271D00 Normal fetal heart baseline pattern 
Z271E00 Sinusoidal pattern of fetal heart 
Z271F00 Fetal heart deceleration 
Z28..00 Obstetric pelvic observation 
Z28..11 Pelvic assessment - childbirth 
Z282300 Flat sacral curve 
Z288.00 Problem of pelvis for delivery 
Z675.00 Antenatal class 
ZL75.00 Referral to midwife 
ZV22.00 [V]Normal pregnancy 
ZV22.11 [V]Supervision of normal pregnancy 
ZV22000 [V]First normal pregnancy supervision 
ZV22100 [V]Other normal pregnancy supervision 
ZV22200 [V]Pregnancy confirmed 
ZV22300 [V]Pregnant state, incidental 
ZV22400 [V]Supervision of other normal pregnancy 
ZV22y00 [V]Other specified pregnant state 
ZV22z00 [V]Unspecified pregnant state 
ZV23.00 [V]High-risk pregnancy supervision 
ZV23000 [V]Pregnancy with history of infertility 
ZV23100 [V]Pregnancy with history of trophoblastic disease 
ZV23111 [V]Pregnancy with history of hydatidiform mole 
ZV23112 [V]Pregnancy with history of vesicular mole 
ZV23200 [V]Pregnancy with history of abortion 
ZV23400 [V]Pregnancy with other poor obstetric history 
ZV23500 [V]Pregnancy with other poor reproductive history 
ZV23600 
[V]Supervisn/pregnancy wth history insufficnt 
antenatal care 
ZV23800 
[V]Supervision of high-risk pregnancy due to social 
problems 
ZV23y00 [V]Other specified high-risk pregnancy 
ZV23z00 [V]Unspecified high-risk pregnancy 
ZV28.00 [V]Antenatal screening 
ZV28y00 [V]Other specified antenatal screening 
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ZV4J000 [V]Problems related to unwanted pregnancy 
ZV61800 [V]Illegitimate pregnancy 
ZV61900 [V]Other unwanted pregnancy 
ZVu2300 [X]Supervision of other normal pregnancy 
l413.00 Antenatal deep vein thrombosis 
 
 
